Delivery of cas9 via arrdc1-mediated microvesicles (armms)

ABSTRACT

Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.

RELATED APPLICATIONS

The present application is a continuation of and claims priority under 35 U.S.C. § 120 to U.S. patent application, U.S. Ser. No. 15/809,470, filed Nov. 10, 2017, which is a divisional of and claims priority under 35 U.S.C. § 120 to U.S. patent application, U.S. Ser. No. 14/929,177, filed Oct. 30, 2015, now U.S. Pat. No. 9,816,080, which claims priority under 35 U.S.C. § 119(e) to U.S. provisional patent application, U.S. Ser. No. 62/073,241, filed Oct. 31, 2014, each of which is incorporated herein by reference.

GOVERNMENT SUPPORT

This invention was made with government support under contract HDTRA1-06-C-0039 awarded by the Defense Threat Reduction Agency, and under contract HL114769 awarded by the National Institutes of Health. The government has certain rights in this invention.

BACKGROUND OF THE INVENTION

The delivery of proteins (e.g., therapeutic proteins) to cells is limited by a number of factors, including the poor permeability and target specificity. Protein transduction represents one emerging technology for delivering proteins into cells by exploiting the ability of certain proteins to penetrate the cell membrane. However, the majority of the proteins delivered by this method are usually trapped and subsequently degraded in the endosomes or lysosomes of the recipient cells. Another option relies on virus mediated gene delivery (gene therapy), which has been widely pursued as viruses have the unique ability to infect cells and deliver the contents in the cytoplasm efficiently. However viruses present a variety of potential problems to the patient relating to toxicity, immune and inflammatory responses, gene control and targeting tissues. In addition, the possibility of the virus becoming virulent in the patient is an added risk.

One particular agent that holds a great deal of promise as a protein-based therapeutic is the RNA-guided DNA nuclease Cas9 that can make edits (e.g., additions or deletions) to single base pairs and longer stretches of DNA (Pennisi, E. “The CRISPR Craze”. Science, 2013; 341 (6148): 833-836.). Cas9 has additionally been modified to make programmable transcription factors that allow the targeted activation or silencing of specific genes (Larson, M. H et al., “CRISPR interference (CRISPRi) for sequence-specific control of gene expression”. Nature Protocols, 2013; 8 (11): 2180-96). Accordingly, Cas9 has the potential to correct specific target genes for treating both recessive and dominant genetic diseases, offering significant advantages over traditional gene therapy approaches, which have only been useful for correcting some recessive genetic disorders. Therefore, it is of critical importance to develop methods and systems for effectively delivering protein therapeutics, such as Cas9, to their desired target cells in order to realize the full potential of protein based therapeutics.

SUMMARY OF THE INVENTION

Some aspects of this invention relate to the discovery that Cas9 proteins and their variants can be loaded in microvesicles, specifically ARRDC1-mediated microvesicles (ARMMs), for delivery to a target cell. The ARMM delivery system, described herein, addresses many limitations of current delivery systems that prevent the safe and efficient delivery of targeted protein therapeutics to cells. As ARMMS are derived from an endogenous budding pathway, they are unlikely to elicit a strong immune response, unlike viral delivery systems, which are known to trigger inflammatory responses (Sen D. et al., “Cellular unfolded protein response against viruses used in gene therapy.”, Front Microbiology. 2014; 5:250, 1-16.). Additionally, ARMMs allow for the specific packaging of any cargo protein of interest (e.g., a Cas9 protein or Cas9 variant with a guide RNA (gRNA)). These cargo proteins can then be delivered by fusion or uptake by specific recipient cells/tissues by incorporating antibodies or other types of molecules in ARMMs that recognize tissue-specific markers. ARMMs are microvesicles that are distinct from exosomes and which, like budding viruses, are produced by direct plasma membrane budding (DPMB). DPMB is driven by a specific interaction of TSG101 with a tetrapeptide PSAP motif of the arrestin-domain-containing protein ARRDC1 accessory protein, which is localized to the plasma membrane through its arrestin domain. ARMMS have been described in detail, for example, in PCT application number PCT/US2013/024839, filed on February 06, 2013 (published as WO2013119602 Al) by Lu Q. et al., and entitled Arrdc1-mediated microvesicles (armms) and uses thereof, the entire contents of which are incorporated herein by reference. The ARRDC1/TSG101 interaction results in relocation of TSG101 from endosomes to the plasma membrane and mediates the release of microvesicles that contain TSG101, ARRDC1, and other cellular components.

Non-naturally occurring cargo proteins including, for example, Cas9 and Cas9 variants can be modified to associate with TSG101 or ARRDC1, facilitating their incorporation in ARMMs, which in turn can be used to deliver the cargo proteins into target cells. As one example, a cargo protein can be fused to one or more WW domains, which associate with the PPXY motif of ARRDC1. This association facilitates loading of the cargo protein into the ARRDC1-containing ARMM. Alternatively, the cargo protein, for example a Cas9 protein or Cas9 variant, can be fused to an ARMM protein (e.g., TSG101 or ARRDC1) to load the Cas9 protein or Cas9 variant in an ARMM. The cargo protein can be fused to the ARMM protein (e.g., TSG101 or ARRDC1) via a linker that may be cleaved upon delivery in a target cell.

In some aspects of this invention, ARMMs containing a cargo protein fused to at least one WW domain are provided. In other aspects, ARMMs containing a Cas9 protein or Cas9 variant fused to an ARRDC1 protein, or variant thereof, or a TSG101 protein, or variant thereof, are provided. Such ARMMs may be derived from a subject, a biological sample, or a cell culture, or ARMMs may be prepared synthetically. Methods for generating and/or isolating ARMMs, including ARMMs that include cargo proteins to be delivered to a target cell or target cell population, are also provided herein. Methods for the use of ARMMs to deliver a cargo protein, for example, a Cas9 protein or Cas9 variant fused to at least one WW domain, to a target cell in vitro, in vivo, and ex vivo are also provided.

Some aspects of this invention include arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (ARMMs) that comprise a lipid bilayer, an ARRDC1 protein, or variant thereof, and a cargo protein, wherein the cargo protein is fused to at least one WW domain or variant thereof. The microvesicle's cargo protein may be fused to multiple WW domains, for example two, three, four or five WW domains. The WW domain may be derived from any WW domain known in the art. For example, the WW domain may be from the ubiquitin ligase WWP1, WWP2, Nedd4-1, Nedd4-2, Smurf1, Smurf2, ITCH, NEDL1 or NEDL2. In certain embodiments, the microvesicle's cargo protein is a Cas9 protein or a Cas9 variant. The Cas9 protein or Cas9 variant may have one or more nuclear localization sequences (NLSs) to facilitate translocation into the nucleus of a target cell. In other embodiments, the microvesicle further comprises a guide RNA (gRNA). The gRNA may be expressed in an ARMM producing cell and load in an ARMM by associating with an RNA-guided nuclease (e.g., Cas9)or a variant of an RNA-guided nuclease fused to one or more WW domains. The gRNA may also be loaded in an ARMM by associating with an RNA-guided nuclease (e.g., Cas9) or a variant of an RNA-guided nuclease that is fused to an ARMM protein (e.g., TSG101 or ARRDC1).

Another aspect of this invention includes arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (ARMMs) that comprise a lipid bilayer and an ARRDC1 protein or variant thereof, a Cas9 cargo protein or Cas9 variant, and/or a TSG101 protein or variant thereof. In certain embodiments, the Cas9 cargo protein or variant is linked to the TSG101 protein or variant thereof that contains a UEV domain. In other embodiments, the Cas9 cargo protein or variant is linked to the ARRDC1 protein or variant thereof. The Cas9 protein, or variant thereof, may be linked to ARRDC1 or TSG101, or variants thereof, by a linker. The linker could be a covalent bond or another linker, such as a cleavable linker. As an example, the linker may be protein linker engineered to have a protease recognition site or a UV-cleavable moiety. The cleavable linker may be cleaved in a target cell to release the cargo protein into the cytoplasm of the target cell.

Some aspects of this invention provide fusion proteins that can be loaded in an ARMM. For example, the fusion protein may be a Cas9 protein or a Cas9 variant fused to an ARRDC1 protein, or variant thereof, or a TSG101protein, or variant thereof. Alternatively, the fusion protein may be a cargo protein (e.g., a Cas9 protein or Cas9 variant) fused to one or more WW domains. In order to facilitate translocation into the nucleus, a Cas9 fusion protein may comprise a nuclear localization sequence (NLS). An additional aspect of the invention provides nucleic acid constructs encoding any of the fusion proteins, or any associated gRNAs, described herein.

Some aspects of this invention provide microvesicle-producing cells containing recombinant expression constructs that encode any of the cargo proteins, described herein. For example, the microvesicle-producing cells may contain an expression construct encoding an ARRDC1 protein, or a variant thereof, under the control of a heterologous promoter, and a recombinant expression construct encoding a cargo protein under the control of a heterologous promoter, where the cargo protein is fused to at least one WW domain or variant thereof. Other aspects of this invention include microvesicle-producing cells containing recombinant expression constructs encoding an ARRDC1 protein or a variant thereof fused to a Cas9 cargo protein or variant thereof. In certain embodiments, the microvesicle-producing cells contain a recombinant expression vector encoding a TSG101 protein or variant thereof fused to a cas9 cargo protein or variant thereof. The microvesicle-producing cells may also contain expression constructs that encode one or more gRNAs which can associate with any of the RNA-guided nucleases, described herein. The microvesicle-producing cells, described herein, may be capable of producing an ARMM.

Various other aspects of this invention provide methods of delivering a cargo protein to a target cell by contacting the target cell with a microvesicle (e.g., an ARMM), which may be done by contacting the target cell with an isolated ARMM or co-culturing the target cell with a cell that produces an ARMM. The target cell may be contacted with an ARMM in vitro, in vivo, or ex vivo. In some embodiments, the target cell is a cell in a subject and the method comprises administering the microvesicle or the microvesicle-producing cell to the subject. The microvesicle may be linked to a targeting moiety, such as a membrane-bound immunoglobulin, that selectively binds an antigen, for example, a surface antigen of the target cell.

Other aspects of this invention provide methods of gene editing and methods of altering expression of at least one gene, comprising contacting the target cell with any of the ARMMs, or an ARMM producing cells, described herein. As one example, a Cas9 cargo protein may be delivered to a target cell, via an ARMM, to correct a genetic mutation in that cell. As another example, a nuclease inactive Cas9 variant fused to a transcriptional activator (e.g., VP64) may be delivered to a target cell, via an ARMM, to increase the expression of a gene of interest.

Other advantages, features, and uses of the invention will be apparent from the detailed description of certain exemplary, non-limiting embodiments; the drawings; the non-limiting working examples; and the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic of a ubiquitin ligase protein (top) showing the conserved protein domains including the phospholipid binding C2 domain, four WW domains that bind PPXY motifs, and the HECT ubiquitin ligase domain. Exemplary ubiquitin ligases (bottom) include Nedd4-1, Nedd4-2, WWP1, WWP2, Smurf1, Smurf2, ITCH, NEDL1, and NEDL2.

FIG. 2 is a schematic of an ARRDC1 protein containing a PPXY motif that binds a WW domain fused to a Cas9 protein.

FIG. 3 is a schematic of the PX330 plasmid (top) which expresses a humanized Streptococcus pyogenes Cas9 protein with nuclear localization sequences (NLSs). The schematic shows that one or more WW domains may be fused toward the N-terminus of the fusion protein using the AgeI restriction site. Additionally, one or more WW domains may be fused toward the N-terminus of the fusion protein using the AgeI restriction site (not shown), which is located between the CBh promoter and the first NLS. The schematic also shows the guide sequence insertion site (bottom), which is under the control of the U6 promoter. A guide sequence (e.g., a gRNA) may be cloned into the plasmid using the BbsI restriction site.

FIG. 4 is a schematic demonstrating the production of an ARMM in a microvesicle-producing cell that contains a Cas9:WW domain fusion protein, which associates with a gRNA and the ARRDC1 protein of the ARMM to facilitate the loading of the Cas9:WW domain fusion protein into the ARMM. The gRNA may be co-expressed with the Cas9 and thus co-incorporated into ARMMs (left). The ARMM may then be delivered to a target cell (right), where the Cas9:WW domain fusion protein is released into the cytoplasm of the target cell. The Cas9:WW domain fusion protein may then translocate into the nucleus, which may be facilitated by one or more NLSs, to perform a gene editing function.

FIG. 5 provides Western blots shows that WW-Cas9 is incorporated into ARMMs. (A) Western blotting result of samples from the total cell lysates. 293T cells were transfected with 2 protein-expressing plasmids. Lane 1: GFP and Cas9; lane 2: GFP and 2WW-Cas9; lane 3: GFP and 4WW-Cas9; lane 4: ARRDC1-GFP and Cas9; lane 5: ARRDC1-GFP and 2WW-Cas9; lane 6: ARRDC1-GFP and 4WW-Cas9; The upper panel shows the Western blotting result using antibody against the FLAG-tag, which is fused to the Cas9 protein. The lower panel shows the Western blotting result using anti-GFP antibody. Western blotting result of samples of purified ARMMs from condition media (B) of transfected 293T cells. The order of the lanes is the same as in (A). The 2WW-Cas9 and 4WW-Cas9 fusion proteins are efficiently incorporated into ARMMs when ARRDC1-GFP is expressed in the microvesicle-producing 293T cells.

FIG. 6 provides representative Western blots showing that little to no Cas9 fusion protein is released from ARRDC1-null cells, but exogenous ARRDC1 expression facilitated the incorporation of Cas9 into ARMMs. Western blotting results of samples from the total cell lysates (A) of 293T ARRDC1-null cells transfected with the following plasmids: GFP and empty vector DNA (lane 1); GFP and Cas9 (lane 2); GFP and 4WW-Cas9 (lane 3); empty vector and Cas9 (lane 4); ARRDC1-GFP and Cas9 (lane 5); ARRDC1-GFP and 4WW-Cas9 (lane 6); The upper panel shows the Western blotting result using antibody against the Flag-tag, which is fused to the Cas9 protein. The lower panel shows the Western blotting result using anti-GFP antibody. The Western blotting result of samples of purified ARMMs (B) from condition media of transfected 293T cells has the same order of the lanes as in (A). The results demonstrate that ARRDC1 is both necessary and sufficient for the incorporation of a WW-Cas9 fusion protein into ARMMs.

FIG. 7 is a graph showing that a guide RNA (gRNA) is also incorporated into ARMMs. 293T cells were transfected with either control DNA (bar 1), or 2WW-Cas9 (bar 2), or 2WW-Cas9 and HA-ARRDC1 (bar 3). 2WW-Cas9 was constructed in a PX330 backbone, which contains the gRNA coding sequences. ARMMs were collected from the condition media of the transfected cells 48 hours post transfection. RNAs were extracted from purified ARMMs. qRT-PCR was done to measure gRNA expression. Values of GAPDH gene expression were used for normalization.

FIG. 8 shows representative fluorescence activated cell sorting (FACS) data showing WW-fused Cas9 is as effective as unmodified Cas9 in genome-editing. 293T-EGFP cells were transfected with different DNA constructs. 48 hours post transfection GFP signal was examined in transfected cells by flow cytometry. (A) Cells were transfected with control DNA. (B) Cells were transfected with Cas9. (C) Cells were transfected with Cas9-anti-GFP, which contains gRNA targeting the GFP gene. (D) Cells were transfected with 2WW-Cas9-anti-GFP, which contains gRNA targeting the GFP gene and in which the Cas 9 is fused to first two WW domains of the ITCH protein.

FIG. 9 is a schematic representation of how the efficiency of WW-Cas9 in ARMMs in decreasing gene expression of recipient cells may be tested. In this representation (A), the microvesicle-producing “donor cells” express 4WW-Cas9, a gRNA that targets GFP (4WW-Cas9-anti-GFP), and an HA tagged ARRDC1 protein (HA-ARRDC1). The ARMMs produced by the donor cell are administered to GFP expressing “recipient cells” and the amount of GFP expression in the recipient cell may be measured by flow cytometry (B) to determine the efficiency of preventing gene expression or even sort the cells using fluorescence-activated cell sorting (FACS).

DEFINITIONS

The term “ARMM,” as used herein, refers to a microvesicle comprising an ARRDC1 protein or variant thereof, and/or TSG101 protein or variant thereof. In some embodiments, the ARMM is shed from a cell, and comprises a molecule, for example, a nucleic acid, protein, or small molecule, present in the cytoplasm or associated with the membrane of the cell. In some embodiments, the ARMM is shed from a transgenic cell comprising a recombinant expression construct that includes the transgene, and the ARMM comprises a gene product, for example, a transcript or a protein (e.g., a cargo protein) encoded by the expression construct. In some embodiments, the protein encoded by the expression construct is a Cas9 cargo protein fused to at least one WW domain, or variant thereof, which may associate with the ARRDC1 protein to facilitate loading of the Cas9 cargo protein into the ARMM. In some embodiments, the ARMM is produced synthetically, for example, by contacting a lipid bilayer within ARRDC1 protein, or variant thereof, in a cell-free system in the presence of TSG101, or a variant thereof. In other embodiments, the ARMM is synthetically produced by further contacting a lipid bilayer with HECT domain ligase, and VPS4a. In some embodiments, an ARMM lacks a late endosomal marker. Some ARMMs as provided herein do not include, or are negative for, one or more exosomal biomarker. Exosomal biomarkers are known to those of skill in the art and include, but are not limited to, CD63, Lamp-1, Lamp-2, CD9, HSPA8, GAPDH, CD81, SDCBP, PDCD6IP, ENO1, ANXA2, ACTB, YWHAZ, HSP90AA1, ANXAS, EEF1A1, YWHAE, PPIA, MSN, CFL1, ALDOA, PGK1, EEF2, ANXA1, PKM2, HLA-DRA, and YWHAB. For example, some ARMMs provided herein lack CD63, some ARMMs lack LAMP1, some ARMMs lack CD9, some ARMMs lack CD81, some ARMMs lack CD63 and Lamp-1, some ARMMs lack CD63, Lamp-1, and CD9, some ARMMs lack CD63, Lamp-1, CD81, and CD9, and so forth. Certain ARMMs provided herein may include an exosomal biomarker. Accordingly, some ARMMs may be negative for one or more exosomal biomarker, but positive for one or more different exosomal biomarker. For example, such an ARMM may be negative for CD63 and Lamp-1, but may include PGK1 or GAPDH; or may be negative for CD63, Lamp-1, CD9, and CD81, but may be positive for HLA-DRA. In some embodiments, ARMMs include an exosomal biomarker, but at a lower level than a level found in exosomes. For example, some ARMMs include one or more exosomal biomarkers at a level of less than about 1%, less than about 5%, less than about 10%, less than about 20%, less than about 30%, less than about 40%, or less than about 50% of the level of that biomarker found in exosomes. To give a non-limiting example, in some embodiments, an ARMM may be negative for CD63 and Lamp-1, include CD9 at a level of less than about 5% of the level of CD9 typically found in exosomes, and be positive for ACTB. Exosomal biomarkers in addition to those listed above are known to those of skill in the art, and the invention is not limited in this regard.

Cargo protein: The term “cargo protein”, as used herein, refers to a protein that may be incorporated in an ARMM, for example, into the liquid phase of the ARMM or into the lipid bilayer of an ARMM. The term “cargo protein to be delivered” refers to any protein that can be delivered via its association with or inclusion in an ARMM to a subject, organ, tissue, or cell. In some embodiments, the cargo protein is to be delivered to a target cell in vitro, in vivo, or ex vivo. In some embodiments, the cargo protein to be delivered is a biologically active agent, i.e., it has activity in a cell, organ, tissue, and/or subject. For instance, a protein that, when administered to a subject, has a biological effect on that subject, is considered to be biologically active. In certain embodiments the cargo protein is a nuclease or variant thereof (e.g., a Cas9 protein or variant thereof). In certain embodiments, the nuclease may be a Cas9 nuclease, a TALE nuclease, a zinc finger nuclease, or any variant thereof. Nucleases, including Cas9 proteins and their variants, are described in more detail elsewhere herein. In some embodiments, the Cas9 protein or variant thereof is associated with a nucleic acid. For example, the cargo protein may be a Cas9 protein associated with a gRNA. In some embodiments, a cargo protein to be delivered is a therapeutic agent. As used herein, the term “therapeutic agent” refers to any agent that, when administered to a subject, has a beneficial effect. In some embodiments, the cargo protein to be delivered to a cell is a transcription factor, a tumor suppressor, a developmental regulator, a growth factor, a metastasis suppressor, a pro-apoptotic protein, a nuclease, or a recombinase. In some embodiments, the protein to be delivered is p53, Rb (retinoblastoma protein), BRCA1, BRCA2, PTEN, APC, CD95, ST7, ST14, a BCL-2 family protein, a caspase; BRMS1, CRSP3, DRG1, KAI1, KISS1, NM23, a TIMP-family protein, a BMP-family growth factor, EGF, EPO, FGF, G-CSF, GM-CSF, a GDF-family growth factor, HGF, HDGF, IGF, PDGF, TPO, TGF-α, TGF-β, VEGF; a zinc finger nuclease, Cre, Dre, or FLP recombinase. In some embodiments, the cargo protein is associated with a small molecule. In some embodiments, the cargo protein to be delivered is a diagnostic agent. In some embodiments, the cargo protein to be delivered is a prophylactic agent. In some embodiments, the cargo protein to be delivered is useful as an imaging agent. In some of these embodiments, the diagnostic or imaging agent is, and in others it is not, biologically active.

The term “linker,” as used herein, refers to a chemical moiety linking two molecules or moieties, e.g., an ARRDC1 protein and a Cas9 nuclease. Typically, the linker is positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond, thus connecting the two. In some embodiments, the linker comprises an amino acid or a plurality of amino acids (e.g., a peptide or protein). In some embodiments, the linker is an organic molecule, group, polymer, or other chemical moiety. In some embodiments, the linker is a cleavable linker, e.g., the linker comprises a bond that can be cleaved upon exposure to, for example, UV light or a hydrolytic enzyme, such as a lysosomal protease. In some embodiments, the linker is any stretch of amino acids having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, or more amino acids. In other embodiments, the linker is a chemical bond (e.g., a covalent bond). Animal: As used herein, the term “animal” refers to any member of the animal kingdom.

In some embodiments, the term “animal” refers to a human of either sex at any stage of development. In some embodiments, the term “animal” refers to a non-human animal at any stage of development. In certain embodiments, the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, or a pig). Animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, and worms. In some embodiments, the animal is a transgenic animal, genetically-engineered animal, or a clone. In some embodiments, the animal is a transgenic non-human animal, genetically-engineered non-human animal, or a non-human clone.

Approximately: As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (for example, when such number would exceed 100% of a possible value).

Associated with: As used herein, the term “associated with,” when used with respect to two or more entities, for example, with chemical moieties, molecules, and/or ARMMs, means that the entities are physically associated or connected with one another, either directly or via one or more additional moieties that serves as a linker, to form a structure that is sufficiently stable so that the entities remain physically associated under the conditions in which the structure is used, e.g., physiological conditions. An ARMM is typically associated with an agent, for example, a nucleic acid, protein, or small molecule, by a mechanism that involves a covalent or non-covalent association. In certain embodiments, the agent to be delivered is covalently bound to a molecule that is part of the ARMM, for example, an ARRCD1 protein or variant thereof, a TSG101 protein or variant thereof, or a lipid or protein that forms part of the lipid bilayer of the ARMM. In some embodiments, a peptide or protein is associated with an ARRCD1 protein or variant thereof, a TSG101 protein or variant thereof, or a lipid bilayer-associated protein by a covalent bond (e.g., an amide bond). In some embodiments, the association is via a linker, for example, a cleavable linker. In some embodiments, an entity is associated with an ARMM by inclusion in the ARMM, for example, by encapsulation of an entity (e.g., a protein) within the ARMM. For example, in some embodiments, an agent present in the cytoplasm of an ARMM-producing cell is associated with an ARMM by encapsulation of the cytoplasm with the agent in the ARMM upon ARMM budding. Similarly, a membrane protein or other molecule associated with the cell membrane of an ARMM producing cell may be associated with an ARMM produced by the cell by inclusion into the ARMM's membrane upon budding.

Biologically active: As used herein, the phrase “biologically active” refers to a characteristic of any substance that has activity in a cell, organ, tissue and/or subject. For instance, a substance that, when administered to an organism, has a biological effect on that organism, is considered to be biologically active. As one example, a nuclease cargo protein may be considered biologically active if it increases or decreases the expression of a gene product when administered to a subject.

Conserved: As used herein, the term “conserved” refers to nucleotides or amino acid residues of a polynucleotide sequence or amino acid sequence, respectively, that are those that occur unaltered in the same position of two or more related sequences being compared. Nucleotides or amino acids that are relatively conserved are those that are conserved amongst more related sequences than nucleotides or amino acids appearing elsewhere in the sequences. In some embodiments, two or more sequences are said to be “completely conserved” if they are 100% identical to one another. In some embodiments, two or more sequences are said to be “highly conserved” if they are at least 70% identical, at least 80% identical, at least 90% identical, or at least 95% identical to one another. In some embodiments, two or more sequences are said to be “highly conserved” if they are about 70% identical, about 80% identical, about 90% identical, about 95% identical, about 98% identical, or about 99% identical to one another. In some embodiments, two or more sequences are said to be “conserved” if they are at least 30% identical, at least 40% identical, at least 50% identical, at least 60% identical, at least 70% identical, at least 80% identical, at least 90% identical, or at least 95% identical to one another. In some embodiments, two or more sequences are said to be “conserved” if they are about 30% identical, about 40% identical, about 50% identical, about 60% identical, about 70% identical, about 80% identical, about 90% identical, about 95% identical, about 98% identical, or about 99% identical to one another.

The term “engineered,” as used herein refers to a protein, nucleic acid, complex, substance, or entity that has been designed, produced, prepared, synthesized, and/or manufactured by a human. Accordingly, an engineered product is a product that does not occur in nature. In some embodiments, an engineered protein or nucleic acid is a protein or nucleic acid that has been designed to meet particular requirements or to have particular design features. For example, a Cas9 cargo protein may be engineered to associate with the ARRDC1 by fusing one or more WW domains to the Cas9 protein to facilitate loading of the Cas9 cargo protein into an ARMM. As another example, a guide RNA (gRNA) may be engineered to target the delivery of a Cas9 cargo protein to a specific genomic sequence.

Expression: As used herein, “expression” of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA transcript from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5′cap formation, and/or 3′ end processing); (3) translation of an RNA transcript into a polypeptide or protein; and (4) post-translational modification of a polypeptide or protein.

Fusion protein: As used herein, a “fusion protein” includes a first protein moiety, e.g., an ARRCD1 protein or variant thereof, or a TSG101 protein or variant thereof, associated with a second protein moiety, for example, a cargo protein to be delivered to a target cell through a peptide linkage. In certain embodiments, the fusion protein is encoded by a single fusion gene.

Gene: As used herein, the term “gene” has its meaning as understood in the art. It will be appreciated by those of ordinary skill in the art that the term “gene” may include gene regulatory sequences (e.g., promoters, enhancers, etc.) and/or intron sequences. It will further be appreciated that definitions of gene include references to nucleic acids that do not encode proteins but rather encode functional RNA molecules such as gRNAs, RNAi agents, ribozymes, tRNAs, etc. For the purpose of clarity it should be noted that, as used in the present application, the term “gene” generally refers to a portion of a nucleic acid that encodes a protein; the term may optionally encompass regulatory sequences, as will be clear from context to those of ordinary skill in the art. This definition is not intended to exclude application of the term “gene” to non-protein-coding expression units but rather to clarify that, in most cases, the term as used in this document refers to a protein-coding nucleic acid.

Gene product or expression product: As used herein, the term “gene product” or “expression product” generally refers to an RNA transcribed from the gene (pre-and/or post-processing) or a polypeptide (pre- and/or post-modification) encoded by an RNA transcribed from the gene.

Green fluorescent protein: As used herein, the term “green fluorescent protein” (GFP) refers to a protein originally isolated from the jellyfish Aequorea victoria that fluoresces green when exposed to blue light or a derivative of such a protein (e.g., an enhanced or wavelength-shifted version of the protein). The amino acid sequence of wild type GFP is as follows:

(SEQ ID NO: 35) MSKGEELFTG VVPILVELDG DVNGHKFSVS GEGEGDATYG KLTLKFICTT GKLPVPWPTL VTTFSYGVQC FSRYPDHMKQ HDFFKSAMPE GYVQERTIFF KDDGNYKTRA EVKFEGDTLV NRIELKGIDF KEDGNILGHK LEYNYNSHNV YIMADKQKNG IKVNFKIRHN IEDGSVQLAD HYQQNTPIGD GPVLLPDNHY LSTQSALSKD PNEKRDHMVL LEFVTAAGIT HGMDELYK Proteins that are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous are also considered to be green fluorescent proteins.

Homology: As used herein, the term “homology” refers to the overall relatedness between nucleic acids (e.g. DNA molecules and/or RNA molecules) or polypeptides. In some embodiments, nucleic acids or proteins are considered to be “homologous” to one another if their sequences are at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical. In some embodiments, nucleic acids or proteins are considered to be “homologous” to one another if their sequences are at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% similar. The term “homologous” necessarily refers to a comparison between at least two sequences (nucleotide sequences or amino acid sequences). In accordance with the invention, two nucleotide sequences are considered to be homologous if the polypeptides they encode are at least about 50% identical, at least about 60% identical, at least about 70% identical, at least about 80% identical, or at least about 90% identical for at least one stretch of at least about 20 amino acids. In some embodiments, homologous nucleotide sequences are characterized by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. Both the identity and the approximate spacing of these amino acids relative to one another must be considered for sequences to be considered homologous. For nucleotide sequences less than 60 nucleotides in length, homology is determined by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. In accordance with the invention, two protein sequences are considered to be homologous if the proteins are at least about 50% identical, at least about 60% identical, at least about 70% identical, at least about 80% identical, or at least about 90% identical for at least one stretch of at least about 20 amino acids.

Identity: As used herein, the term “identity” refers to the overall relatedness between nucleic acids or proteins (e.g. DNA molecules, RNA molecules, and/or polypeptides). Calculation of the percent identity of two nucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and second nucleic acid sequence for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be determined using methods such as those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; each of which is incorporated herein by reference. For example, the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4:11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleotide sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix. Methods commonly employed to determine percent identity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., SIAM J Applied Math., 48:1073 (1988); incorporated herein by reference. Techniques for determining identity are codified in publicly available computer programs. Exemplary computer software to determine homology between two sequences include, but are not limited to, GCG program package, Devereux, J., et al., Nucleic Acids Research, 12(1), 387 (1984)), BLASTP, BLASTN, and FASTA Atschul, S. F. et al., J. Molec. Biol., 215, 403 (1990)).

In vitro: As used herein, the term “in vitro” refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, in a Petri dish, etc., rather than within an organism (e.g., animal, plant, or microbe).

In vivo: As used herein, the term “in vivo” refers to events that occur within an organism (e.g., animal, plant, or microbe).

Isolated: As used herein, the term “isolated” refers to a substance or entity that has been (1) separated from at least some of the components with which it was associated when initially produced (whether in nature or in an experimental setting), and/or (2) produced, prepared, and/or manufactured by the hand of man. Isolated substances and/or entities may be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more of the other components with which they were initially associated. In some embodiments, isolated substances are more than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is “pure” if it is substantially free of other components.

Nucleic acid: As used herein, the term “nucleic acid,” in its broadest sense, refers to a compound and/or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester linkage. In some embodiments, “nucleic acid” refers to individual nucleic acid residues (e.g. nucleotides and/or nucleosides). In some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising individual nucleic acid residues. As used herein, the terms “oligonucleotide” and “polynucleotide” can be used interchangeably to refer to a polymer of nucleotides (e.g., a string of at least two nucleotides). In some embodiments, “nucleic acid” encompasses RNA as well as single and/or double-stranded DNA and/or cDNA. Furthermore, the terms “nucleic acid,” “DNA,” “RNA,” and/or similar terms include nucleic acid analogs, i.e. analogs having other than a phosphodiester backbone. For example, the so-called “peptide nucleic acids,” which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention. The term “nucleotide sequence encoding an amino acid sequence” includes all nucleotide sequences that are degenerate versions of each other and/or encode the same amino acid sequence. Nucleotide sequences that encode proteins and/or RNA may include introns. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, backbone modifications, etc. A nucleic acid sequence is presented in the 5′ to 3′ direction unless otherwise indicated. The term “nucleic acid segment” is used herein to refer to a nucleic acid sequence that is a portion of a longer nucleic acid sequence. In many embodiments, a nucleic acid segment comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more residues. In some embodiments, a nucleic acid is or comprises natural nucleosides (e.g. adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadeno sine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (e.g., 2′-fluororibose, ribose, 2′-deoxyribose, arabinose, and hexose); and/or modified phosphate groups (e.g., phosphorothioates and 5′-N-phosphoramidite linkages). In some embodiments, the present invention is specifically directed to “unmodified nucleic acids,” meaning nucleic acids (e.g. polynucleotides and residues, including nucleotides and/or nucleosides) that have not been chemically modified in order to facilitate or achieve delivery.

Protein: As used herein, the term “protein,” refers to a string of at least two amino acids linked to one another by one or more peptide bonds. Proteins may include moieties other than amino acids (e.g., may be glycoproteins) and/or may be otherwise processed or modified. Those of ordinary skill in the art will appreciate that a “protein” can be a complete protein chain as produced by a cell (with or without a signal sequence), or can be a functional portion thereof. Those of ordinary skill will further appreciate that a protein can sometimes include more than one protein chain, for example linked by one or more disulfide bonds or associated by other means. Proteins may contain L-amino acids, D-amino acids, or both and may contain any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, e.g., addition of a chemical entity such as a carbohydrate group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, an amide group, a terminal acetyl group, a linker for conjugation, functionalization, or other modification (e.g., alpha amidation), etc. In certain embodiments, the modifications of the protein lead to a more stable protein (e.g., greater half-life in vivo). These modifications may include cyclization of the protein, the incorporation of D-amino acids, etc. None of the modifications should substantially interfere with the desired biological activity of the protein. In certain embodiments, the modifications of the protein lead to a more biologically active protein. In some embodiments, proteins may comprise natural amino acids, non-natural amino acids, synthetic amino acids, amino acid analogs, and combinations thereof.

Reprogramming factor: As used herein, the term “reprogramming factor” refers to a factor that, alone or in combination with other factors, can change the state of a cell from a somatic, differentiated state into a pluripotent stem cell state. Non-limiting examples of reprogramming factors include a protein (e.g., a transcription factor), a peptide, a nucleic acid, or a small molecule. Known reprogramming factors that are useful for cell reprogramming include, but are not limited to Oct4, Sox2, Klf4, and c-myc. Similarly, a programming factor may be used to modulate cell differentiation, for example, to facilitate or induce cell differentiation towards a desired lineage.

Subject: As used herein, the term “subject” or “patient” refers to any organism to which a composition in accordance with the invention may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans) and/or plants.

Therapeutically effective amount: As used herein, the term “therapeutically effective amount” means an amount of an agent to be delivered (e.g., nucleic acid, protein, drug, therapeutic agent, diagnostic agent, prophylactic agent, etc.) that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and/or condition, to treat, improve symptoms of, diagnose, prevent, and/or delay the onset of the disease, disorder, and/or condition.

Transcription factor: As used herein, the term “transcription factor” refers to a DNA-binding protein that regulates transcription of DNA into RNA, for example, by activation or repression of transcription. Some transcription factors effect regulation of transcription alone, while others act in concert with other proteins. Some transcription factor can both activate and repress transcription under certain conditions. In general, transcription factors bind a specific target sequence or sequences highly similar to a specific consensus sequence in a regulatory region of a target gene. Transcription factors may regulate transcription of a target gene alone or in a complex with other molecules. Examples of transcription factors include, but are not limited to, Sp1, NF1, CCAAT, GATA, HNF, PIT-1, MyoD, Myf5, Hox, Winged Helix, SREBP, p53, CREB, AP-1, Mef2, STAT, R-SMAD, NF-KB, Notch, TUBBY, and NFAT.

Treating: As used herein, the term “treating” refers to partially or completely preventing, and/or reducing incidence of one or more symptoms or features of a particular disease or condition. For example, “treating” cancer may refer to inhibiting survival, growth, and/or spread of a tumor. Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition and/or to a subject who exhibits only early signs of a disease, or condition for the purpose of decreasing the risk of developing more severe effects associated with the disease, or condition.

Vector: As used herein, “vector” refers to a nucleic acid molecule which can transport another nucleic acid to which it has been linked. In some embodiment, vectors can achieve extra-chromosomal replication and/or expression of nucleic acids to which they are linked in a host cell such as a eukaryotic and/or prokaryotic cell. Vectors capable of directing the expression of operatively linked genes are referred to herein as “expression vectors.”

The term “Cas9” or “Cas9 protein” refers to an RNA-guided nuclease comprising a Cas9 protein, or a variant thereof (e.g., a protein comprising an active, inactive, or altered DNA cleavage domain of Cas9, and/or the gRNA binding domain of Cas9). A Cas9 nuclease is also referred to sometimes as a casnl nuclease or a CRISPR (clustered regularly interspaced short palindromic repeat)-associated nuclease. CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and a Cas9 protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently, Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer. The target strand not complementary to crRNA is first cut endonucleolytically, then trimmed 3′-5′ exonucleolytically. In nature, DNA-binding and cleavage typically requires protein and both RNAs. However, single guide RNAs (“sgRNA”, or simply “gNRA”) can be engineered so as to incorporate aspects of both the crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science 337:816-821(2012), the entire contents of which is hereby incorporated by reference. Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus non-self. Cas9 nuclease sequences and structures are well known to those of skill in the art (see, e.g., “Complete genome sequence of an M1 strain of Streptococcus pyogenes.” Ferretti et al., J. J., McShan W. M., Ajdic D. J., Savic D. J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A. N., Kenton S., Lai H. S., Lin S. P., Qian Y., Jia H. G., Najar F. Z., Ren Q., Zhu H., Song L., White J., Yuan X., Clifton S. W., Roe B. A., McLaughlin R. E., Proc. Natl. Acad. Sci. U.S.A. 98:4658-4663(2001); “CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.” Deltcheva E., Chylinski K., Sharma C. M., Gonzales K., Chao Y., Pirzada Z. A., Eckert M. R., Vogel J., Charpentier E., Nature 471:602-607(2011); and “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.” Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science 337:816-821(2012), the entire contents of each of which are incorporated herein by reference). Cas9 orthologs have been described in various species, including, but not limited to, S. pyogenes and S. thermophilus. Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, “The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems” (2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by reference. In some embodiments, a Cas9 nuclease has an inactive (e.g., an inactivated) DNA cleavage domain.

A nuclease-inactivated Cas9 protein may interchangeably be referred to as a “dCas9” protein (for nuclease-“dead” Cas9). Methods for generating a Cas9 protein (or a variant thereof) having an inactive DNA cleavage domain are known (See, e.g., Jinek et al., Science. 337:816-821(2012); Qi et al., “Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression” (2013) Cell. 28; 152(5):1173-83, the entire contents of each of which are incorporated herein by reference). For example, the DNA cleavage domain of Cas9 is known to include two subdomains, the HNH nuclease subdomain and the RuvC1 subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, whereas the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, the mutations D10A and H841A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al., Science. 337:816-821(2012); Qi et al., Cell. 28; 152(5):1173-83 (2013). In some embodiments, proteins comprising variants of Cas9 are provided. For example, in some embodiments, a protein comprises one of two Cas9 domains: (1) the gRNA binding domain of Cas9; or (2) the DNA cleavage domain of Cas9. In some embodiments, proteins comprising Cas9 or variants thereof are referred to as “Cas9 variants.” A Cas9 variant shares homology to Cas9, or a variant thereof. For example a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to wild type Cas9. In some embodiments, the Cas9 variant comprises a variant of Cas9 (e.g., a gRNA binding domain or a DNA-cleavage domain), such that the variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to the corresponding variant of wild type Cas9. In some embodiments, wild type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence: NC_017053.1, SEQ ID NO:1 (nucleotide); SEQ ID NO:2 (amino acid)).

(SEQ ID NO: 1) ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACAAATAGCGTCGGATGGGCGGTGATCACTGATGATTATAA GGTTCCGTCTAAAAAGTTCAAGGTTCTGGGAAATACAGACCGCCACAGTATCAAAAAAAATCTTATAGGGGCTCTTT TATTTGGCAGTGGAGAGACAGCGGAAGCGACTCGTCTCAAACGGACAGCTCGTAGAAGGTATACACGTCGGAAGAAT CGTATTTGTTATCTACAGGAGATTTTTTCAAATGAGATGGCGAAAGTAGATGATAGTTTCTTTCATCGACTTGAAGA GTCTTTTTTGGTGGAAGAAGACAAGAAGCATGAACGTCATCCTATTTTTGGAAATATAGTAGATGAAGTTGCTTATC ATGAGAAATATCCAACTATCTATCATCTGCGAAAAAAATTGGCAGATTCTACTGATAAAGCGGATTTGCGCTTAATC TATTTGGCCTTAGCGCATATGATTAAGTTTCGTGGTCATTTTTTGATTGAGGGAGATTTAAATCCTGATAATAGTGA TGTGGACAAACTATTTATCCAGTTGGTACAAATCTACAATCAATTATTTGAAGAAAACCCTATTAACGCAAGTAGAG TAGATGCTAAAGCGATTCTTTCTGCACGATTGAGTAAATCAAGACGATTAGAAAATCTCATTGCTCAGCTCCCCGGT GAGAAGAGAAATGGCTTGTTTGGGAATCTCATTGCTTTGTCATTGGGATTGACCCCTAATTTTAAATCAAATTTTGA TTTGGCAGAAGATGCTAAATTACAGCTTTCAAAAGATACTTACGATGATGATTTAGATAATTTATTGGCGCAAATTG GAGATCAATATGCTGATTTGTTTTTGGCAGCTAAGAATTTATCAGATGCTATTTTACTTTCAGATATCCTAAGAGTA AATAGTGAAATAACTAAGGCTCCCCTATCAGCTTCAATGATTAAGCGCTACGATGAACATCATCAAGACTTGACTCT TTTAAAAGCTTTAGTTCGACAACAACTTCCAGAAAAGTATAAAGAAATCTTTTTTGATCAATCAAAAAACGGATATG CAGGTTATATTGATGGGGGAGCTAGCCAAGAAGAATTTTATAAATTTATCAAACCAATTTTAGAAAAAATGGATGGT ACTGAGGAATTATTGGTGAAACTAAATCGTGAAGATTTGCTGCGCAAGCAACGGACCTTTGACAACGGCTCTATTCC CCATCAAATTCACTTGGGTGAGCTGCATGCTATTTTGAGAAGACAAGAAGACTTTTATCCATTTTTAAAAGACAATC GTGAGAAGATTGAAAAAATCTTGACTTTTCGAATTCCTTATTATGTTGGTCCATTGGCGCGTGGCAATAGTCGTTTT GCATGGATGACTCGGAAGTCTGAAGAAACAATTACCCCATGGAATTTTGAAGAAGTTGTCGATAAAGGTGCTTCAGC TCAATCATTTATTGAACGCATGACAAACTTTGATAAAAATCTTCCAAATGAAAAAGTACTACCAAAACATAGTTTGC TTTATGAGTATTTTACGGTTTATAACGAATTGACAAAGGTCAAATATGTTACTGAGGGAATGCGAAAACCAGCATTT CTTTCAGGTGAACAGAAGAAAGCCATTGTTGATTTACTCTTCAAAACAAATCGAAAAGTAACCGTTAAGCAATTAAA AGAAGATTATTTCAAAAAAATAGAATGTTTTGATAGTGTTGAAATTTCAGGAGTTGAAGATAGATTTAATGCTTCAT TAGGCGCCTACCATGATTTGCTAAAAATTATTAAAGATAAAGATTTTTTGGATAATGAAGAAAATGAAGATATCTTA GAGGATATTGTTTTAACATTGACCTTATTTGAAGATAGGGGGATGATTGAGGAAAGACTTAAAACATATGCTCACCT CTTTGATGATAAGGTGATGAAACAGCTTAAACGTCGCCGTTATACTGGTTGGGGACGTTTGTCTCGAAAATTGATTA ATGGTATTAGGGATAAGCAATCTGGCAAAACAATATTAGATTTTTTGAAATCAGATGGTTTTGCCAATCGCAATTTT ATGCAGCTGATCCATGATGATAGTTTGACATTTAAAGAAGATATTCAAAAAGCACAGGTGTCTGGACAAGGCCATAG TTTACATGAACAGATTGCTAACTTAGCTGGCAGTCCTGCTATTAAAAAAGGTATTTTACAGACTGTAAAAATTGTTG ATGAACTGGTCAAAGTAATGGGGCATAAGCCAGAAAATATCGTTATTGAAATGGCACGTGAAAATCAGACAACTCAA AAGGGCCAGAAAAATTCGCGAGAGCGTATGAAACGAATCGAAGAAGGTATCAAAGAATTAGGAAGTCAGATTCTTAA AGAGCATCCTGTTGAAAATACTCAATTGCAAAATGAAAAGCTCTATCTCTATTATCTACAAAATGGAAGAGACATGT ATGTGGACCAAGAATTAGATATTAATCGTTTAAGTGATTATGATGTCGATCACATTGTTCCACAAAGTTTCATTAAA GACGATTCAATAGACAATAAGGTACTAACGCGTTCTGATAAAAATCGTGGTAAATCGGATAACGTTCCAAGTGAAGA AGTAGTCAAAAAGATGAAAAACTATTGGAGACAACTTCTAAACGCCAAGTTAATCACTCAACGTAAGTTTGATAATT TAACGAAAGCTGAACGTGGAGGTTTGAGTGAACTTGATAAAGCTGGTTTTATCAAACGCCAATTGGTTGAAACTCGC CAAATCACTAAGCATGTGGCACAAATTTTGGATAGTCGCATGAATACTAAATACGATGAAAATGATAAACTTATTCG AGAGGTTAAAGTGATTACCTTAAAATCTAAATTAGTTTCTGACTTCCGAAAAGATTTCCAATTCTATAAAGTACGTG AGATTAACAATTACCATCATGCCCATGATGCGTATCTAAATGCCGTCGTTGGAACTGCTTTGATTAAGAAATATCCA AAACTTGAATCGGAGTTTGTCTATGGTGATTATAAAGTTTATGATGTTCGTAAAATGATTGCTAAGTCTGAGCAAGA AATAGGCAAAGCAACCGCAAAATATTTCTTTTACTCTAATATCATGAACTTCTTCAAAACAGAAATTACACTTGCAA ATGGAGAGATTCGCAAACGCCCTCTAATCGAAACTAATGGGGAAACTGGAGAAATTGTCTGGGATAAAGGGCGAGAT TTTGCCACAGTGCGCAAAGTATTGTCCATGCCCCAAGTCAATATTGTCAAGAAAACAGAAGTACAGACAGGCGGATT CTCCAAGGAGTCAATTTTACCAAAAAGAAATTCGGACAAGCTTATTGCTCGTAAAAAAGACTGGGATCCAAAAAAAT ATGGTGGTTTTGATAGTCCAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGAAAAAGGGAAATCGAAGAAG TTAAAATCCGTTAAAGAGTTACTAGGGATCACAATTATGGAAAGAAGTTCCTTTGAAAAAAATCCGATTGACTTTTT AGAAGCTAAAGGATATAAGGAAGTTAAAAAAGACTTAATCATTAAACTACCTAAATATAGTCTTTTTGAGTTAGAAA ACGGTCGTAAACGGATGCTGGCTAGTGCCGGAGAATTACAAAAAGGAAATGAGCTGGCTCTGCCAAGCAAATATGTG AATTTTTTATATTTAGCTAGTCATTATGAAAAGTTGAAGGGTAGTCCAGAAGATAACGAACAAAAACAATTGTTTGT GGAGCAGCATAAGCATTATTTAGATGAGATTATTGAGCAAATCAGTGAATTTTCTAAGCGTGTTATTTTAGCAGATG CCAATTTAGATAAAGTTCTTAGTGCATATAACAAACATAGAGACAAACCAATACGTGAACAAGCAGAAAATATTATT CATTTATTTACGTTGACGAATCTTGGAGCTCCCGCTGCTTTTAAATATTTTGATACAACAATTGATCGTAAACGATA TACGTCTACAAAAGAAGTTTTAGATGCCACTCTTATCCATCAATCCATCACTGGTCTTTATGAAACACGCATTGATT TGAGTCAGCTAGGAGGTGACTGA (SEQ ID NO: 2) MDKKYSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFGSGETAEATRLKRTARRRYTRRKN RICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLADSTDKADLRLI YLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQIYNQLFEENPINASRVDAKAILSARLSKSRRLENLIAQLPG EKRNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRV NSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDG TEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRF AWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAF LSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGAYHDLLKIIKDKDFLDNEENEDIL EDIVLTLTLFEDRGMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGHSLHEQIANLAGSPAIKKGILQTVKIVDELVKVMGHKPENIVIEMARENQTTQ KGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFIK DDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETR QITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYP KLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRD FATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKK LKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYV NFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENII HLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD (single underline: HNH domain; double underline: RuvC domain)

In some embodiments, wild type Cas9 corresponds to, or comprises SEQ ID NO:3 (nucleotide) and/or SEQ ID NO: 4 (amino acid):

(SEQ ID NO: 3) ATGGATAAAAAGTATTCTATTGGTTTAGACATCGGCACTAATTCCGTTG GATGGGCTGTCATAACCGATGAATACAAAGTACCTTCAAAGAAATTTAA GGTGTTGGGGAACACAGACCGTCATTCGATTAAAAAGAATCTTATCGGT GCCCTCCTATTCGATAGTGGCGAAACGGCAGAGGCGACTCGCCTGAAAC GAACCGCTCGGAGAAGGTATACACGTCGCAAGAACCGAATATGTTACTT ACAAGAAATTTTTAGCAATGAGATGGCCAAAGTTGACGATTCTTTCTTT CACCGTTTGGAAGAGTCCTTCCTTGTCGAAGAGGACAAGAAACATGAAC GGCACCCCATCTTTGGAAACATAGTAGATGAGGTGGCATATCATGAAAA GTACCCAACGATTTATCACCTCAGAAAAAAGCTAGTTGACTCAACTGAT AAAGCGGACCTGAGGTTAATCTACTTGGCTCTTGCCCATATGATAAAGT TCCGTGGGCACTTTCTCATTGAGGGTGATCTAAATCCGGACAACTCGGA TGTCGACAAACTGTTCATCCAGTTAGTACAAACCTATAATCAGTTGTTT GAAGAGAACCCTATAAATGCAAGTGGCGTGGATGCGAAGGCTATTCTTA GCGCCCGCCTCTCTAAATCCCGACGGCTAGAAAACCTGATCGCACAATT ACCCGGAGAGAAGAAAAATGGGTTGTTCGGTAACCTTATAGCGCTCTCA CTAGGCCTGACACCAAATTTTAAGTCGAACTTCGACTTAGCTGAAGATG CCAAATTGCAGCTTAGTAAGGACACGTACGATGACGATCTCGACAATCT ACTGGCACAAATTGGAGATCAGTATGCGGACTTATTTTTGGCTGCCAAA AACCTTAGCGATGCAATCCTCCTATCTGACATACTGAGAGTTAATACTG AGATTACCAAGGCGCCGTTATCCGCTTCAATGATCAAAAGGTACGATGA ACATCACCAAGACTTGACACTTCTCAAGGCCCTAGTCCGTCAGCAACTG CCTGAGAAATATAAGGAAATATTCTTTGATCAGTCGAAAAACGGGTACG CAGGTTATATTGACGGCGGAGCGAGTCAAGAGGAATTCTACAAGTTTAT CAAACCCATATTAGAGAAGATGGATGGGACGGAAGAGTTGCTTGTAAAA CTCAATCGCGAAGATCTACTGCGAAAGCAGCGGACTTTCGACAACGGTA GCATTCCACATCAAATCCACTTAGGCGAATTGCATGCTATACTTAGAAG GCAGGAGGATTTTTATCCGTTCCTCAAAGACAATCGTGAAAAGATTGAG AAAATCCTAACCTTTCGCATACCTTACTATGTGGGACCCCTGGCCCGAG GGAACTCTCGGTTCGCATGGATGACAAGAAAGTCCGAAGAAACGATTAC TCCATGGAATTTTGAGGAAGTTGTCGATAAAGGTGCGTCAGCTCAATCG TTCATCGAGAGGATGACCAACTTTGACAAGAATTTACCGAACGAAAAAG TATTGCCTAAGCACAGTTTACTTTACGAGTATTTCACAGTGTACAATGA ACTCACGAAAGTTAAGTATGTCACTGAGGGCATGCGTAAACCCGCCTTT CTAAGCGGAGAACAGAAGAAAGCAATAGTAGATCTGTTATTCAAGACCA ACCGCAAAGTGACAGTTAAGCAATTGAAAGAGGACTACTTTAAGAAAAT TGAATGCTTCGATTCTGTCGAGATCTCCGGGGTAGAAGATCGATTTAAT GCGTCACTTGGTACGTATCATGACCTCCTAAAGATAATTAAAGATAAGG ACTTCCTGGATAACGAAGAGAATGAAGATATCTTAGAAGATATAGTGTT GACTCTTACCCTCTTTGAAGATCGGGAAATGATTGAGGAAAGACTAAAA ACATACGCTCACCTGTTCGACGATAAGGTTATGAAACAGTTAAAGAGGC GTCGCTATACGGGCTGGGGACGATTGTCGCGGAAACTTATCAACGGGAT AAGAGACAAGCAAAGTGGTAAAACTATTCTCGATTTTCTAAAGAGCGAC GGCTTCGCCAATAGGAACTTTATGCAGCTGATCCATGATGACTCTTTAA CCTTCAAAGAGGATATACAAAAGGCACAGGTTTCCGGACAAGGGGACTC ATTGCACGAACATATTGCGAATCTTGCTGGTTCGCCAGCCATCAAAAAG GGCATACTCCAGACAGTCAAAGTAGTGGATGAGCTAGTTAAGGTCATGG GACGTCACAAACCGGAAAACATTGTAATCGAGATGGCACGCGAAAATCA AACGACTCAGAAGGGGCAAAAAAACAGTCGAGAGCGGATGAAGAGAATA GAAGAGGGTATTAAAGAACTGGGCAGCCAGATCTTAAAGGAGCATCCTG TGGAAAATACCCAATTGCAGAACGAGAAACTTTACCTCTATTACCTACA AAATGGAAGGGACATGTATGTTGATCAGGAACTGGACATAAACCGTTTA TCTGATTACGACGTCGATCACATTGTACCCCAATCCTTTTTGAAGGACG ATTCAATCGACAATAAAGTGCTTACACGCTCGGATAAGAACCGAGGGAA AAGTGACAATGTTCCAAGCGAGGAAGTCGTAAAGAAAATGAAGAACTAT TGGCGGCAGCTCCTAAATGCGAAACTGATAACGCAAAGAAAGTTCGATA ACTTAACTAAAGCTGAGAGGGGTGGCTTGTCTGAACTTGACAAGGCCGG ATTTATTAAACGTCAGCTCGTGGAAACCCGCCAAATCACAAAGCATGTT GCACAGATACTAGATTCCCGAATGAATACGAAATACGACGAGAACGATA AGCTGATTCGGGAAGTCAAAGTAATCACTTTAAAGTCAAAATTGGTGTC GGACTTCAGAAAGGATTTTCAATTCTATAAAGTTAGGGAGATAAATAAC TACCACCATGCGCACGACGCTTATCTTAATGCCGTCGTAGGGACCGCAC TCATTAAGAAATACCCGAAGCTAGAAAGTGAGTTTGTGTATGGTGATTA CAAAGTTTATGACGTCCGTAAGATGATCGCGAAAAGCGAACAGGAGATA GGCAAGGCTACAGCCAAATACTTCTTTTATTCTAACATTATGAATTTCT TTAAGACGGAAATCACTCTGGCAAACGGAGAGATACGCAAACGACCTTT AATTGAAACCAATGGGGAGACAGGTGAAATCGTATGGGATAAGGGCCGG GACTTCGCGACGGTGAGAAAAGTTTTGTCCATGCCCCAAGTCAACATAG TAAAGAAAACTGAGGTGCAGACCGGAGGGTTTTCAAAGGAATCGATTCT TCCAAAAAGGAATAGTGATAAGCTCATCGCTCGTAAAAAGGACTGGGAC CCGAAAAAGTACGGTGGCTTCGATAGCCCTACAGTTGCCTATTCTGTCC TAGTAGTGGCAAAAGTTGAGAAGGGAAAATCCAAGAAACTGAAGTCAGT CAAAGAATTATTGGGGATAACGATTATGGAGCGCTCGTCTTTTGAAAAG AACCCCATCGACTTCCTTGAGGCGAAAGGTTACAAGGAAGTAAAAAAGG ATCTCATAATTAAACTACCAAAGTATAGTCTGTTTGAGTTAGAAAATGG CCGAAAACGGATGTTGGCTAGCGCCGGAGAGCTTCAAAAGGGGAACGAA CTCGCACTACCGTCTAAATACGTGAATTTCCTGTATTTAGCGTCCCATT ACGAGAAGTTGAAAGGTTCACCTGAAGATAACGAACAGAAGCAACTTTT TGTTGAGCAGCACAAACATTATCTCGACGAAATCATAGAGCAAATTTCG GAATTCAGTAAGAGAGTCATCCTAGCTGATGCCAATCTGGACAAAGTAT TAAGCGCATACAACAAGCACAGGGATAAACCCATACGTGAGCAGGCGGA AAATATTATCCATTTGTTTACTCTTACCAACCTCGGCGCTCCAGCCGCA TTCAAGTATTTTGACACAACGATAGATCGCAAACGATACACTTCTACCA AGGAGGTGCTAGACGCGACACTGATTCACCAATCCATCACGGGATTATA TGAAACTCGGATAGATTTGTCACAGCTTGGGGGTGACGGATCCCCCAAG AAGAAGAGGAAAGTCTCGAGCGACTACAAAGACCATGACGGTGATTATA AAGATCATGACATCGATTACAAGGATGACGATGACAAGGCTGCAGGA (SEQ ID NO: 4) MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIG ALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFF HRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTD KADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALS LGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAK NLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQL PEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVK LNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIE KILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQS FIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAF LSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFN ASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSD GFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIK KGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMK RIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDI NRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKK MKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETR QITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQF YKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVR KMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETN GETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPK RNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQ KQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLI HQSITGLYETRIDLSQLGGD  (single underline: HNH domain; double underline: RuvC domain)

In some embodiments, dCas9 corresponds to, or comprises in part or in whole, a Cas9 amino acid sequence having one or more mutations that inactivate the Cas9 nuclease activity. For example, in some embodiments, a dCas9 domain comprises D10A and/or H820A mutation. dCas9 (D10A and H840A):

(SEQ ID NO: 5) MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKN RICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLI YLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPG EKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRV NTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDG TEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRF AWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAF LSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDIL EDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTT QKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFL KDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVET RQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSK KLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKY VNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD (single underline: HNH domain; double underline: RuvC domain)

In other embodiments, dCas9 variants having mutations other than D10A and H820A are provided, which e.g., result in nuclease inactivated Cas9 (dCas9). Such mutations, by way of example, include other amino acid substitutions at D10 and H820, or other substitutions within the nuclease domains of Cas9 (e.g., substitutions in the HNH nuclease subdomain and/or the RuvC1 subdomain). In some embodiments, variants or homologues of dCas9 (e.g., variants of SEQ ID NO: 5) are provided which are at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to SEQ ID NO:5. In some embodiments, variants of dCas9 (e.g., variants of SEQ ID NO: 5) are provided having amino acid sequences which are shorter, or longer than SEQ ID NO: 5, by about 5 amino acids, by about 10 amino acids, by about 15 amino acids, by about 20 amino acids, by about 25 amino acids, by about 30 amino acids, by about 40 amino acids, by about 50 amino acids, by about 75 amino acids, by about 100 amino acids or more.

In some embodiments, Cas9 fusion proteins as provided herein comprise the full-length amino acid of a Cas9 protein, e.g., one of the sequences provided above. In other embodiments, however, fusion proteins as provided herein do not comprise a full-length Cas9 sequence, but only a fragment thereof. For example, in some embodiments, a Cas9 fusion protein provided herein comprises a Cas9 fragment, wherein the fragment binds crRNA and tracrRNA or sgRNA, but does not comprise a functional nuclease domain, e.g., in that it comprises only a truncated version of a nuclease domain or no nuclease domain at all. Exemplary amino acid sequences of suitable Cas9 domains and Cas9 fragments are provided herein, and additional suitable sequences of Cas9 domains and fragments will be apparent to those of skill in the art.

In some embodiments, Cas9 refers to Cas9 from: Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC_017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquisI (NCBI Ref: NC_018721.1); Streptococcus thermophilus (NCBI Ref: YP_820832.1); Listeria innocua (NCBI Ref: NP_472073.1); Campylobacter jejuni (NCBI Ref: YP_002344900.1); or Neisseria meningitidis (NCBI Ref: YP_002342100.1). The term “deaminase” refers to an enzyme that catalyzes a deamination reaction. In some embodiments, the deaminase is a cytidine deaminase, catalyzing the hydrolytic deamination of cytidine or deoxycytidine to uracil or deoxyuracil, respectively.

The terms “RNA-programmable nuclease” and “RNA-guided nuclease” are used interchangeably herein and refer to a nuclease that forms a complex with (e.g., binds or associates with) one or more RNA molecule that is not a target for cleavage. In some embodiments, an RNA-programmable nuclease, when in a complex with an RNA, may be referred to as a nuclease:RNA complex. RNA-programmable nucleases include Cas9 nucleases. Typically, the bound RNA(s) is referred to as a guide RNA (gRNA). gRNAs can exist as a complex of two or more RNAs, or as a single RNA molecule. gRNAs that exist as a single RNA molecule may be referred to as single-guide RNAs (sgRNAs), though “gRNA” is used interchangeably to refer to guide RNAs that exist as either single molecules or as two or more molecules. Typically, gRNAs that exist as single RNA species comprise two domains: (1) a domain that shares homology to a target nucleic acid (e.g., and directs binding of a Cas9 complex to the target); and (2) a domain that binds a Cas9 protein. The gRNA comprises a nucleotide sequence that complements a target site, which mediates binding of the nuclease/RNA complex to said target site and providing the sequence specificity of the nuclease:RNA complex.

The term “recombinase,” as used herein, refers to a site-specific enzyme that mediates the recombination of DNA between recombinase recognition sequences, which results in the excision, integration, inversion, or exchange (e.g., translocation) of DNA fragments between the recombinase recognition sequences. Recombinases can be classified into two distinct families: serine recombinases (e.g., resolvases and invertases) and tyrosine recombinases (e.g., integrases).

Examples of serine recombinases include, without limitation, Hin, Gin, Tn3, β-six, CinH, ParA, γδ, Bxb1, ϕC31, TP901, TG1, φBT1, R4, φRV1, φFC1, MR11, A118, U153, and gp29. Examples of tyrosine recombinases include, without limitation, Cre, FLP, R, Lambda, HK101, HK022, and pSAM2. The serine and tyrosine recombinase names stem from the conserved nucleophilic amino acid residue that the recombinase uses to attack the DNA and which becomes covalently linked to the DNA during strand exchange. Recombinases have numerous applications, including the creation of gene knockouts/knock-ins and gene therapy applications. See, e.g., Brown et al., “Serine recombinases as tools for genome engineering.” Methods. 2011; 53(4):372-9; Hirano et al., “Site-specific recombinases as tools for heterologous gene integration.” Appl. Microbiol. Biotechnol. 2011; 92(2):227-39; Chavez and Calos, “Therapeutic applications of the ΦC31 integrase system.” Curr. Gene Ther. 2011; 11(5):375-81; Turan and Bode, “Site-specific recombinases: from tag-and-target- to tag-and-exchange-based genomic modifications.” FASEB J. 2011; 25(12):4088-107; Venken and Bellen, “Genome-wide manipulations of Drosophila melanogaster with transposons, Flp recombinase, and ΦC31 integrase.” Methods Mol. Biol. 2012; 859:203-28; Murphy, “Phage recombinases and their applications.” Adv. Virus Res. 2012; 83:367-414; Zhang et al., “Conditional gene manipulation: Cre-ating a new biological era.” J. Zhejiang Univ. Sci. B. 2012; 13(7):511-24; Karpenshif and Bernstein, “From yeast to mammals: recent advances in genetic control of homologous recombination.” DNA Repair (Amst). 2012; 1; 11(10):781-8; the entire contents of each are hereby incorporated by reference in their entirety. The recombinases provided herein are not meant to be exclusive examples of recombinases that can be used in embodiments of the invention. The methods and compositions of the invention can be expanded by mining databases for new orthogonal recombinases or designing synthetic recombinases with defined DNA specificities (See, e.g., Groth et al., “Phage integrases: biology and applications.” J. Mol. Biol. 2004; 335, 667-678; Gordley et al., “Synthesis of programmable integrases.” Proc. Natl. Acad. Sci. USA. 2009; 106, 5053-5058; the entire contents of each are hereby incorporated by reference in their entirety). Other examples of recombinases that are useful in the methods and compositions described herein are known to those of skill in the art, and any new recombinase that is discovered or generated is expected to be able to be used in the different embodiments of the invention. In some embodiments, a recombinase (or catalytic domain thereof) is fused to a Cas9 protein (e.g., dCas9).

The term “recombine” or “recombination,” in the context of a nucleic acid modification (e.g., a genomic modification), is used to refer to the process by which two or more nucleic acid molecules, or two or more regions of a single nucleic acid molecule, are modified by the action of a recombinase protein. Recombination can result in, inter alia, the insertion, inversion, excision, or translocation of a nucleic acid sequence, e.g., in or between one or more nucleic acid molecules.

The term “WW domain” as described herein, is a protein domain having two basic residues at the C-terminus that mediates protein-protein interactions with short proline-rich or proline-containing motifs. The WW domain possessing the two basic C-terminal amino acid residues may have the ability to associate with short proline-rich or proline-containing motifs (i.e., a PPXY motif). WW domains bind a variety of distinct peptide ligands including motifs with core proline-rich sequences, such as PPXY, which is found in AARDC1. A WW domain may be a 30-40 amino acid protein interaction domain with two signature tryptophan residues spaced by 20-22 amino acids. The three-dimensional structure of WW domains shows that they generally fold into a three-stranded, antiparallel β sheet with two ligand-binding grooves.

WW domains are found in many eukaryotes and are present in approximately 50 human proteins (Bork, P. & Sudol, M. The WW domain: a signaling site in dystrophin? Trends Biochem Sci 19, 531-533 (1994)). WW domains may be present together with several other interaction domains, including membrane targeting domains, such as C2 in the NEDD4 family proteins, the phosphotyrosine-binding (PTB) domain in FE65 protein, FF domains in CA150 and FBPI1, and pleckstrin homology (PH) domains in PLEKHAS. WW domains are also linked to a variety of catalytic domains, including HECT E3 protein-ubiquitin ligase domains in NEDD4 family proteins, rotomerase or peptidyl prolyisomerase domains in Pinl, and Rho GAP domains in ArhGAP9 and ArhGAP12.

In the instant disclosure, the WW domain may be a WW domain that naturally possesses two basic amino acids at the C-terminus, for example a WW domain or WW domain variant may be from the human ubiquitin ligase WWP1, WWP2, Nedd4-1, Nedd4-2, Smurf1, Smurf2, ITCH, NEDL1, or NEDL2. Exemplary amino acid sequences of WW domain containing proteins (WW domains underlined) are listed below. It should be appreciated that any of the WW domains or WW domain variants of the exemplary proteins may be used in the invention, described herein, and are not meant to be limiting.

Human WWP1 amino acid sequence (uniprot.org/uniprot/Q9HOM0). The four underlined WW domains correspond to amino acids 349-382 (WW1), 381-414 (WW2), 456-489 (WW3), and 496-529 (WW4).

(SEQ ID NO: 6) MATASPRSDT SNNHSGRLQL QVTVSSAKLK RKKNWFGTAI YTEVVVDGEI  50 TKTAKSSSSS NPKWDEQLTV NVTPQTTLEF QVWSHRTLKA DALLGKATID 100 LKQALLIHNR KLERVKEQLK LSLENKNGIA QTGELTVVLD GLVIEQENIT 150 NCSSSPTIEI QENGDALHEN GEPSARTTAR LAVEGTNGID NHVPTSTLVQ 200 NSCCSYVVNG DNTPSSPSQV AARPKNTPAP KPLASEPADD TVNGESSSFA 250 PTDNASVTGT PVVSEENALS PNCTSTTVED PPVQEILTSS ENNECIPSTS 300 AELESEARSI LEPDTSNSRS SSAFEAAKSR QPDGCMDPVR QQSGNANTET 350 LPSGWEQRKD PHGRTYYVDH NTRTTTWERP QPLPPGWERR VDDRRRVYYV 400 DHNTRTTTWQ RPTMESVRNF EQWQSQRNQL QGAMQQFNQR YLYSASMLAA 450 ENDPYGPLPP GWEKRVDSTD RVYFVNHNTK TTQWEDPRTQ GLQNEEPLPE 500 GWEIRYTREG VRYFVDHNTR TTTFKDPRNG KSSVTKGGPQ IAYERGFRWK 550 LAHFRYLCQS NALPSHVKIN VSRQTLFEDS FQQIMALKPY DLRRRLYVIF 600 RGEEGLDYGG LAREWFFLLS HEVLNTMYCL FEYAGKNNYC LQINPASTIN 650 PDHLSYFCFI GRFIAMALFH GKFIDTGFSL PFYKRMLSKK LTIKDLESID 700 TEFYNSLIWI RDNNIEECGL EMYFSVDMEI LGKVTSHDLK LGGSNILVTE 750 ENKDEYIGLM TEWRFSRGVQ EQTKAFLDGF NEVVPLQWLQ YFDEKELEVM 800 LCGMQEVDLA DWQRNTVYRH YTRNSKQIIW FWQFVKETDN EVRMRLLQFV 850 TGTCRLPLGG FAELMGSNGP QKFCIEKVGK DTWLPRSHTC FNRLDLPPYK 900 SYEQLKEKLL FAIEETEGFG QE 922 WW1 (349-382): (SEQ ID NO: 36) ETLPSGWEQRKDPHGRTYYVDHNTRTTTWERPQP. WW2 (381-414): (SEQ ID NO: 37) QPLPPGWERRVDDRRRVYYVDHNTRTTTWQRPTM. WW3 (456-489): (SEQ ID NO: 38) ENDPYGPLPPGWEKRVDSTDRVYFVNHNTKTTQWEDPRT. WW4 (496-529): (SEQ ID NO: 39) EPLPEGWEIRYTREGVRYFVDHNTRTTTFKDPRN.

Human WWP2 amino acid sequence (uniprot.org/uniprot/ O00308). The four underlined WW domains correspond to amino acids 300-333 (WW1), 330-363 (WW2), 405-437 (WW3), and 444-547 (WW4).

(SEQ ID NO: 7) MASASSSRAG VALPFEKSQL TLKVVSAKPK VHNRQPRINS YVEVAVDGLP  50 SETKKTGKRI GSSELLWNEI IILNVTAQSH LDLKVWSCHT LRNELLGTAS 100 VNLSNVLKNN GGKMENMQLT LNLQTENKGS VVSGGELTIF LDGPTVDLGN 150 VPNGSALTDG SQLPSRDSSG TAVAPENRHQ PPSTNCFGGR SRTHRHSGAS 200 ARTTPATGEQ SPGARSRHRQ PVKNSGHSGL ANGTVNDEPT TATDPEEPSV 250 VGVTSPPAAP LSVTPNPNTT SLPAPATPAE GEEPSTSGTQ QLPAAAQAPD 300 ALPAGWEQRE LPNGRVYYVD HNTKTTTWER PLPPGWEKRT DPRGRFYYVD 350 HNIRTTTWQR PTAEYVRNYE QWQSQRNQLQ GAMQHFSQRF LYQSSSASTD 400 HDPLGPLPPG WEKRQDNGRV YYVNHNTRTT QWEDPRTQGM IQEPALPPGW 450 EMKYTSEGVR YFVDHNTRTT TFKDPRPGFE SGTKQGSPGA YDRSFRWKYH 500 QFRFLCHSNA LPSHVKISVS RQTLFEDSFQ QIMNMKPYDL RRRLYIIMRG 550 EEGLDYGGIA REWFFLLSHE VLNPMYCLFE YAGKNNYCLQ INPASSINPD  600 HLTYFRFIGR FIAMALYHGK FIDTGFTLPF YKRMLNKRPT LKDLESIDPE 650 FYNSIVWIKE NNLEECGLEL YFIQDMEILG KVTTHELKEG GESIRVTEEN 700 KEEYIMLLTD WRFTRGVEEQ TKAYLDGFNE VAPLEWLRYF DEKELELMLC 750 GMQEIDMSDW QKSTIYRHYT KNSKQIQWFW QVVKEMDNEK RIRLLQFVTG 300 TCRLPVGGFA ELIGSNGPQK FCIDKVGKET WLPRSHTCFN RLDLPPYKSY 850 EQLREKLLYA IEETEGFGQE   870 WW1 (300-333): (SEQ ID NO: 40) DALPAGWEQRELPNGRVYYVDHNTKTTTWERPLP. WW2 (330-363): (SEQ ID NO: 41) PLPPGWEKRT DPRGRFYYVDHNTRTTTWQRPTA. WW3 (405-437): (SEQ ID NO: 42) HDPLGPLPPGWEKRQDNGRVYYVNHNTRTTQWEDPRT. WW4 (444-477): (SEQ ID NO: 43) PALPPGWEMKYTSEGVRYFVDHNTRTTTFKDPRP.

Human Nedd4-1 amino acid sequence (uniprot.org/uniprot/ P46934). The four underlined WW domains correspond to amino acids 610-643 (WW1), 767-800 (WW2), 840-873 (WW3), and 892-925 (WW4).

(SEQ ID NO: 8) MAQSLRLHFA ARRSNTYPLS ETSGDDLDSH VHMCFKRPTR ISTSNVVQMK   50 LTPRQTALAP LIKENVQSQE RSSVPSSENV NKKSSCLQIS LQPTRYSGYL  100 QSSNVLADSD DASFTCILKD GIYSSAVVDN ELNAVNDGHL VSSPAICSGS  150 LSNFSTSDNG SYSSNGSDFG SCASITSGGS YTNSVISDSS SYTFPPSDDT  200 FLGGNLPSDS TSNRSVPNRN TTPCEIFSRS TSTDPFVQDD LEHGLEIMKL  250 PVSRNTKIPL KRYSSLVIFP RSPSTTRPTS PTSLCTLLSK GSYQTSHQFI  300 ISPSEIAHNE DGTSAKGFLS TAVNGLRLSK TICTPGEVRD IRPLHRKGSL  250 QKKIVLSNNT PRQTVCEKSS EGYSCVSVHF TQRKAATLDC ETTNGDCKPE  400 MSEIKLNSDS EYIKLMHRTS ACLPSSQNVD CQININGELE RPHSQMNKNH  450 GILRRSISLG GAYPNISCLS SLKHNCSKGG PSQLLIKFAS GNEGKVDNLS  500 RDSNRDCTNE LSNSCKTRDD FLGQVDVPLY PLPTENPRLE RPYTFKDFVL  550 HPRSHKSRVK GYLRLKMTYL PKTSGSEDDN AEQAEELEPG WVVLDQPDAA  600 CHLQQQQEPS PLPPGWEERQ DILGRTYYVN HESRRTQWKR PTPQDNLTDA  650 ENGNIQLQAQ RAFTTPPQIS EETESVDNRE SSENWEIIRE DEATMYSNQA  700 FPSPPPSSNL DVPTHLAEEL NARLTIFGNS AVSQPASSSN HSSRRGSLQA  750 YTFEEQPTLP VLLPTSSGLP PGWEEKQDER GRSYYVDHNS RTTTWTKPTV  800 QATVETSQLT SSQSSAGPQS QASTSDSGQQ VTQPSEIEQG FLPKGWEVRH  850 APNGRPFFID HNTKTTTWED PRLKIPAHLR GKTSLDTSND LGPLPPGWEE  900 RTHTDGRIFY INHNIKRTQW EDPRLENVAI TGPAVPYSRD YKRKYEFFPR  950 KLKKQNDIPN KFEMKLRRAT VLEDSYRRIM GVKRADFLKA RLWIEFDGEK 1000 GLDYGGVARE WFFLISKEMF NPYYGLFEYS ATDNYTLOIN PNSGLCNEDH 1050 LSYFKFIGRV AGMAVYHGKL LDGFFIRPFY KMMLHKPITL HDMESVDSEY 1100 YNSLRWILEN DPTELDLRFI IDEELFGQTH QHELKNGGSE IVVTNKNKKE 1150 YIYLVIQWRF VNRIQKQMAA FKEGFFELIP QDLIKIFDEN ELELLMCGLG 1200 DVDVNDWREH TKYKNGYSAN HQVIQWFWKA VLMMDSEKRI RLLQFVTGTS 1250 RVPMNGFAEL YGSNGPQSFT VEQWGTPEKL PRAHTCFNRL DLPPYESFEE 1300 LWDKLQMAIE NTQGFDGVD 1319 WW1 (610-643): (SEQ ID NO: 44) SPLPPGWEERQDILGRTYYVNHESRRTQWKRPTP. WW2 (767-800): (SEQ ID NO: 45) SGLPPGWEEKQDERGRSYYVDHNSRTTTWTKPTV. WW3 (840-873): (SEQ ID NO: 46) GFLPKGWEVRHAPNGRPFFIDHNTKTTTWEDPRL. WW4 (892-925): (SEQ ID NO: 47) GPLPPGWEERTHTDGRIFYINHNIKRTQWEDPRL.

Human Nedd4-2 amino acid sequence (>gi|21361472|ref|NP_056092.2|E3 ubiquitin-protein ligase NEDD4-like isoform 3 [Homo sapiens]). The four underlined WW domains correspond to amino acids 198-224 (WW1), 368-396 (WW2), 480-510 (WW3), and 531-561 (WW4).

(SEQ ID NO: 9) MATGLGEPVYGLSEDEGESRILRVKVVSGIDLAKKDIFGASDPYVKLSLYVADENRELA LVQTKTIKKTLNPKWNEEFYFRVNPSNHRLLFEVFDENRLTRDDFLGQVDVPLSHLPTE DPTMERPYTFKDFLLRPRSHKSRVKGFLRLKMAYMPKNGGQDEENSDQRDDMEHGWE VVDSNDSASQHQEELPPPPLPPGWEEKVDNLGRTYYVNHNNRTTQWHRPSLMDVSSES DNNIRQINQEAAHRRFRSRRHISEDLEPEPSEGGDVPEPWETISEEVNIAGDSLGLALPPPP ASPGSRTSPQELSEELSRRLQITPDSNGEQFSSLIQREPSSRLRSCSVTDAVAEQGHLPPPS VAYVHTTPGLPSGWEERKDAKGRTYYVNHNNRTTTWTRPIMQLAEDGASGSATNSNN HLIEPQIRRPRSLSSPTVTLSAPLEGAKDSPVRRAVKDTLSNPQSPQPSPYNSPKPQHKVT QSFLPPGWEMRIAPNGRPFFIDHNTKTTTWEDPRLKFPVHMRSKTSLNPNDLGPLPPGW EERIFILDGRTFYIDHNSKITQWEDPRLQNPAITGPAVPYSREFKQKYDYFRKKLKKPADI PNRFEMKLHRNNIFEESYRRIMSVKRPDVLKARLWIEFESEKGLDYGGVAREWFFLLSK EMFNPYYGLFEYSATDNYTLQINPNSGLCNEDHLSYFTFIGRVAGLAVFHGKLLDGFFIR PFYKMMLGKQITLNDMESVDSEYYNSLKWILENDPTELDLMFCIDEENFGQTYQVDLKP NGSEIMVTNENKREYIDLVIQWRFVNRVQKQMNAFLEGFTELLPIDLIKIFDENELELLM CGLGDVDVNDWRQHSIYKNGYCPNHPVIQWFWKAVLLMDAEKRIRLLQFVTGTSRVP MNGFAELYGSNGPQLFTIEQWGSPEKLPRAHTCFNRLDLPPYETFEDLREKLLMAVENA QGFEGVD WW1 (198-224): (SEQ ID NO: 61) GWEEKVDNLGRTYYVNHNNRTTQWHRP. WW2 (368-396): (SEQ ID NO: 62) PSGWEERKDAKGRTYYVNHNNRTTTWTRP. WW3 (480-510): (SEQ ID NO: 63) PPGWEMRIAPNGRPFFIDHNTKTTTWEDPRL. WW4 (531-561): (SEQ ID NO: 64) PPGWEERIHLDGRTFYIDHNSKITQWEDPRL. (SEQ ID NO: 12) MSDSGSQLGS MGSLTMKSQL QITVISAKLK ENKKNWFGPS PYVEVTVDGQ  50 SKKTEKCNNT NSPKWKQPLT VIVTPVSKLH FRVWSHQTLK SDVLLGTAAL 100 DIYETLKSNN MKLEEVVVTL QLGGDKEPTE TIGDLSICLD GLQLESEVVT 150 NGETTCSENG VSLCLPRLEC NSAISAHCNL CLPGLSDSPI SASRVAGFTG 200 ASQNDDGSRS KDETRVSTNG SDDPEDAGAG ENRRVSGNNS PSLSNGGFKP 250 SRPPRPSRPP PPTPRRPASV NGSPSATSES DGSSTGSLPP TNTNTNTSEG 300 ATSGLIIPLT ISGGSGPRPL NPVTQAPLPP GWEQRVDQHG RVYYVDHVEK 350 RTTWDRPEPL PPGWERRVDN MGRIYYVDHF TRTTTWQRPT LESVRNYEQW 400 QLQRSQLQGA MQQFNQRFIY GNQDLFATSQ SKEFDPLGPL PPGWEKRTDS 450 NGRVYFVNHN TRITQWEDPR SQGQLNEKPL PEGWEMRFTV DGIPYFVDHN 500 RRTTTYIDPR TGKSALDNGP QIAYVRDFKA KVQYFRFWCQ QLAMPQHIKI 550 TVTRKTLFED SFQQIMSFSP QDLRRRLWVI FPGEEGLDYG GVAREWFFLL 600 SHEVLNPMYC LFEYAGKDNY CLQINPASYI NPDHLKYFRF IGRFIAMALF 650 HGKFIDTGFS LPFYKRILNK PVGLKDLESI DPEFYNSLIW VKENNIEECD 700 LEMYFSVDKE ILGEIKSHDL KPNGGNILVT EENKEEYIRM VAEWRLSRGV 750 EEQTQAFFEG FNEILPQQYL QYFDAKELEV LLCGMQEIDL NDWQRHAIYR 800 HYARTSKQIM WFWQFVKEID NEKRMRLLQF VTGTCRLPVG GFADLMGSNG 850 PQKFCIEKVG KENWLPRSHT CFNRLDLPPY KSYEQLKEKL LFAIEETEGF 900 GQE 903 ITCH WW1 (326-359): (SEQ ID NO: 53) APLPPGWEQRVDQHGRVYYVDHVEKRTTWDRPEP. ITCH WW2 (358-391): (SEQ ID NO: 54) EPLPPGWERRVDNMGRIYYVDHFTRTTTWQRPTL. ITCH WW3 (438-471): (SEQ ID NO: 55) GPLPPGWEKRTDSNGRVYFVNHNTRITQWEDPRS. ITCH WW4 (478-511): (SEQ ID NO: 56) KPLPEGWEMRFTVDGIPYFVDHNRRTTTYIDPRT. (SEQ ID NO: 14) MASSAREHLL FVRRRNPQMR YTLSPENLQS LAAQSSMPEN MTLQRANSDT   50 DLVTSESRSS LTASMYEYTL GQAQNLIIFW DIKEEVDPSD WIGLYHIDEN  100 SPANFWDSKN RGVTGTQKGQ IVWRIEPGPY FMEPEIKICF KYYHGISGAL  150 RATTPCITVK NPAVMMGAEG MEGGASGNLH SRKLVSFTLS DLRAVGLKKG  200 MFFNPDPYLK MSIQPGKKSS FPTCAHHGQE RRSTIISNTT NPIWHREKYS  250 FFALLTDVLE IEIKDKFAKS RPIIKRFLGK LTIPVQRLLE RQAIGDQMLS  300 YNLGRRLPAD HVSGYLQFKV EVTSSVHEDA SPEAVGTILG VNSVNGDLGS  350 PSDDEDMPGS HHDSQVCSNG PVSEDSAADG TPKHSFRTSS TLEIDTEELT  400 STSSPTSPPR GRQDSLNDYL DAIEHNGHSR PGTATCSERS MGASPKLRSS  450 FPTDTRLNAM LHIDSDEEDH EFQQDLGYPS SLEEEGGLIM FSRASRADDG  500 SLTSQTKLED NPVENEEAST HEAASFEDKP ENLPELAESS LPAGPAPEEG  550 EGGPEPQPSA DQGSAELCGS QEVDQPTSGA DTGTSDASGG SRRAVSETES  600 LDQGSEPSQV SSETEPSDPA RTESVSEAST RPEGESDLEC ADSSCNESVT  650 TQLSSVDTRC SSLESARFPE TPAFSSQEEE DGACAAEPTS SGPAEGSQES  700 VCTAGSLPVV QVPSGEDEGP GAESATVPDQ EELGEVWQRR GSLEGAAAAA  750 ESPPQEEGSA GRAQGTCEGA TAQEEGATGG SQANGHQPLR SLPSVRQDVS  800 RYQRVDEALP PNWEARIDSH GRIFYVDHVN RTTTWQRPTA PPAPQVLORS  850 NSIQQMEQLN RRYQSIRRTM TNERPEENTN AIDGAGEEAD FHQASADFRR  900 ENILPHSTSR SRITLLLQSP PVKFLISPEF FTVLHSNPSA YRMFTNNTCL  950 KHMITKVRRD THHFERYQHN RDLVGFLNMF ANKQLELPRG WEMKHDHQGK 1000 AFFVDHNSRT TTFIDPRLPL QSSRPTSALV HRQHLTRQRS HSAGEVGEDS 1050 RHAGPPVLPR PSSTFNTVSR PQYQDMVPVA YNDKIVAFLR QPNIFEILQE 1100 RQPDLTRNHS LREKIQFIRT EGTPGLVRLS SDADLVMLLS LFEEEIMSYV 1150 PPHALLHPSY CQSPROSPVS SPQNSPGTQR ANARAPAPYK RDFEANLRNF 1200 YRKLETKGYG QGPGKLKLII RRDHLLEDAF NQIMGYSRKD LQRNKLYVTF 1250 VGEEGLDYSG PSREFFFLVS RELFNPYYGL FEYSANDTYT VQISPMSAFV 1300 DNHHEWERFS GRILGLALIH QYLLDAFFTR PFYKALLRIL CDLSDLEYLD 1350 EEFHQSLQWM KDNDIHDILD LTFTVNEEVF GQITERELKP GGANIPVTEK 1400 NKREYIERMV KWRIERGVVQ QTESLVRGFY EVVDARLVSV FDARELELVI 1450 AGTAEIDLSD WRNNTEYRGG YHDNHIVIRW FWAAVERFNN EQRLRLLQFV 1500 TGTSSIPYEG FASLRGSNGP RRFCVEKWGK ITALPRAHTC FNRLDLPPYP 1550 SFSMLYEKLL TAVEETSTFG LE 1572 WW1 (807-840): (SEQ ID NO: 59) EALPPNWEARIDSHGRIFYVDHVNRTTTWQRPTA. WW2 (985-1018): (SEQ ID NO: 60) LELPRGWEMKHDHQGKAFFVDHNSRTTTFIDPRL.

Human Smurf1 amino acid sequence (uniprot.org/uniprot/ Q9HCE7). The two underlined WW domains correspond to amino acids 234-267 (WW1), and 306-339 (WW2).

(SEQ ID NO: 10) MSNPGTRRNG SSIKIRLTVL CAKNLAKKDF FRLPDPFAKI VVDGSGQCHS  50 TDTVKNTLDP KWNQHYDLYV GKTDSITISV WNHKKIHKKQ GAGFLGCVRL 100 LSNAISRLKD TGYQRLDLCK LNPSDTDAVR GQIVVSLQTR DRIGTGGSVV 150 DCRGLLENEG TVYEDSGPGR PLSCEMEEPA PYTDSTGAAA GGGNCRFVES 200 PSQDQRLQAQ RLRNPDVRGS LQTPQNRPHG HQSPELPEGY EQRTTVQGQV 250 YFLHTQTGVS TWHDPRIPSP SGTIPGGDAA FLYEFLLQGH TSEPRDLNSV 300 NCDELGPLPP GWEVRSTVSG RIYFVDHNNR TTQFTDPRLH HIMNHQCOLK 350 EPSQPLPLPS EGSLEDEELP AQRYERDLVQ KLKVLRHELS LQQPQAGHCR 400 IEVSREEIFE ESYRQIMKMR PKDLKKRLMV KFRGEEGLDY GGVAREWLYL 450 LCHEMLNPYY GLFQYSTDNI YMLQINPDSS INPDHLSYFH FVGRIMGLAV 500 FHGHYINGGF TVPFYKQLLG KPIQLSDLES VDPELHKSLV WILENDITPV 550 LDHTFCVEHN AFGRILQHEL KPNGRNVPVT EENKKEYVRL YVNWRFMRGI 600 EAQFLALQKG FNELIPQHLL KPFDQKELEL IIGGLDKIDL NDWKSNTRLK 650 HCVADSNIVR WFWQAVETFD EERRARLLQF VTGSTRVPLQ GFKALQGSTG 700 AAGPRLFTIH LIDANTDNLP KAHTCFNRID IPPYNSYEKL YEKLLTAVEE 750 TCGFAVE 757 WW1 (234-267): (SEQ ID NO: 48) PELPEGYEQRTTVQGQVYFLHTQTGVSTWHDPRI. WW2 (306-339): (SEQ ID NO: 49) GPLPPGWEVRSTVSGRIYFVDHNNRTTQFTDPRL.

Human Smurf2 amino acid sequence (uniprot.org/uniprot/Q9HAU4). The three underlined WW domains correspond to amino acids 157-190 (WW1), 251-284 (WW2), and 297-330 (WW3).

(SEQ ID NO: 11) MSNPGGRRNG PVKLRLTVLC AKNLVKKDFF RLPDPFAKVV VDGSGQCHST  50 DTVKNTLDPK WNQHYDLYIG KSDSVTISVW NHKKIHKKQG AGFLGCVRLL 100 SNAINRLKDT GYQRLDLCKL GPNDNDTVRG QIVVSLQSRD RIGTGGQVVD 150 CSRLFDNDLP DGWEERRTAS GRIQYLNHIT RTTQWERPTR PASEYSSPGR 200 PLSCFVDENT PISGTNGATC GQSSDPRLAE RRVRSQRHRN YMSRTHLHTP 250 PDLPEGYEQR TTQQGQVYFL HTQTGVSTWH DPRVPRDLSN INCEELGPLP 300 PGWEIRNTAT GRVYFVDHNN RTTQFTDPRL SANLHLVLNR QNQLKDQQQQ 350 QVVSLCPDDT ECLTVPRYKR DLVQKLKILR QELSQQQPQA GHCRIEVSRE 400 EIFEESYRQV MKMRPKDLWK RLMIKFRGEE GLDYGGVARE WLYLLSHEML 450 NPYYGLFQYS RDDIYTLQIN PDSAVNPEHL SYFHFVGRIM GMAVFHGHYI 500 DGGFTLPFYK QLLGKSITLD DMELVDPDLH NSLVWILEND ITGVLDHTFC 550 VEHNAYGEII QHELKPNGKS IPVNEENKKE YVRLIVNWRF LRGIEAQFLA 600 LQKGFNEVIP QHLLKTFDEK ELELIICGLG KIDVNDWKVN TRLKHCTPDS 650 NIVKWFWKAV EFFDEERRAR LLQFVTGSSR VPLQGFKALQ GAAGPRLFTI 700 HQIDACTNNL PKAHTCFNRI DIPPYESYEK LYEKLLTAIE ETCGFAVE 748 WW1 (157-190): (SEQ ID NO: 50) NDLPDGWEERRTASGRIQYLNHITRTTQWERPTR. WW2 (251-284): (SEQ ID NO: 51) PDLPEGYEQRTTQQGQVYFLHTQTGVSTWHDPRV. WW3 (297-330): (SEQ ID NO: 52) GPLPPGWEIRNTATGRVYFVDHNNRTTQFTDPRL.

Human ITCH amino acid sequence (uniprot.org/uniprot/Q96J02). The four underlined WW domains correspond to amino acids 326-359 (WW1), 358-391 (WW2), 438-471 (WW3), and 478-511 (WW4).

Human NEDL1 amino acid sequence (uniprot.org/uniprot/Q76N89). The two underlined WW domains correspond to amino acids 829-862 (WW1). and 1018-1051 (WW2).

(SEQ ID NO: 13) MLLHLCSVKN LYQNRFLGLA AMASPSRNSQ SRRRCKEPLR YSYNPDQFHN   50 MDLRGGPHDG VTIPRSTSDT DLVTSDSRST LMVSSSYYSI GHSQDLVIHW  100 DIKEEVDAGD WIGMYLIDEV LSENFLDYKN RCVNGSHRGQ IIWKIDASSY  150 FVEPETKICF KYYHGVSGAL RATTPSVTVK NSAAPIFKSI GADETVQGQG  200 SRRLISFSLS DFQAMGLKKG MFFNPDPYLK ISIQPGKHSI FPALPHHGQE  250 RRSKIIGNTV NPIWQAEQFS FVSLPTDVLE IEVKDKFAKS RPIIKRFLGK  200 LSMPVQRLLE RHAIGDRVVS YTLGRRLPTD HVSGQLQFRF EITSSIHPDD  350 EEISLSTEPE SAQIQDSPMN NLMESGSGEP RSEAPESSES WKPEQLGEGS  400 VPDGPGNQSI ELSRPAEEAA VITEAGDQGM VSVGPEGAGE LLAQVQKDIQ  450 PAPSAEELAE QLDLGEEASA LLLEDGEAPA STKEEPLEEE ATTQSRAGRE  500 EEEKEQEEEG DVSTLEQGEG RLQLRASVKR KSRPCSLPVS ELETVIASAC  550 GDPETPRTHY IRIHTLLHSM PSAQGGSAAE EEDGALEEST LKDSSEKDGL  600 SEVDTVAADP SALEEDREEP EGATPGTAHP GHSGGHFPSL ANGAAQDGDT  650 HPSTGSESDS SPRQGGDHSC EGCDASCCSP SCYSSSCYST SCYSSSCYSA  700 SCYSPSCYNG NRFASHTRFS SVDSAKISES TVFSSQDDEE EENSAFESVP  750 DSMQSPELDP ESTNGAGPWQ DELAAPSGHV ERSPEGLESP VAGPSNRREG  800 ECPILHNSQP VSQLPSLRPE HHHYPTIDEP LPPNWEARID SHGRVFYVDH  850 VNRTTTWQRP TAAATPDGMR RSGSIQQMEQ LNRRYQNIQR TIATERSEED  900 SGSQSCEQAP AGGGGGGGSD SEAESSQSSL DLRREGSLSP VNSQKITLLL  950 QSPAVKFITN PEFFTVLHAN YSAYRVFTSS TCLKHMILKV RRDARNFERY 1000 QHNRDLVNFI NMFADTRLEL PRGWEIKTDQ QGKSFFVDHN SRATTFIDPR 1050 IPLQNGRLPN HLTHRQHLQR LRSYSAGEAS EVSRNRGASL LARPGHSLVA 1100 AIRSQHQHES LPLAYNDKIV AFLRQPNIFE MLQERQPSLA RNHTLREKIH 1150 YIRTEGNHGL EKLSCDADLV ILLSLFEEEI MSYVPLQAAF HPGYSFSPRC 1200 SPCSSPQNSP GLQRASARAP SPYRRDFEAK LRNFYRKLEA KGFGQGPGKI 1250 KLIIRRDHLL EGTFNQVMAY SRKELQRNKL YVTFVGEEGL DYSGPSREFF 1300 FLLSQELFNP YYGLFEYSAN DTYTVQISPM SAFVENHLEW FRFSGRILGL 1350 ALIHQYLLDA FFTRPFYKAL LRLPCDLSDL EYLDEEFHQS LQWMKDNNIT 1400 DILDLTFTVN EEVFGQVTER ELKSGGANTQ VTEKNEKEYI ERMVKWRVER 1450 GVVQQTEALV RGFYEVVDSR LVSVFDAREL ELVIAGTAEI DLNDWRNNTE 1500 YRGGYHDGHL VIRWFWAAVE RFNNEQRLRL LQFVTGTSSV PYEGFAALRG 1550 SNGERRFCIE KWGKITSLPR AHTCFNRLDL PPYPSYSMLY EKLLTAVEET 1600 STFGLE 1606 WW1 (829-862): (SEQ ID NO: 57) PLPPNWEARIDSHGRVFYVDHVNRTTTWQRPTA. WW2 (1018-1051): (SEQ ID NO: 58) LELPRGWEIKTDQQGKSFFVDHNSRATTFIDPRI.

Human NEDL2 amino acid sequence (uniprot.org/uniprot/ Q9P2P5). The two underlined WW domains correspond to amino acids 807-840 (WW1), and 985-1018 (WW2).

In some embodiments, the WW domain comprises a WW domain or WW domain variant from the amino acid sequence (SEQ ID NO: 6); (SEQ ID NO: 7); (SEQ ID NO: 8); (SEQ ID NO: 9); (SEQ ID NO: 10); (SEQ ID NO: 11); (SEQ ID NO: 12); (SEQ ID NO: 13); or (SEQ ID NO: 14). In other embodiments, the WW domain consists of a WW domain or WW domain variant from the amino acid sequence (SEQ ID NO: 6); (SEQ ID NO: 7); (SEQ ID NO: 8); (SEQ ID NO: 9); (SEQ ID NO: 10); (SEQ ID NO: 11); (SEQ ID NO: 12); (SEQ ID NO: 13); or (SEQ ID NO: 14). In another embodiment, the WW domain consists essentially of a WW domain or WW domain variant from the amino acid sequence (SEQ ID NO: 6); (SEQ ID NO: 7); (SEQ ID NO: 8); (SEQ ID NO: 9); (SEQ ID NO: 10); (SEQ ID NO: 11); (SEQ ID NO: 12); (SEQ ID NO: 13); or (SEQ ID NO: 14). Consists essentially of means that a domain, peptide or polypeptide consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example, from about 1 to about 10 or so additional residues, typically from 1 to about 5 additional residues in the domain, peptide or polypeptide.

Alternatively, the WW domain may be a WW domain that has been modified to include two basic amino acids at the C-terminus of the domain. Techniques are known in the art and are described in the art, for example, in Sambrook et al. ((2001) Molecular Cloning: a Laboratory Manual, 3rd ed., Cold Spring Harbour Laboratory Press). Thus, a skilled person could readily modify an existing WW domain that does not normally have two C-terminal basic residues so as to include two basic residues at the C-terminus.

Basic amino acids are amino acids that possess a side-chain functional group that has a pKa of greater than 7 and include lysine, arginine, and histidine, as well as basic amino acids that are not included in the twenty a-amino acids commonly included in proteins. The two basic amino acids at the C-terminus of the WW domain may be the same basic amino acid or may be different basic amino acids. In one embodiment, the two basic amino acids are two arginines.

The term WW domain also includes variants of a WW domain provided that any such variant possesses two basic amino acids at its C-terminus and maintains the ability of the WW domain to associate with the PPXY motif. A variant of such a WW domain refers to a WW domain which retains the ability to associate with the PPXY motif (i.e., the PPXY motif of ARRDC1) and that has been mutated at one or more amino acids, including point, insertion or deletion mutations, but still retains the ability to associate with the PPXY motif. A variant or derivative therefore includes deletions, including truncations and fragments; insertions and additions, for example conservative substitutions, site-directed mutants and allelic variants; and modifications, including one or more non-amino acyl groups (e.g., sugar, lipid, etc.) covalently linked to the peptide and post-translational modifications. In making such changes, substitutions of like amino acid residues can be made on the basis of relative similarity of side-chain substituents, for example, their size, charge, hydrophobicity, hydrophilicity, and the like, and such substitutions may be assayed for their effect on the function of the peptide by routine testing.

The WW domain may be part of a longer protein. Thus, the protein, in various different embodiments, comprises the WW domain, consists of the WW domain or consists essentially of the WW domain, as defined herein. The polypeptide may be a protein that includes a WW domain as a functional domain within the protein sequence. In one embodiment, the polypeptide is a Cas9 protein. In other embodiments, the polypeptide comprises the sequence set forth in (SEQ ID NO: 6); (SEQ ID NO: 7); (SEQ ID NO: 8); (SEQ ID NO: 9); (SEQ ID NO: 10); (SEQ ID NO: 11); (SEQ ID NO: 12); (SEQ ID NO: 13); or (SEQ ID NO: 14), consists of (SEQ ID NO: 6); (SEQ ID NO: 7); (SEQ ID NO: 8); (SEQ ID NO: 9); (SEQ ID NO: 10); (SEQ ID NO: 11); (SEQ ID NO: 12); (SEQ ID NO: 13); or (SEQ ID NO: 14), or consists essentially of (SEQ ID NO: 6); (SEQ ID NO: 7); (SEQ ID NO: 8); (SEQ ID NO: 9); (SEQ ID NO: 10); (SEQ ID NO: 11); (SEQ ID NO: 12); (SEQ ID NO: 13); or (SEQ ID NO: 14).

The term “target site,” as used herein in the context of functional effector proteins that bind a nucleic acid molecule, such as nucleases and transcriptional activators or repressors, refers to a sequence within a nucleic acid molecule that is bound and acted upon by the effector protein, e.g., cleaved by the nuclease or transcriptionally activated or repressed by the transcriptional activator or repressor, respectively. A target site may be single-stranded or double-stranded. In the context of RNA-guided (e.g., RNA-programmable) nucleases (e.g., a protein dimer comprising a Cas9 gRNA binding domain and an active Cas9 DNA cleavage domain), a target site typically comprises a nucleotide sequence that is complementary to the gRNA of the RNA-programmable nuclease, and a protospacer adjacent motif (PAM) at the 3′ end adjacent to the gRNA-complementary sequence. For the RNA-guided nuclease Cas9, the target site may be, in some embodiments, 20 base pairs plus a 3 base pair PAM (e.g., NNN, wherein N represents any nucleotide). Typically, the first nucleotide of a PAM can be any nucleotide, while the two downstream nucleotides are specified depending on the specific RNA-guided nuclease. Exemplary target sites for RNA-guided nucleases, such as Cas9, are known to those of skill in the art and include, without limitation, NNG, NGN, NAG, and NGG, wherein N represents any nucleotide. In addition, Cas9 nucleases from different species (e.g., S. thermophilus instead of S. pyogenes) recognizes a PAM that comprises the sequence NGGNG. Additional PAM sequences are known, including, but not limited to, NNAGAAW and NAAR (see, e.g., Esvelt and Wang, Molecular Systems Biology, 9:641 (2013), the entire contents of which are incorporated herein by reference). For example, the target site of an RNA-guided nuclease, such as, e.g., Cas9, may comprise the structure [NZ]-[PAM], where each N is, independently, any nucleotide, and Z is an integer between 1 and 50, inclusive. In some embodiments, Z is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50. In some embodiments, Z is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,49, or 50. In some embodiments, Z is 20. In some embodiments, “target site” may also refer to a sequence within a nucleic acid molecule that is bound but not cleaved by a nuclease. For example, certain embodiments described herein provide proteins comprising an inactive (or inactivated) Cas9 DNA cleavage domain. Such proteins (e.g., when also including a Cas9 RNA binding domain) are able to bind the target site specified by the gRNA, however because the DNA cleavage site is inactivated, the target site is not cleaved by the particular protein. However, such proteins as described herein are typically associated with another protein (e.g., a nuclease or transcription factor) or molecule that mediates cleavage of the nucleic acid molecule. In some embodiments, the sequence actually cleaved will depend on the protein (e.g., nuclease) or molecule that mediates cleavage of the nucleic acid molecule, and in some cases, for example, will relate to the proximity or distance from which the inactivated Cas9 protein(s) is/are bound.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

The instant disclosure relates to the discovery that a Cas9:WW domain fusion protein along with a guide RNA sequence (gRNA) can be loaded into ARMMs. Furthermore, fusion of the WW domain to Cas9 nuclease does not interfere with Cas9 nuclease function. As described in more detail herein, cargo proteins (e.g. Cas9 nuclease; Oct4, Sox2, c-Myc, or KLF4 reprogramming factor; or therapeutic protein) may be fused to one or more WW domains or WW domain variant s to facilitate their incorporation into ARMMs which may be used to deliver the fusion proteins into a target cell.

Microvesicles with WW Domain Containing Cargo Proteins

Some aspects of this invention provide arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (ARMMs) containing a cargo protein that is fused to a WW domain. Such ARMMs typically include a lipid bilayer and an ARRDC1 protein or variant thereof. In some embodiments, the cargo protein is fused to a WW domain that associates with the PPXY (where x=any amino acid) domain of ARRDC1 which may facilitate loading of the cargo protein into an ARMM. In some embodiments, the cargo protein is a Cas9 protein or Cas9 variant. In some embodiments the Cas9 protein or variant is a fusion protein. For example, the Cas9 protein or Cas9 variant may be fused to one or more WW domains to facilitate loading into an ARMM. In some embodiments, the Cas9 fusion protein or Cas9 variant is fused to one or more nuclear localization sequences (NLSs) to facilitate translocation of the Cas9 fusion protein into the nucleus of a target cell. In certain embodiments the Cas9 variant is a Cas9 protein or Cas9 protein variant comprising an active or inactive DNA cleavage domain of Cas9 or a partially inactive DNA cleavage domain (e.g., a Cas9 “nickase”), and/or the gRNA binding domain of Cas9. It should be appreciated that any number of proteins known in the art can be fused to one or more WW domains to generate a cargo protein that can be loaded into an ARMM, for example, a reprogramming factor (e.g., Oct4, Sox2, c-Myc, or KLF4) may be fused to one or more WW domains to facilitate loading of one or more reprogramming factors into an ARMM. In some embodiments, the cargo protein is a therapeutic protein (e.g., a transcription factor, a tumor suppressor, a developmental regulator, a growth factor, a metastasis suppressor, a pro-apoptotic protein, a zinc finger nuclease, or a recombinase) that is fused to one or more WW domains. In other embodiments, an ARMM further includes a non-cargo protein, such as a TSG101 protein or variant thereof to facilitate the release of ARMMs. The TSG101 protein interacts with ARRDC1, which results in relocation of TSG101 from endosomes to the plasma membrane and mediates the release of microvesicles that contain TSG101, ARRDC1, and other cellular components, including, for example, cargo proteins and nucleic acids (i.e., gRNAs).

ARRDC1

ARRDC1 is a protein that comprises a PSAP and a PPXY motif, also referred to herein as a PSAP and PPXY motif, respectively, in its C-terminus, and interacts with TSG101 as shown herein. Exemplary, non-limiting ARRDC1 protein sequences are provided herein, and additional, suitable ARRDC1 protein variants according to aspects of this invention are known in the art. It will be appreciated by those of skill in the art that this invention is not limited in this respect. Exemplary ARRDC1 sequences include the following (PSAP and PPXY motifs are marked):

>gi122748653|ref|NP_689498.1|arrestindomain- containing protein 1 [Homo sapiens] (SEQ ID NO: 15) MGRVQLFEISLSHGRVVYSPGEPLAGTVRVRLGAPLPFRAIRVTCIGSCG VSNKANDTAWVVEEGYFNSSLSLADKGSLPAGEHSFPFQFLLPATAPTSF EGPFGKIVHQVRAAIHTPRFSKDHKCSLVFYILSPLNLNSIPDIEQPNVA SATKKFSYKLVKTGSVVLTASTDLRGYVVGQALQLHADVENQSGKDTSPV VASLLQKVSYKAKRWIHDVRTIAEVEGAGVKAWRRAQWHEQILVPALPQS ALPGCSLIHIDYYLQVSLKAPEATVTLPVFIGNIAVNHAPVSPRPGLGLP

SVPGAPEPCPQDGSPASHPLHPPLCISTGATVPYFAEGSGGPVPTTSTLI

>gi1244798004|ref|NP_001155957.1|arrestin domain- containing protein 1 isoform a [Mus musculus] (SEQ ID NO: 16) MGRVQLFEIRLSQGRVVYGPGEPLAGTVHLRLGAPLPFRAIRVTCMGSCG ANDGAWVVEESYFNSSLSLADKGSLPAGEHNFPFQFLLPATAVSTKPTSF EGPFGKIVHQVRASIDTPRFSKDHKCSLVFYILSPLNLNSIPDIEQPNVA STTKKFSYKLVKTGNVVLTASTDLRGYVVGQVLRLQADIENQSGKDTSPV VASLLQKVSYKAKRWIYDVRTIAEVEGTGVKAWRRAQWQEQILVPALPQS ALPGCSLIHIDYYLQVSMKAPEATVTLPLFVGNIAVNQTPLSPCPGRESS

SVTTTEPWVQVGSPARHSLHPPLCISIGATVPYFAEGSAGPVPTTSALIL

>gi1244798112|ref|NP_848495.2|arrestin domain- containing protein 1 isoform b [Mus musculus] (SEQ ID NO: 17) MGRVQLFEIRLSQGRVVYGPGEPLAGTVHLRLGAPLPFRAIRVTCMGSCG VSTKANDGAWVVEESYFNSSLSLADKGSLPAGEHNFPFQFLLPATAPTSF EGPFGKIVHQVRASIDTPRFSKDHKCSLVFYILSPLNLNSIPDIEQPNVA STTKKFSYKLVKTGNVVLTASTDLRGYVVGQVLRLQADIENQSGKDTSPV VASLLQVSYKAKRWIYDVRTIAEVEGTGVKAWRRAQWQEQILVPALPQSA LPGCSLIHIDYYLQVSMKAPEATVTLPLFVGNIAVNQTPLSPCPGRESSP

WW Domain Containing Cargo Proteins

Aspects of the disclosure relate to ARMMs comprising a cargo protein associated with at least one WW domain. In some aspects, fusion proteins are provided that comprise a cargo protein with at least one WW domain. In some aspects, expression constructs are provided that encode a cargo protein associated with at least one WW domain. The WW domain of a cargo protein may associate with the PPXY motif of ARRDC1, or variant thereof, to facilitate association with or inclusion of the cargo protein into an ARMM. A schematic representation of a Cas9 cargo protein fused to a WW domain that associates with the PPXY motif of ARRDC1 can be seen in FIG. 2. In some embodiments, the cargo protein is fused to at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or more WW domains. The WW domain may be derived from a WW domain of the ubiquitin ligase WWP1, WWP2, Nedd4-1, Nedd4-2, Smurf1, Smurf2, ITCH, NEDL1, or NEDL2 (FIG. 1). For example, the WW domain may comprise a WW domain or WW domain variant from the amino acid sequence set forth in (SEQ ID NO: 6); (SEQ ID NO: 7); (SEQ ID NO: 8); (SEQ ID NO: 9); (SEQ ID NO: 10); (SEQ ID NO: 11); (SEQ ID NO: 12); (SEQ ID NO: 13); or (SEQ ID NO: 14). In certain embodiments, the cargo proteins may comprise two WW domains or WW domain variants from the human ITCH protein having the amino acid sequence:

(SEQ ID NO: 18) PLPPGWEQRVDQHGRVYYVDHVEKRTTWDRPEPLPPGWERRVDNMGRIYY VDHFTRTTTWQRPTL. In other embodiments, the cargo proteins may comprise four WW domains or WW domain variants from the human ITCH protein having the amino acid sequence:

(SEQ ID NO: 19) PLPPGWEQRVDQHGRVYYVDHVEKRTTWDRPEPLPPGWERRVDNMGRIYY VDHFTRTTTWQRPTLESVRNYEQWQLQRSQLQGAMQQFNQRFIYGNQDLF ATSQSKEFDPLGPLPPGWEKRTDSNGRVYFVNHNTRITQWEDPRSQGQLN EKPLPEGWEMRFTVDGIPYFVDHNRRTTTYIDPRT. The cargo proteins, described herein, that are fused to at least one WW domain or WW domain variant are non-naturally occurring, that is, they do not exist in nature.

In some embodiments, one or more WW domains may be fused to the N-terminus of a cargo protein. In other embodiments, one or more WW domains may be fused to the C-terminus or the N-terminus of a cargo protein. In yet other embodiments, one or more WW domains may be inserted into a cargo protein. It should be appreciated that the WW domains may be configured in any number of ways to maintain function of the cargo protein, which can be tested by methods known to one of ordinary skill in the art.

The cargo protein of the inventive microvesicles may be a protein comprising at least one WW domain. For example, the cargo protein may be a WW domain containing protein or a protein fused to at least one WW domain. In some embodiments, the cargo protein may be a Cas9 protein or Cas9 variant fused to at least one WW domain. In some embodiments, the cargo protein may be a recombinant cargo protein. For example the recombinant cargo protein may be a Cas9 protein, or Cas9 variant, fused to at least one nuclear localization sequence (NLS). A NLS, as referred to herein, is an amino acid sequence that facilitates the import of a protein into the cell nucleus by nuclear transport. In some embodiments, a NLS is fused to the N-terminus of a Cas9 protein, or Cas9 variant. In some embodiments, a NLS is fused to the C-terminus of Cas9 protein, or Cas9 variant. In some embodiments, Cas9 is fused to at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or more nuclear localization sequences (NLSs). In certain embodiments, one NLS is fused to the N-terminus, and one NLS is fused to the C-terminus of the Cas9 protein to create a recombinant NLS:Cas9:NLS fusion protein. In certain embodiments, the Cas9 protein, or Cas9 variant, fused to at least one NLS may also be fused to at least one WW domain. It should be appreciated that, as described above, the WW domains may be configured in any number of ways such that the Cas9 protein or Cas9 variant may be loaded into an ARMM for delivery to a target cell and translocate into the nucleus of the target cell to perform its nuclease function. In certain embodiments, one or more WW domains are fused to the N-terminus of a recombinant NLS:Cas9:NLS fusion protein. In certain embodiments, one or more WW domains are fused to the C-terminus of a recombinant NLS:Cas9:NLS fusion protein. In certain embodiments, the cargo protein comprises the sequence (SEQ ID NO: 65) or (SEQ ID NO: 66). In certain embodiments, the cargo protein consists of the sequence (SEQ ID NO: 65) or (SEQ ID NO: 66). In certain embodiments, the cargo protein consists essentially of (SEQ ID NO: 65) or (SEQ ID NO: 66).

The following amino acid sequences are exemplary Cas9 cargo protein sequences that have either 2 WW domains (SEQ ID NO: 65) or 4 WW domains (SEQ ID NO: 66), which were cloned into the AgeI site of the pX330 plasmid (Addgene).

(SEQ ID NO: 65) MPLPPGWEQRVDQHGRVYYVDHVEKRITWDRPEPLPPGWERRVDNMGRIY YVDHFIRITTWQRPTLIGATMDYKDHDGDYKDHDIDYKDDDDKMAPKKKR KVGIHGVPAADKKYSIGLDIGINSVGWAVITDEYKVPSKKFKVLGNIDRH SIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMA KVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKK LVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQT YNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNL IALSLGLIPNEKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFL AAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLILLKALVRQ QLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLV KLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIE KILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSF IERMINFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLS GEQKKAIVDLLFKINRKVIVKQLKEDYFKKIECFDSVEISGVEDRFNASL GTYHDLLKIIKDKDFLDNEENEDILEDIVLILTLFEDREMIEERLKTYAH LFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANR NFMQLIHDDSLIFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTV KVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKEL GSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHI VPQSFLKDDSIDNKVLIRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKL ITQRKFDNLIKAERGGLSELDKAGFIKRQLVETRQIIKHVAQILDSRMNI KYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNA VVGIALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSN IMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQ VNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAY SVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVK KDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASH YEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVL SAYNKHRDKPIREQAENIIHLFTLINLGAPAAFKYFDTTIDRKRYISTKE VLDATLIHQSITGLYETRIDLSQLGGDKRPAATKKAGQAKKKK (SEQ ID NO: 66) MPLPPGWEQRVDQHGRVYYVDHVEKRITWDRPEPLPPGWERRVDNMGRIY YVDHFIRITTWQRPTLESVRNYEQWQLQRSQLQGAMQQFNQRFIYGNQDL FATSQSKEFDPLGPLPPGWEKRIDSNGRVYFVNHNTRITQWEDPRSQGQL NEKPLPEGWEMRFTVDGIPYFVDHNRRITTYIDPRIGGGIGATMDYKDHD GDYKDHDIDYKDDDDKMAPKKKRKVGIHGVPAADKKYSIGLDIGINSVGW AVITDEYKVPSKKFKVLGNIDRHSIKKNLIGALLFDSGETAEATRLKRTA RRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPI FGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHF LIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSK SRRLENLIAQLPGEKKNGLFGNLIALSLGLIPNEKSNFDLAEDAKLQLSK DTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLS ASMIKRYDEHHQDLILLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGAS QEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGE LHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRK SEETITPWNFEEVVDKGASAQSFIERMINFDKNLPNEKVLPKHSLLYEYF TVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKINRKVIVKQLKEDY FKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILED IVLILTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLIN GIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLIFKEDIQKAQVSGQGD SLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQ TTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQN GRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLIRSDKNRGKSD NVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLIKAERGGLSELDKAGFIK RQLVETRQIIKHVAQILDSRMNIKYDENDKLIREVKVITLKSKLVSDFRK DFQFYKVREINNYHHAHDAYLNAVVGIALIKKYPKLESEFVYGDYKVYDV RKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGE TGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK LIARKKDWDPKKYGGFDSPIVAYSVLVVAKVEKGKSKKLKSVKELLGITI MERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAG ELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDE IIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLINL GAPAAFKYFDTTIDRKRYISTKEVLDATLIHQSITGLYETRIDLSQLGGD KRPAATKKAGQAKKKK

The microvesicles described herein may further comprise a nucleic acid. In some embodiments, the microvesicles may comprise at least one guide RNA (gRNA), which may be associated, for example, with a nuclease or a nickase. As one example, a gRNA may be associated with a Cas9 cargo protein or Cas9 variant cargo protein. The gRNA may comprise a nucleotide sequence that complements a target site, which mediates binding of the nuclease/RNA complex to said target site and providing the sequence specificity of the nuclease:RNA complex. In certain embodiments, the gRNA comprises a nucleotide sequence that is complementary to any target known in the art. For example the gRNA may comprise a nucleotide sequence that is complementary to a therapeutic target (e.g., APOC3, alpha 1 antitrypsin, HBV or HIV). In certain embodiments the gRNA comprises the sequence complementary to enhanced green fluorescent protein (EGFP). For example the gRNA sequence may be encoded by the nucleic acid sequence set forth in SEQ ID NO: 69.

The following is an exemplary nucleic acid sequence that encodes a guide RNA (gRNA) that targets EGFP. The EGFP target sequence is underlined below.

(SEQ ID NO: 69) ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTC GAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGC GAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACC GGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGC GTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTC AAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAG GACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACC CTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAAC ATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATC ATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCAC AACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACC CCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACC CAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTG CTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTAC AAG

TSG101

In certain embodiments, the inventive microvesicles further comprise TSG101. Tumor susceptibility gene 101, also referred to herein as TSG101, is a protein encoded by this gene belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. The protein contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. TSG101 is a protein that comprises a UEV domain, and interacts with ARRDC1. Exemplary, non-limiting TSG101 protein sequences are provided herein, and additional, suitable TSG101 protein sequences, isoforms, and variants according to aspects of this invention are known in the art. It will be appreciated by those of skill in the art that this invention is not limited in this respect. Exemplary TSG101 sequences include the following:

>gi|5454140|ref|NP_006283.1| tumor susceptibility gene 101 protein [Homo sapiens] (SEQ ID NO: 20) MAVSESQLKKMVSKYKYRDLTVRETVNVITLYKDLKPVLDSYVFNDGSSR ELMNLTGTIPVPYRGNTYNIPICLWLLDTYPYNPPICFVKPTSSMTIKTG KHVDANGKIYLPYLHEWKHPQSDLLGLIQVMIVVFGDEPPVFSRPISASY PPYQATGPPNTSYMPGMPGGISPYPSGYPPNPSGYPGCPYPPGGPYPATT SSQYPSQPPVTTVGPSRDGTISEDTIRASLISAVSDKLRWRMKEEMDRAQ AELNALKRTEEDLKKGHQKLEEMVTRLDQEVAEVDKNIELLKKKDEELSS ALEKMENQSENNDIDEVIIPTAPLYKQILNLYAEENAIEDTIFYLGEALR RGVIDLDVFLKHVRLLSRKQFQLRALMQKARKTAGLSDLY >gi|11230780|ref|NP_068684.1| tumor susceptibility gene 101 protein [Mus musculus] (SEQ ID NO: 21) MAVSESQLKKMMSKYKYRDLTVRQTVNVIAMYKDLKPVLDSYVFNDGSSR ELVNLTGTIPVRYRGNIYNIPICLWLLDTYPYNPPICFVKPTSSMTIKTG KHVDANGKIYLPYLHDWKHPRSELLELIQIMIVIFGEEPPVFSRPTVSAS YPPYTATGPPNTSYMPGMPSGISAYPSGYPPNPSGYPGCPYPPAGPYPAT TSSQYPSQPPVTTVGPSRDGTISEDTIRASLISAVSDKLRWRMKEEMDGA QAELNALKRTEEDLKKGHQKLEEMVTRLDQEVAEVDKNIELLKKKDEELS SALEKMENQSENNDIDEVIIPTAPLYKQILNLYAEENAIEDTIFYLGEAL RRGVIDLDVFLKHVRLLSRKQFQLRALMQKARKTAGLSDLY >gi|48374087|ref|NP_853659.2| tumor susceptibility gene 101 protein [Rattus norvegicus] (SEQ ID NO: 22) MAVSESQLKKMMSKYKYRDLTVRQTVNVIAMYKDLKPVLDSYVFNDGSSR ELVNLTGTIPVRYRGNIYNIPICLWLLDTYPYNPPICFVKPTSSMTIKTG KHVDANGKIYLPYLHDWKHPRSELLELIQIMIVIFGEEPPVFSRPTVSAS YPPYTAAGPPNTSYLPSMPSGISAYPSGYPPNPSGYPGCPYPPAGPYPAT TSSQYPSQPPVTTAGPSRDGTISEDTIRASLISAVSDKLRWRMKEEMDGA QAELNALKRTEEDLKKGHQKLEEMVTRLDQEVAEVDKNIELLKKKDEELS SALEKMENQSENNDIDEVIIPTAPLYKQILNLYAEENAIEDTIFYLGEAL RRGVIDLDVFLKHVRLLSRKQFQLRALMQKARKTAGLSDLY

The UEV domain in these sequences includes amino acids 1-145 (underlined in the sequences above). The structure of UEV domains is known to those of skill in the art (see, e.g., Owen Pornillos et al., Structure and functional interactions of the Tsg101 UEV domain, EMBO J. 2002 May 15; 21(10): 2397-2406, the entire contents of which are incorporated herein by reference).

Cas9 Cargo Proteins Fused to ARRDC1 or TSG101

In some aspects, microvesicles, e.g., ARMMs, are provided that comprise an ARRDC1 protein, or variant thereof, fused to a Cas9 protein or Cas9 variant. In some aspects, microvesicles are provided that comprise a TSG101 protein, or variant thereof, fused to a Cas9 protein. In some aspects, fusion proteins are provided that comprise an ARRDC1 protein, or variant thereof, fused to a Cas9 protein and/or a TSG101 protein, or variant thereof, fused to a Cas9 protein. In some aspects, expression constructs are provided that encode an ARRDC1 protein, or variant thereof, fused to a Cas9 cargo protein and/or a TSG101 protein, or variant thereof, fused to a Cas9 cargo protein. In some embodiments, the ARRDC1 protein variant is a C-terminal ARRDC1 protein variant. In some embodiments, the ARRDC1 protein variant has a PSAP motif and at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290, or at least 300 contiguous amino acids of the ARRCD1 sequence. In some embodiments, the TSG101 protein variant comprises a TSG101 UEV domain. In some embodiments, the TSG101 protein variant comprises the UEV domain and comprises at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290, or at least 300 contiguous amino acids of the TSG101 sequence.

Some aspects of this invention provide ARRDC1 fusion proteins that comprise an ARRDC1 protein or a variant thereof, and a Cas9 protein, or Cas9 variant, associated with the ARRDC1 protein or variant thereof. In some embodiments the Cas9 protein is covalently linked to the ARRDC1 protein, or variant thereof. The Cas 9 protein, for example, may be covalently linked to the N-terminus, the C-terminus, or within the amino acid sequence of the ARRDC1 protein. In some embodiments, the ARRDC1 variant comprises a PSAP motif or domain (comprising the amino acid sequence PSAP). In some embodiments, the ARRDC1 protein variant comprises the PSAP motif and at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290, or at least 300 contiguous amino acids of the ARRCD1 sequence.

Some aspects of this invention provide TSG101 fusion proteins, comprising an TSG101 protein, or a variant thereof, and a Cas9 protein, or Cas9 variant, associated with the TSG101 protein or variant thereof. In some embodiments the Cas9 protein is covalently linked to the TSG101 protein or variant thereof. The Cas9 protein, for example, may be covalently linked to the N-terminus, the C-terminus, or within the amino acid sequence of the TSG101 protein. In some embodiments, the TSG101 variant comprises a UEV domain. UEV domains are well known to those of skill in the art, and exemplary UEV domains are described herein (e.g., the 145 N-terminal amino acids of the human, rat, and mouse TSG101 protein sequence provided herein). Additional UEV domain sequences will be apparent to those of skill in the art, and the invention is not limited in this respect. In some embodiments, the TSG101 protein variant comprises the UEV domain and at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290, or at least 300 contiguous amino acids of the TSG101 sequence.

In certain embodiments, the Cas9 protein or Cas9 variant is fused to the C-terminus of the ARRDC1 protein or protein variant, or to the C-terminus of the TSG101 protein or protein variant. The Cas9 protein or Cas9 variant may also be fused to the N terminus of the ARRDC1 protein or protein variant, or to the N terminus of the TSG101 protein or protein variant. In some embodiments, the Cas9 protein or Cas9 variant may be within the ARRDC1 or TSG101 protein or variants thereof.

In certain embodiments, the Cas9 protein is associated with an ARRDC1 protein, an ARRDC1 variant, a TSG101 protein, or a TSG101 variant via a covalent bond. In some embodiments, the Cas9 protein is associated with the ARRDC1 protein, the ARRDC1 protein variant, the TSG101 protein, or the TSG101 protein variant via a linker. In some embodiments, the linker is a cleavable linker, for example, the linker may contain a protease recognition site. The protease recognition site of the linker may be recognized by a protease expressed in a target cell, resulting in the Cas9 protein fused to the ARRDC1 protein or variant thereof or the TSG101 protein variant thereof being released into the cytoplasm of the target cell upon uptake of the ARMM. A person skilled in the art would appreciate that any number of linkers may be used to fuse the Cas9 protein or Cas9 variant to the ARRDC1 protein or variant thereof or the TSG101 protein or variant thereof.

The linker may be cleavable or uncleavable. In some embodiments, the linker comprises an amide, ester, ether, carbon-carbon, or disulfide bond, although any covalent bond in the chemical art may be used. In some embodiments, the linker comprises a labile bond, cleavage of which results in separation of the cargo protein from the ARRDC1 protein, an ARRDC1 variant, a TSG101 protein, or a TSG101 variant. In some embodiments, the linker is cleaved under conditions found in the target cell (e.g., a specific pH, a reductive environment, or the presence of a cellular enzyme). In some embodiments, the linker is cleaved by a cellular enzyme. In some embodiments, the cellular enzyme is a cellular protease or a cellular esterase. In some embodiments, the cellular protease is a cytoplasmic protease, an endosomal protease, or an endosomal esterase. In some embodiments, the cellular enzyme is specifically expressed in a target cell or cell type, resulting in preferential or specific release of the functional cargo protein or peptide in the target cell or cell type. The target sequence of the protease may be engineered into the linker between the Cas9 fusion protein and the ARRDC1 protein or the TSG101 protein or variant thereof. The target cell may be any cell type found in a subject, including normal and pathologic or diseased cells , and the linker is cleaved by an enzyme or based on a characteristic specific for the target cell. In some embodiments, the linker comprises an amino acid sequence chosen from the group including, but not limited to, AGVF, GFLG, FK, AL, ALAL, or ALALA. Other suitable linkers will be apparent to those of skill in the art. In some embodiments, the linker is a cleavable linker. In some embodiments, the linker comprises a protease recognition site. In certain embodiments, the linker is a UV-cleavable moiety. Suitable linkers, for example, linkers comprising a protease recognition site, or linkers comprising a UV cleavable moiety are known to those of skill in the art. In some embodiments, the Cas9 fusion protein is associated with the ARRDC1 protein or variant thereof, or the TSG101 protein or variant thereof, via a sortase reaction, and the linker comprises an LPXTG motif. Methods and reagents for conjugating proteins according to some aspects of this invention to proteins are known to those of skill in the art. Accordingly, suitable methods for conjugating and Cas9 fusion proteins to be included in an ARMM to an ARRDC1 protein or variant thereof or a TSG101 protein or variant thereof will be apparent to those of skill in the art based on this disclosure.

Any of the linkers, described herein, may be fused to the C-terminus of the ARRDC1 protein or variant thereof and the N-terminus of the Cas9 protein or Cas9 variant, thereby linking the ARRDC1 protein or variant thereof to the Cas9 protein or Cas9 variant. In other embodiments, the linker may be fused to the C-terminus of the Cas9 protein Cas9 variant and the N-terminus of the ARRDC1 protein or variant thereof. Similarly, the linker may be fused to the C-terminus of the TSG101 protein or variant thereof and the N-terminus of the Cas9 protein or Cas9 variant, thereby linking the TSG101 protein or variant thereof to the Cas9 protein or Cas9 variant. In other embodiments, the linker may be fused to the C-terminus of the Cas9 protein Cas9 variant and the N-terminus of the TSG101 protein or variant thereof.

The Cas9 protein or Cas9 variant associated with an ARRDC1 protein, an ARRDC1 protein variant, a TSG101 protein, or a TSG101 protein variant, may further include a nuclear localization sequence (NLS). In some embodiments, the Cas9 fusion protein is fused to at least one NLS. In some embodiments, one or more nuclear localization sequences (NLSs) are fused to the N-terminus of Cas9. In some embodiments, one or more NLSs are fused to the C-terminus of Cas9. In some embodiments, Cas9 is fused to at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or more NLSs. It should be appreciated that one or more NLSs may be fused to Cas9 to allow translocation of Cas9 fusion protein into the nucleus of a target cell. In some embodiments, the Cas9 protein fused to at least one NLS is associated with ARRDC1, an ARRDC1 protein variant, a TSG101 protein, or a TSG101 protein variant via a linker. In some embodiments, the linker contains a protease recognition site. In other embodiments, the linker contains a UV-cleavable moiety. In some embodiments, the protease recognition site is recognized by a protease expressed in a target cell, resulting in the Cas9 protein fused to at least one NLS being released from the ARRDC1 protein or variant thereof or the TSG101 protein or variant thereof into the cytoplasm, where it may translocate into the nucleus upon uptake of the ARMM.

Expression Constructs

Some aspects of this invention provide expression constructs that encode any of the Cas9 fusion proteins, ARRDC1 fusion proteins, TSG101 fusion proteins, or cargo fusion proteins described herein. In some embodiments, the expression constructs described herein may further encode a guide RNA (gRNA). It should be appreciated that the gRNA may be expressed under the control of the same promoter sequence or a different promoter sequence as any of the fusion proteins described herein. In some embodiments, an expression construct encoding a gRNA may be co-expressed with any of the expression constructs described herein.

In some embodiments, the expression constructs described herein may further encode a gene product or gene products that induce or facilitate the generation of ARMMs in cells harboring such a construct. In some embodiments, the expression constructs encode an ARRDC1 protein, or variant thereof, and/or a TSG101 protein, or variant thereof. In some embodiments, overexpression of either or both of these gene products in a cell increase the production of ARMMs in the cell, thus turning the cell into a microvesicle producing cell. In some embodiments, such an expression construct comprises at least one restriction or recombination site that allows in-frame cloning of a Cas9 sequence to be fused, either at the C-terminus, or at the N-terminus of the encoded ARRDC1 and/or TSG101 protein or variant thereof.

In some embodiments, the expression construct comprises (a) a nucleotide sequence encoding an ARRDC1 protein, or variant thereof, operably linked to a heterologous promoter, and (b) a restriction site or a recombination site positioned adjacent to the ARRDC1-encoding nucleotide sequence allowing for the insertion of a Cas9 or Cas9 variant sequence in frame with the ARRDC1-encoding nucleotide sequence. Some aspects of this invention provide an expression construct comprising (a) a nucleotide sequence encoding a TSG101 protein, or variant thereof, operably linked to a heterologous promoter, and (b) a restriction site or a recombination site positioned adjacent to the TSG101-encoding nucleotide sequence allowing for the insertion of a Cas9 or Cas9 variant sequence in frame with the TSG101-encoding nucleotide sequence.

The expression constructs may encode a cargo protein fused to at least one WW domain. In some embodiments, the expression constructs encode a Cas9 protein, or variant thereof, fused to at least one WW domain, or variant thereof. Any of the expression constructs, described herein, may encode any WW domain or variant thereof. For example, the expression constructs may comprise any nucleotide sequence capable of encoding a WW domain or variant thereof from the poly peptide sequence (SEQ ID NO: 6); (SEQ ID NO: 7); (SEQ ID NO: 8); (SEQ ID NO: 9); (SEQ ID NO: 10); (SEQ ID NO: 11); (SEQ ID NO: 12); (SEQ ID NO: 13); (SEQ ID NO: 14); (SEQ ID NO: 18) or (SEQ ID NO: 19).

The expression constructs, described herein, may comprise any nucleic acid sequence capable of encoding a WW domain or variant thereof. For example a nucleic acid sequence encoding a WW domain or WW domain variant may be from the human ubiquitin ligase WWP1, WWP2, Nedd4-1, Nedd4-2, Smurf1, Smurf2, ITCH, NEDL1, or NEDL2. Exemplary nucleic acid sequences of WW domain containing proteins are listed below. It should be appreciated that any of the nucleic acids encoding WW domains or WW domain variants of the exemplary proteins may be used in the invention, described herein, and are not meant to be limiting.

Human WWP1 nucleic acid sequence (uniprot.org/uniprot/Q9HOM0).

(SEQ ID NO: 23) GAATTCGCGGCCGCGTCGACCGCTTCTGTGGCCACGGCAGATGAAACAGA AAGGCTAAAGAGGGCTGGAGTCAGGGGACTTCTCTTCCACCAGCTTCACG GTGATGATATGGCATCTGCCAGCTCTAGCCGGGCAGGAGTGGCCCTGCCT TTTGAGAAGTCTCAGCTCACTTTGAAAGTGGTGTCCGCAAAGCCCAAGGT GCATAATCGTCAACCTCGAATTAACTCCTACGTGGAGGTGGCGGTGGATG GACTCCCCAGTGAGACCAAGAAGACTGGGAAGCGCATTGGGAGCTCTGAG CTTCTCTGGAATGAGATCATCATTTTGAATGTCACGGCACAGAGTCATTT AGATTTAAAGGTCTGGAGCTGCCATACCTTGAGAAATGAACTGCTAGGCA CCGCATCTGTCAACCTCTCCAACGTCTTGAAGAACAATGGGGGCAAAATG GAGAACATGCAGCTGACCCTGAACCTGCAGACGGAGAACAAAGGCAGCGT TGTCTCAGGCGGAAAACTGACAATTTTCCTGGACGGGCCAACTGTTGATC TGGGAAATGTGCCTAATGGCAGTGCCCTGACAGATGGATCACAGCTGCCT TCGAGAGACTCCAGTGGAACAGCAGTAGCTCCAGAGAACCGGCACCAGCC CCCCAGCACAAACTGCTTTGGTGGAAGATCCCGGACGCACAGACATTCGG GTGCTTCAGCCAGAACAACCCCAGCAACCGGCGAGCAAAGCCCCGGTGCT CGGAGCCGGCACCGCCAGCCCGTCAAGAACTCAGGCCACAGTGGCTTGGC CAATGGCACAGTGAATGATGAACCCACAACAGCCACTGATCCCGAAGAAC CTTCCGTTGTTGGTGTGACGTCCCCACCTGCTGCACCCTTGAGTGTGACC CCGAATCCCAACACGACTTCTCTCCCTGCCCCAGCCACACCGGCTGAAGG AGAGGAACCCAGCACTTCGGGTACACAGCAGCTCCCAGCGGCTGCCCAGG CCCCCGACGCTCTGCCTGCTGGATGGGAACAGCGAGAGCTGCCCAACGGA CGTGTCTATTATGTTGACCACAATACCAAGACCACCACCTGGGAGCGGCC CCTTCCTCCAGGCTGGGAAAAACGCACAGATCCCCGAGGCAGGTTTTACT ATGTGGATCACAATACTCGGACCACCACCTGGCAGCGTCCGACCGCGGAG TACGTGCGCAACTATGAGCAGTGGCAGTCGCAGCGGAATCAGCTCCAGGG GGCCATGCAGCACTTCAGCCAAAGATTCCTATACCAGTTTTGGAGTGCTT CGACTGACCATGATCCCCTGGGCCCCCTCCCTCCTGGTTGGGAGAAAAGA CAGGACAATGGACGGGTGTATTACGTGAACCATAACACTCGCACGACCCA GTGGGAGGATCCCCGGACCCAGGGGATGATCCAGGAACCAGCTTTGCCCC CAGGATGGGAGATGAAATACACCAGCGAGGGGGTGCGATACTTTGTGGAC CACAATACCCGCACCACCACCTTTAAGGATCCTCGCCCGGGGTTTGAGTC GGGGACGAAGCAAGGTTCCCCTGGTGCTTATGACCGCAGTTTTCGGTGGA AGTATCACCAGTTCCGTTTCCTCTGCCATTCAAATGCCCTACCTAGCCAC GTGAAGATCAGCGTTTCCAGGCAGACGCTTTTCGAAGATTCCTTCCAACA GATCATGAACATGAAACCCTATGACCTGCGCCGCCGGCTTTACATCATCA TGCGTGGCGAGGAGGGCCTGGACTATGGGGGCATCGCCAGAGAGTGGTTT TTCCTCCTGTCTCACGAGGTGCTCAACCCTATGTATTGTTTATTTGAATA TGCCGGAAAGAACAATTACTGCCTGCAGATCAACCCCGCCTCCTCCATCA ACCCGGACCACCTCACCTACTTTCGCTTTATAGGCAGATTCATCGCCATG GCGCTGTACCATGGAAAGTTCATCGACACGGGCTTCACCCTCCCTTTCTA CAAGCGGATGCTCAATAAGAGACCAACCCTGAAAGACCTGGAGTCCATTG ACCCTGAGTTCTACAACTCCATTGTCTGGATCAAAGAGAACAACCTGGAA GAATGTGGCCTGGAGCTGTACTTCATCCAGGACATGGAGATACTGGGCAA GGTGACGACCCACGAGCTGAAGGAGGGCGGCGAGAGCATCCGGGTCACGG AGGAGAACAAGGAAGAGTACATCATGCTGCTGACTGACTGGCGTTTCACC CGAGGCGTGGAAGAGCAGACCAAAGCCTTCCTGGATGGCTTCAACGAGGT GGCCCCGCTGGAGTGGCTGCGCTACTTTGACGAGAAAGAGCTGGAGCTGA TGCTGTGCGGCATGCAGGAGATAGACATGAGCGACTGGCAGAAGAGCACC ATCTACCGGCACTACACCAAGAACAGCAAGCAGATCCAGTGGTTCTGGCA GGTGGTGAAGGAGATGGACAACGAGAAGAGGATCCGGCTGCTGCAGTTTG TCACCGGTACCTGCCGCCTGCCCGTCGGGGGATTTGCCGAACTCATCGGT AGCAACGGACCACAGAAGTTTTGCATTGACAAAGTTGGCAAGGAAACCTG GCTGCCCAGAAGCCACACCTGCTTCAACCGTCTGGATCTTCCACCCTACA AGAGCTACGAACAGCTGAGAGAGAAGCTGCTGTATGCCATTGAGGAGACC GAGGGCTTTGGACAGGAGTAACCGAGGCCGCCCCTCCCACGCCCCCCAGC GCACATGTAGTCCTGAGTCCTCCCTGCCTGAGAGGCCACTGGCCCCGCAG CCCTTGGGAGGCCCCCGTGGATGTGGCCCTGTGTGGGACCACACTGTCAT CTCGCTGCTGGCAGAAAAGCCTGATCCCAGGAGGCCCTGCAGTTCCCCCG ACCCGCGGATGGCAGTCTGGAATAAAGCCCCCTAGTTGCCTTTGGCCCCA CCTTTGCAAAGTTCCAGAGGGCTGACCCTCTCTGCAAAACTCTCCCCTGT CCTCTAGACCCCACCCTGGGTGTATGTGAGTGTGCAAGGGAAGGTGTTGC ATCCCCAGGGGCTGCCGCAGAGGCCGGAGACCTCCTGGACTAGTTCGGCG AGGAGACTGGCCACTGGGGGTGGCTGTTCGGGACTGAGAGCGCCAAGGGT CTTTGCCAGCAAAGGAGGTTCTGCCTGTAATTGAGCCTCTCTGATGATGG AGATGAAGTGAAGGTCTGAGGGACGGGCCCTGGGGCTAGGCCATCTCTGC CTGCCTCCCTAGCAGGCGCCAGCGGTGGAGGCTGAGTCGCAGGACACATG CCGGCCAGTTAATTCATTCTCAGCAAATGAAGGTTTGTCTAAGCTGCCTG GGTATCCACGGGACAAAAACAGCAAACTCCCTCCAGACTTTGTCCATGTT ATAAACTTGAAAGTTGGTTGTTGTTTGTTAGGTTTGCCAGGTTTTTTTGT TTACGCCTGCTGTCACTTTCCTGTC

Human WWP2 nucleic acid sequence (uniprot.org/uniprot/ O00308).

(SEQ ID NO: 24) GAATTCGCGGCCGCGTCGACCGCTTCTGTGGCCACGGCAGATGAAACAGA AAGGCTAAAGAGGGCTGGAGTCAGGGGACTTCTCTTCCACCAGCTTCACG GTGATGATATGGCATCTGCCAGCTCTAGCCGGGCAGGAGTGGCCCTGCCT TTTGAGAAGTCTCAGCTCACTTTGAAAGTGGTGTCCGCAAAGCCCAAGGT GCATAATCGTCAACCTCGAATTAACTCCTACGTGGAGGTGGCGGTGGATG GACTCCCCAGTGAGACCAAGAAGACTGGGAAGCGCATTGGGAGCTCTGAG CTTCTCTGGAATGAGATCATCATTTTGAATGTCACGGCACAGAGTCATTT AGATTTAAAGGTCTGGAGCTGCCATACCTTGAGAAATGAACTGCTAGGCA CCGCATCTGTCAACCTCTCCAACGTCTTGAAGAACAATGGGGGCAAAATG GAGAACATGCAGCTGACCCTGAACCTGCAGACGGAGAACAAAGGCAGCGT TGTCTCAGGCGGAAAACTGACAATTTTCCTGGACGGGCCAACTGTTGATC TGGGAAATGTGCCTAATGGCAGTGCCCTGACAGATGGATCACAGCTGCCT TCGAGAGACTCCAGTGGAACAGCAGTAGCTCCAGAGAACCGGCACCAGCC CCCCAGCACAAACTGCTTTGGTGGAAGATCCCGGACGCACAGACATTCGG GTGCTTCAGCCAGAACAACCCCAGCAACCGGCGAGCAAAGCCCCGGTGCT CGGAGCCGGCACCGCCAGCCCGTCAAGAACTCAGGCCACAGTGGCTTGGC CAATGGCACAGTGAATGATGAACCCACAACAGCCACTGATCCCGAAGAAC CTTCCGTTGTTGGTGTGACGTCCCCACCTGCTGCACCCTTGAGTGTGACC CCGAATCCCAACACGACTTCTCTCCCTGCCCCAGCCACACCGGCTGAAGG AGAGGAACCCAGCACTTCGGGTACACAGCAGCTCCCAGCGGCTGCCCAGG CCCCCGACGCTCTGCCTGCTGGATGGGAACAGCGAGAGCTGCCCAACGGA CGTGTCTATTATGTTGACCACAATACCAAGACCACCACCTGGGAGCGGCC CCTTCCTCCAGGCTGGGAAAAACGCACAGATCCCCGAGGCAGGTTTTACT ATGTGGATCACAATACTCGGACCACCACCTGGCAGCGTCCGACCGCGGAG TACGTGCGCAACTATGAGCAGTGGCAGTCGCAGCGGAATCAGCTCCAGGG GGCCATGCAGCACTTCAGCCAAAGATTCCTATACCAGTTTTGGAGTGCTT CGACTGACCATGATCCCCTGGGCCCCCTCCCTCCTGGTTGGGAGAAAAGA CAGGACAATGGACGGGTGTATTACGTGAACCATAACACTCGCACGACCCA GTGGGAGGATCCCCGGACCCAGGGGATGATCCAGGAACCAGCTTTGCCCC CAGGATGGGAGATGAAATACACCAGCGAGGGGGTGCGATACTTTGTGGAC CACAATACCCGCACCACCACCTTTAAGGATCCTCGCCCGGGGTTTGAGTC GGGGACGAAGCAAGGTTCCCCTGGTGCTTATGACCGCAGTTTTCGGTGGA AGTATCACCAGTTCCGTTTCCTCTGCCATTCAAATGCCCTACCTAGCCAC GTGAAGATCAGCGTTTCCAGGCAGACGCTTTTCGAAGATTCCTTCCAACA GATCATGAACATGAAACCCTATGACCTGCGCCGCCGGCTTTACATCATCA TGCGTGGCGAGGAGGGCCTGGACTATGGGGGCATCGCCAGAGAGTGGTTT TTCCTCCTGTCTCACGAGGTGCTCAACCCTATGTATTGTTTATTTGAATA TGCCGGAAAGAACAATTACTGCCTGCAGATCAACCCCGCCTCCTCCATCA ACCCGGACCACCTCACCTACTTTCGCTTTATAGGCAGATTCATCGCCATG GCGCTGTACCATGGAAAGTTCATCGACACGGGCTTCACCCTCCCTTTCTA CAAGCGGATGCTCAATAAGAGACCAACCCTGAAAGACCTGGAGTCCATTG ACCCTGAGTTCTACAACTCCATTGTCTGGATCAAAGAGAACAACCTGGAA GAATGTGGCCTGGAGCTGTACTTCATCCAGGACATGGAGATACTGGGCAA GGTGACGACCCACGAGCTGAAGGAGGGCGGCGAGAGCATCCGGGTCACGG AGGAGAACAAGGAAGAGTACATCATGCTGCTGACTGACTGGCGTTTCACC CGAGGCGTGGAAGAGCAGACCAAAGCCTTCCTGGATGGCTTCAACGAGGT GGCCCCGCTGGAGTGGCTGCGCTACTTTGACGAGAAAGAGCTGGAGCTGA TGCTGTGCGGCATGCAGGAGATAGACATGAGCGACTGGCAGAAGAGCACC ATCTACCGGCACTACACCAAGAACAGCAAGCAGATCCAGTGGTTCTGGCA GGTGGTGAAGGAGATGGACAACGAGAAGAGGATCCGGCTGCTGCAGTTTG TCACCGGTACCTGCCGCCTGCCCGTCGGGGGATTTGCCGAACTCATCGGT AGCAACGGACCACAGAAGTTTTGCATTGACAAAGTTGGCAAGGAAACCTG GCTGCCCAGAAGCCACACCTGCTTCAACCGTCTGGATCTTCCACCCTACA AGAGCTACGAACAGCTGAGAGAGAAGCTGCTGTATGCCATTGAGGAGACC GAGGGCTTTGGACAGGAGTAACCGAGGCCGCCCCTCCCACGCCCCCCAGC GCACATGTAGTCCTGAGTCCTCCCTGCCTGAGAGGCCACTGGCCCCGCAG CCCTTGGGAGGCCCCCGTGGATGTGGCCCTGTGTGGGACCACACTGTCAT CTCGCTGCTGGCAGAAAAGCCTGATCCCAGGAGGCCCTGCAGTTCCCCCG ACCCGCGGATGGCAGTCTGGAATAAAGCCCCCTAGTTGCCTTTGGCCCCA CCTTTGCAAAGTTCCAGAGGGCTGACCCTCTCTGCAAAACTCTCCCCTGT CCTCTAGACCCCACCCTGGGTGTATGTGAGTGTGCAAGGGAAGGTGTTGC ATCCCCAGGGGCTGCCGCAGAGGCCGGAGACCTCCTGGACTAGTTCGGCG AGGAGACTGGCCACTGGGGGTGGCTGTTCGGGACTGAGAGCGCCAAGGGT CTTTGCCAGCAAAGGAGGTTCTGCCTGTAATTGAGCCTCTCTGATGATGG AGATGAAGTGAAGGTCTGAGGGACGGGCCCTGGGGCTAGGCCATCTCTGC CTGCCTCCCTAGCAGGCGCCAGCGGTGGAGGCTGAGTCGCAGGACACATG CCGGCCAGTTAATTCATTCTCAGCAAATGAAGGTTTGTCTAAGCTGCCTG GGTATCCACGGGACAAAAACAGCAAACTCCCTCCAGACTTTGTCCATGTT ATAAACTTGAAAGTTGGTTGTTGTTTGTTAGGTTTGCCAGGTTTTTTTGT TTACGCCTGCTGTCACTTTCCTGTC

Human Nedd4-1 nucleic acid sequence (uniprot.org/uniprot/ P46934).

(SEQ ID NO: 25) ACAGTTGCCTGCCCTGGGCGGGGGCGAGCGCGTCCGGTTTGCTGGAAGC GTTCGGAAATGGCAACTTGCGCGGTGGAGGTGTTCGGGCTCCTGGAGGA CGAGGAAAATTCACGAATTGTGAGAGTAAGAGTTATAGCCGGAATAGGC CTTGCCAAGAAGGATATATTGGGAGCTAGTGATCCTTACGTGAGAGTGA CGTTATATGACCCAATGAATGGAGTTCTTACAAGTGTGCAAACAAAAAC CATTAAAAAGAGTTTGAATCCAAAGTGGAATGAAGAAATATTATTCAGA GTTCATCCTCAGCAGCACCGGCTTCTTTTTGAAGTGTTTGACGAAAACC GATTGACAAGAGATGATTTCCTAGGTCAAGTGGATGTTCCACTTTATCC ATTACCGACAGAAAATCCAAGATTGGAGAGACCATATACATTTAAGGAT TTTGTTCTTCATCCAAGAAGTCACAAATCAAGAGTTAAAGGTTATCTGA GACTAAAAATGACTTATTTACCTAAAACCAGTGGCTCAGAAGATGATAA TGCAGAACAGGCTGAGGAATTAGAGCCTGGCTGGGTTGTTTTGGACCAA CCAGATGCTGCTTGCCATTTGCAGCAACAACAAGAACCTTCTCCTCTAC CTCCAGGGTGGGAAGAGAGGCAGGATATCCTTGGAAGGACCTATTATGT AAACCATGAATCTAGAAGAACACAGTGGAAAAGACCAACCCCTCAGGAC AACCTAACAGATGCTGAGAATGGCAACATTCAACTGCAAGCACAACGTG CATTTACCACCAGGCGGCAGATATCCGAGGAAACAGAAAGTGTTGACAA CCAAGAGTCTTCCGAGAACTGGGAAATTATAAGAGAAGATGAAGCCACC ATGTATAGCAGCCAGGCCTTCCCATCACCTCCACCGTCAAGTAACTTGG ATGTTCCAACTCATCTTGCAGAAGAATTGAATGCCAGACTCACCATTTT TGGAAATTCAGCCGTGAGCCAGCCAGCATCGAGCTCAAATCATTCCAGC AGAAGAGGCAGCTTACAAGCCTATACTTTTGAGGAACAACCTACACTTC CTGTGCTTTTGCCTACTTCATCTGGATTACCACCAGGTTGGGAAGAAAA ACAAGATGAAAGAGGAAGATCATATTATGTAGATCACAATTCCAGAACG ACTACTTGGACAAAGCCCACTGTACAGGCCACAGTGGAGACCAGTCAGC TGACCTCAAGCCAGAGTTCTGCAGGCCCTCAATCACAAGCCTCCACCAG TGATTCAGGCCAGCAGGTGACCCAGCCATCTGAAATTGAGCAAGGATTC CTTCCTAAAGGCTGGGAAGTCCGGCATGCACCAAATGGGAGGCCTTTCT TTATTGACCACAACACTAAAACCACCACCTGGGAAGATCCAAGATTGAA AATTCCAGCCCATCTGAGAGGAAAGACATCACTTGATACTTCCAATGAT CTAGGGCCTTTACCTCCAGGATGGGAAGAGAGAACTCACACAGATGGAA GAATCTTCTACATAAATCACAATATAAAAAGAACACAATGGGAAGATCC TCGGTTGGAGAATGTAGCAATAACTGGACCAGCAGTGCCCTACTCCAGG GATTACAAAAGAAAGTATGAGTTCTTCCGAAGAAAGTTGAAGAAGCAGA ATGACATTCCAAACAAATTTGAAATGAAACTTCGCCGAGCAACTGTTCT TGAAGACTCTTACCGGAGAATTATGGGTGTCAAGAGAGCAGACTTCCTG AAGGCTCGACTGTGGATTGAGTTTGATGGTGAAAAGGGATTGGATTATG GAGGAGTTGCCAGAGAATGGTTCTTCCTGATCTCAAAGGAAATGTTTAA CCCTTATTATGGGTTGTTTGAATATTCTGCTACGGACAATTATACCCTA CAGATAAATCCAAACTCTGGATTGTGTAACGAAGATCACCTCTCTTACT TCAAGTTTATTGGTCGGGTAGCTGGAATGGCAGTTTATCATGGCAAACT GTTGGATGGTTTTTTCATCCGCCCATTTTACAAGATGATGCTTCACAAA CCAATAACCCTTCATGATATGGAATCTGTGGATAGTGAATATTACAATT CCCTAAGATGGATTCTTGAAAATGACCCAACAGAATTGGACCTCAGGTT TATCATAGATGAAGAACTTTTTGGACAGACACATCAACATGAGCTGAAA AATGGTGGATCAGAAATAGTTGTCACCAATAAGAACAAAAAGGAATATA TTTATCTTGTAATACAATGGCGATTTGTAAACCGAATCCAGAAGCAAAT GGCTGCTTTTAAAGAGGGATTCTTTGAACTAATACCACAGGATCTCATC AAAATTTTTGATGAAAATGAACTAGAGCTTCTTATGTGTGGACCGGGAG ATGTTGATGTGAATGACTGGAGGGAACATACAAAGTATAAAAATGGCTA CAGTGCAAATCATCAGGTTATACAGTGGTTTTGGAAGGCTGTTTTAATG ATGGATTCAGAAAAAAGAATAAGATTACTTCAGTTTGTCACTGGCACAT CTCGGGTGCCTATGAATGGATTTGCTGAACTATACGGTTCAAATGGACC ACAGTCATTTACAGTTGAACAGTGGGGTACTCCTGAAAAGCTGCCAAGA GCTCATACCTGTTTTAATCGCCTGGACTTGCCACCTTATGAATCATTTG AAGAATTATGGGATAAACTTCAGATGGCAATTGAAAACACCCAGGGCTT TGATGGAGTTGATTAGATTACAAATAACAATCTGTAGTGTTTTTACTGC CATAGTTTTATAACCAAAATCTTGACTTAAAATTTTCCGGGGAACTACT AAAATGTGGCCACTGAGTCTTCCCAGATCTTGAAGAAAATCATATAAAA AGCATTTGAAGAAATAGTACGAC

Human Nedd4-2 nucleic acid sequence (>gi|345478679|ref|NM_015277.5|Homo sapiens neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase (NEDD4L), transcript variant d, mRNA).

(SEQ ID NO: 26) ATGGCGACCGGGCTCGGGGAGCCGGTCTATGGACTTTCCGAAGACGAGG GAGAGTCCCGTATTCTCAGAGTAAAAGTTGTTTCTGGAATTGATCTCGC CAAAAAGGACATCTTTGGAGCCAGTGATCCGTATGTGAAACTTTCATTG TACGTAGCGGATGAGAATAGAGAACTTGCTTTGGTCCAGACAAAAACAA TTAAAAAGACACTGAACCCAAAATGGAATGAAGAATTTTATTTCAGGGT AAACCCATCTAATCACAGACTCCTATTTGAAGTATTTGACGAAAATAGA CTGACACGAGACGACTTCCTGGGCCAGGTGGACGTGCCCCTTAGTCACC TTCCGACAGAAGATCCAACCATGGAGCGACCCTATACATTTAAGGACTT TCTCCTCAGACCAAGAAGTCATAAGTCTCGAGTTAAGGGATTTTTGCGA TTGAAAATGGCCTATATGCCAAAAAATGGAGGTCAAGATGAAGAAAACA GTGACCAGAGGGATGACATGGAGCATGGATGGGAAGTTGTTGACTCAAA TGACTCGGCTTCTCAGCACCAAGAGGAACTTCCTCCTCCTCCTCTGCCT CCCGGGTGGGAAGAAAAAGTGGACAATTTAGGCCGAACTTACTATGTCA ACCACAACAACCGGACCACTCAGTGGCACAGACCAAGCCTGATGGACGT GTCCTCGGAGTCGGACAATAACATCAGACAGATCAACCAGGAGGCAGCA CACCGGCGCTTCCGCTCCCGCAGGCACATCAGCGAAGACTTGGAGCCCG AGCCCTCGGAGGGCGGGGATGTCCCCGAGCCTTGGGAGACCATTTCAGA GGAAGTGAATATCGCTGGAGACTCTCTCGGTCTGGCTCTGCCCCCACCA CCGGCCTCCCCAGGATCTCGGACCAGCCCTCAGGAGCTGTCAGAGGAAC TAAGCAGAAGGCTTCAGATCACTCCAGACTCCAATGGGGAACAGTTCAG CTCTTTGATTCAAAGAGAACCCTCCTCAAGGTTGAGGTCATGCAGTGTC ACCGACGCAGTTGCAGAACAGGGCCATCTACCACCGCCATCAGTGGCCT ATGTACATACCACGCCGGGTCTGCCTTCAGGCTGGGAAGAAAGAAAAGA TGCTAAGGGGCGCACATACTATGTCAATCATAACAATCGAACCACAACT TGGACTCGACCTATCATGCAGCTTGCAGAAGATGGTGCGTCCGGATCAG CCACAAACAGTAACAACCATCTAATCGAGCCTCAGATCCGCCGGCCTCG TAGCCTCAGCTCGCCAACAGTAACTTTATCTGCCCCGCTGGAGGGTGCC AAGGACTCACCCGTACGTCGGGCTGTGAAAGACACCCTTTCCAACCCAC AGTCCCCACAGCCATCACCTTACAACTCCCCCAAACCACAACACAAAGT CACACAGAGCTTCTTGCCACCCGGCTGGGAAATGAGGATAGCGCCAAAC GGCCGGCCCTTCTTCATTGATCATAACACAAAGACTACAACCTGGGAAG ATCCACGTTTGAAATTTCCAGTACATATGCGGTCAAAGACATCTTTAAA CCCCAATGACCTTGGCCCCCTTCCTCCTGGCTGGGAAGAAAGAATTCAC TTGGATGGCCGAACGTTTTATATTGATCATAATAGCAAAATTACTCAGT GGGAAGACCCAAGACTGCAGAACCCAGCTATTACTGGTCCGGCTGTCCC TTACTCCAGAGAATTTAAGCAGAAATATGACTACTTCAGGAAGAAATTA AAGAAACCTGCTGATATCCCCAATAGGTTTGAAATGAAACTTCACAGAA ATAACATATTTGAAGAGTCCTATCGGAGAATTATGTCCGTGAAAAGACC AGATGTCCTAAAAGCTAGACTGTGGATTGAGTTTGAATCAGAGAAAGGT CTTGACTATGGGGGTGTGGCCAGAGAATGGTTCTTCTTACTGTCCAAAG AGATGTTCAACCCCTACTACGGCCTCTTTGAGTACTCTGCCACGGACAA CTACACCCTTCAGATCAACCCTAATTCAGGCCTCTGTAATGAGGATCAT TTGTCCTACTTCACTTTTATTGGAAGAGTTGCTGGTCTGGCCGTATTTC ATGGGAAGCTCTTAGATGGTTTCTTCATTAGACCATTTTACAAGATGAT GTTGGGAAAGCAGATAACCCTGAATGACATGGAATCTGTGGATAGTGAA TATTACAACTCTTTGAAATGGATCCTGGAGAATGACCCTACTGAGCTGG ACCTCATGTTCTGCATAGACGAAGAAAACTTTGGACAGACATATCAAGT GGATTTGAAGCCCAATGGGTCAGAAATAATGGTCACAAATGAAAACAAA AGGGAATATATCGACTTAGTCATCCAGTGGAGATTTGTGAACAGGGTCC AGAAGCAGATGAACGCCTTCTTGGAGGGATTCACAGAACTACTTCCTAT TGATTTGATTAAAATTTTTGATGAAAATGAGCTGGAGTTGCTCATGTGC GGCCTCGGTGATGTGGATGTGAATGACTGGAGACAGCATTCTATTTACA AGAACGGCTACTGCCCAAACCACCCCGTCATTCAGTGGTTCTGGAAGGC TGTGCTACTCATGGACGCCGAAAAGCGTATCCGGTTACTGCAGTTTGTC ACAGGGACATCGCGAGTACCTATGAATGGATTTGCCGAACTTTATGGTT CCAATGGTCCTCAGCTGTTTACAATAGAGCAATGGGGCAGTCCTGAGAA ACTGCCCAGAGCTCACACATGCTTTAATCGCCTTGACTTACCTCCATAT GAAACCTTTGAAGATTTACGAGAGAAACTTCTCATGGCCGTGGAAAATG CTCAAGGATTTGAAGGGGTGGATTAA 

Human Smurf1 nucleic acid sequence (uniprot.org/uniprot/ Q9HCE7).

(SEQ ID NO: 27) ATGTCGAACCCCGGGACACGCAGGAACGGCTCCAGCATCAAGATCCGTC TGACAGTGTTATGTGCCAAGAACCTTGCAAAGAAAGACTTCTTCAGGCT CCCTGACCCTTTTGCAAAGATTGTCGTGGATGGGTCTGGGCAGTGCCAC TCAACCGACACTGTGAAAAACACATTGGACCCAAAGTGGAACCAGCACT ATGATCTATATGTTGGGAAAACGGATTCGATAACCATTAGCGTGTGGAA CCATAAGAAAATTCACAAGAAACAGGGAGCTGGCTTCCTGGGCTGTGTG CGGCTGCTCTCCAATGCCATCAGCAGATTAAAAGATACCGGATACCAGC GTTTGGATCTATGCAAACTAAACCCCTCAGATACTGATGCAGTTCGTGG CCAGATAGTGGTCAGTTTACAGACACGAGACAGAATAGGAACCGGCGGC TCGGTGGTGGACTGCAGAGGACTGTTAGAAAATGAAGGAACGGTGTATG AAGACTCCGGGCCTGGGAGGCCGCTCAGCTGCTTCATGGAGGAACCAGC CCCTTACACAGATAGCACCGGTGCTGCTGCTGGAGGAGGGAATTGCAGG TTCGTGGAGTCCCCAAGTCAAGATCAAAGACTTCAGGCACAGCGGCTTC GAAACCCTGATGTGCGAGGTTCACTACAGACGCCCCAGAACCGACCACA CGGCCACCAGTCCCCGGAACTGCCCGAAGGCTACGAACAAAGAACAACA GTCCAGGGCCAAGTTTACTTTTTGCATACACAGACTGGAGTTAGCACGT GGCACGACCCCAGGATACCAAGTCCCTCGGGGACCATTCCTGGGGGAGA TGCAGCTTTTCTATACGAATTCCTTCTACAAGGCCATACATCTGAGCCC AGAGACCTTAACAGTGTGAACTGTGATGAACTTGGACCACTGCCGCCAG GCTGGGAAGTCAGAAGTACAGTTTCTGGGAGGATATATTTTGTAGATCA TAATAACCGAACAACCCAGTTTACAGACCCAAGGTTACACCACATCATG AATCACCAGTGCCAACTCAAGGAGCCCAGCCAGCCGCTGCCACTGCCCA GTGAGGGCTCTCTGGAGGACGAGGAGCTTCCTGCCCAGAGATACGAAAG AGATCTAGTCCAGAAGCTGAAAGTCCTCAGACACGAACTGTCGCTTCAG CAGCCCCAAGCTGGTCATTGCCGCATCGAAGTGTCCAGAGAAGAAATCT TTGAGGAGTCTTACCGCCAGATAATGAAGATGCGACCGAAAGACTTGAA AAAACGGCTGATGGTGAAATTCCGTGGGGAAGAAGGTTTGGATTACGGT GGTGTGGCCAGGGAGTGGCTTTACTTGCTGTGCCATGAAATGCTGAATC CTTATTACGGGCTCTTCCAGTATTCTACGGACAATATTTACATGTTGCA AATAAATCCGGATTCTTCAATCAACCCCGACCACTTGTCTTATTTCCAC TTTGTGGGGCGGATCATGGGGCTGGCTGTGTTCCATGGACACTACATCA ACGGGGGCTTCACAGTGCCCTTCTACAAGCAGCTGCTGGGGAAGCCCAT CCAGCTCTCAGATCTGGAATCTGTGGACCCAGAGCTGCATAAGAGCTTG GTGTGGATCCTAGAGAACGACATCACGCCTGTACTGGACCACACCTTCT GCGTGGAACACAACGCCTTCGGGCGGATCCTGCAGCATGAACTGAAACC CAATGGCAGAAATGTGCCAGTCACAGAGGAGAATAAGAAAGAATACGTC CGGTTGTATGTAAACTGGAGGTTTATGAGAGGAATCGAAGCCCAGTTCT TAGCTCTGCAGAAGGGGTTCAATGAGCTCATCCCTCAACATCTGCTGAA GCCTTTTGACCAGAAGGAACTGGAGCTGATCATAGGCGGCCTGGATAAA ATAGACTTGAACGACTGGAAGTCGAACACGCGGCTGAAGCACTGTGTGG CCGACAGCAACATCGTGCGGTGGTTCTGGCAAGCGGTGGAGACGTTCGA TGAAGAAAGGAGGGCCAGGCTCCTGCAGTTTGTGACTGGGTCCACGCGA GTCCCGCTCCAAGGCTTCAAGGCTTTGCAAGGTTCTACAGGCGCGGCAG GGCCCCGGCTGTTCACCATCCACCTGATAGACGCGAACACAGACAACCT TCCGAAGGCCCATACCTGCTTTAACCGGATCGACATTCCACCATATGAG TCCTATGAGAAGCTCTACGAGAAGCTGCTGACAGCCGTGGAGGAGACCT GCGGGTTTGCTGTGGAGTGA

Human Smurf2 nucleic acid sequence (uniprot.org/uniprot/Q9HAU4).

(SEQ ID NO: 28) GCAAAAAACCTGGTGAAAAAGGATTTTTTCCGACTTCCTGATCCATTTG CTAAGGTGGTGGTTGATGGATCTGGGCAATGCCATTCTACAGATACTGT GAAGAATACGCTTGATCCAAAGTGGAATCAGCATTATGACCTGTATATT GGAAAGTCTGATTCAGTTACGATCAGTGTATGGAATCACAAGAAGATCC ATAAGAAACAAGGTGCTGGATTTCTCGGTTGTGTTCGTCTTCTTTCCAA TGCCATCAACCGCCTCAAAGACACTGGTTATCAGAGGTTGGATTTATGC AAACTCGGGCCAAATGACAATGATACAGTTAGAGGACAGATAGTAGTAA GTCTTCAGTCCAGAGACCGAATAGGCACAGGAGGACAAGTTGTGGACTG CAGTCGTTTATTTGATAACGATTTACCAGACGGCTGGGAAGAAAGGAGA ACCGCCTCTGGAAGAATCCAGTATCTAAACCATATAACAAGAACTACGC AATGGGAGCGCCCAACACGACCGGCATCCGAATATTCTAGCCCTGGCAG ACCTCTTAGCTGCTTTGTTGATGAGAACACTCCAATTAGTGGAACAAAT GGTGCAACATGTGGACAGTCTTCAGATCCCAGGCTGGCAGAGAGGAGAG TCAGGTCACAACGACATAGAAATTACATGAGCAGAACACATTTACATAC TCCTCCAGACCTACCAGAAGGCTATGAACAGAGGACAACGCAACAAGGC CAGGTGTATTTCTTACATACACAGACTGGTGTGAGCACATGGCATGATC CAAGAGTGCCCAGGGATCTTAGCAACATCAATTGTGAAGAGCTTGGTCC ATTGCCTCCTGGATGGGAGATCCGTAATACGGCAACAGGCAGAGTTTAT TTCGTTGACCATAACAACAGAACAACACAATTTACAGATCCTCGGCTGT CTGCTAACTTGCATTTAGTTTTAAATCGGCAGAACCAATTGAAAGACCA ACAGCAACAGCAAGTGGTATCGTTATGTCCTGATGACACAGAATGCCTG ACAGTCCCAAGGTACAAGCGAGACCTGGTTCAGAAACTAAAAATTTTGC GGCAAGAACTTTCCCAACAACAGCCTCAGGCAGGTCATTGCCGCATTGA GGTTTCCAGGGAAGAGATTTTTGAGGAATCATATCGACAGGTCATGAAA ATGAGACCAAAAGATCTCTGGAAGCGATTAATGATAAAATTTCGTGGAG AAGAAGGCCTTGACTATGGAGGCGTTGCCAGGGAATGGTTGTATCTCTT GTCACATGAAATGTTGAATCCATACTATGGCCTCTTCCAGTATTCAAGA GATGATATTTATACATTGCAGATCAATCCTGATTCTGCAGTTAATCCGG AACATTTATCCTATTTCCACTTTGTTGGACGAATAATGGGAATGGCTGT GTTTCATGGACATTATATTGATGGTGGTTTCACATTGCCTTTTTATAAG CAATTGCTTGGGAAGTCAATTACCTTGGATGACATGGAGTTAGTAGATC CGGATCTTCACAACAGTTTAGTGTGGATACTTGAGAATGATATTACAGG TGTTTTGGACCATACCTTCTGTGTTGAACATAATGCATATGGTGAAATT ATTCAGCATGAACTTAAACCAAATGGCAAAAGTATCCCTGTTAATGAAG AAAATAAAAAAGAATATGTCAGGCTCTATGTGAACTGGAGATTTTTACG AGGCATTGAGGCTCAATTCTTGGCTCTGCAGAAAGGATTTAATGAAGTA ATTCCACAACATCTGCTGAAGACATTTGATGAGAAGGAGTTAGAGCTCA TTATTTGTGGACTTGGAAAGATAGATGTTAATGACTGGAAGGTAAACAC CCGGTTAAAACACTGTACACCAGACAGCAACATTGTCAAATGGTTCTGG AAAGCTGTGGAGTTTTTTGATGAAGAGCGACGAGCAAGATTGCTTCAGT TTGTGACAGGATCCTCTCGAGTGCCTCTGCAGGGCTTCAAAGCATTGCA AGGTGCTGCAGGCCCGAGACTCTTTACCATACACCAGATTGATGCCTGC ACTAACAACCTGCCGAAAGCCCACACTTGCTTCAATCGAATAGACATTC CACCCTATGAAAGCTATGAAAAGCTATATGAAAAGCTGCTAACAGCCAT TGAAGAAACATGTGGATTTGCTGTGGAATGA

Human ITCH nucleic acid sequence (uniprot.org/uniprot/Q96J02).

(SEQ ID NO: 29) GGAGTCGCCGCCGCCCCGAGTTCCGGTACCATGCATTTCACGGTGGCCT TGTGGAGACAACGCCTTAACCCAAGGAAGTGACTCAAACTGTGAGAACT CCAGGTTTTCCAACCTATTGGTGGTATGTCTGACAGTGGATCACAACTT GGTTCAATGGGTAGCCTCACCATGAAATCACAGCTTCAGATCACTGTCA TCTCAGCAAAACTTAAGGAAAATAAGAAGAATTGGTTTGGACCAAGTCC TTACGTAGAGGTCACAGTAGATGGACAGTCAAAGAAGACAGAAAAATGC AACAACACAAACAGTCCCAAGTGGAAGCAACCCCTTACAGTTATCGTTA CCCCTGTGAGTAAATTACATTTTCGTGTGTGGAGTCACCAGACACTGAA ATCTGATGTTTTGTTGGGAACTGCTGCATTAGATATTTATGAAACATTA AAGTCAAACAATATGAAACTTGAAGAAGTAGTTGTGACTTTGCAGCTTG GAGGTGACAAAGAGCCAACAGAGACAATAGGAGACTTGTCAATTTGTCT TGATGGGCTACAGTTAGAGTCTGAAGTTGTTACCAATGGTGAAACTACA TGTTCAGAAAGTGCTTCTCAGAATGATGATGGCTCCAGATCCAAGGATG AAACAAGAGTGAGCACAAATGGATCAGATGACCCTGAAGATGCAGGAGC TGGTGAAAATAGGAGAGTCAGTGGGAATAATTCTCCATCACTCTCAAAT GGTGGTTTTAAACCTTCTAGACCTCCAAGACCTTCACGACCACCACCAC CCACCCCACGTAGACCAGCATCTGTCAATGGTTCACCATCTGCCACTTC TGAAAGTGATGGGTCTAGTACAGGCTCTCTGCCGCCGACAAATACAAAT ACAAATACATCTGAAGGAGCAACATCTGGATTAATAATTCCTCTTACTA TATCTGGAGGCTCAGGCCCTAGGCCATTAAATCCTGTAACTCAAGCTCC CTTGCCACCTGGTTGGGAGCAGAGAGTGGACCAGCACGGGCGAGTTTAC TATGTAGATCATGTTGAGAAAAGAACAACATGGGATAGACCAGAACCTC TACCTCCTGGCTGGGAACGGCGGGTTGACAACATGGGACGTATTTATTA TGTTGACCATTTCACAAGAACAACAACGTGGCAGAGGCCAACACTGGAA TCCGTCCGGAACTATGAACAATGGCAGCTACAGCGTAGTCAGCTTCAAG GAGCAATGCAGCAGTTTAACCAGAGATTCATTTATGGGAATCAAGATTT ATTTGCTACATCACAAAGTAAAGAATTTGATCCTCTTGGTCCATTGCCA CCTGGATGGGAGAAGAGAACAGACAGCAATGGCAGAGTATATTTCGTCA ACCACAACACACGAATTACACAATGGGAAGACCCCAGAAGTCAAGGTCA ATTAAATGAAAAGCCCTTACCTGAAGGTTGGGAAATGAGATTCACAGTG GATGGAATTCCATATTTTGTGGACCACAATAGAAGAACTACCACCTATA TAGATCCCCGCACAGGAAAATCTGCCCTAGACAATGGACCTCAGATAGC CTATGTTCGGGACTTCAAAGCAAAGGTTCAGTATTTCCGGTTCTGGTGT CAGCAACTGGCCATGCCACAGCACATAAAGATTACAGTGACAAGAAAAA CATTGTTTGAGGATTCCTTTCAACAGATAATGAGCTTCAGTCCCCAAGA TCTGCGAAGACGTTTGTGGGTGATTTTTCCAGGAGAAGAAGGTTTAGAT TATGGAGGTGTAGCAAGAGAATGGTTCTTTCTTTTGTCACATGAAGTGT TGAACCCAATGTATTGCCTGTTTGAATATGCAGGGAAGGATAACTACTG CTTGCAGATAAACCCCGCTTCTTACATCAATCCAGATCACCTGAAATAT TTTCGTTTTATTGGCAGATTTATTGCCATGGCTCTGTTCCATGGGAAAT TCATAGACACGGGTTTTTCTTTACCATTCTATAAGCGTATCTTGAACAA ACCAGTTGGACTCAAGGATTTAGAATCTATTGATCCAGAATTTTACAAT TCTCTCATCTGGGTTAAGGAAAACAATATTGAGGAATGTGATTTGGAAA TGTACTTCTCCGTTGACAAAGAAATTCTAGGTGAAATTAAGAGTCATGA TCTGAAACCTAATGGTGGCAATATTCTTGTAACAGAAGAAAATAAAGAG GAATACATCAGAATGGTAGCTGAGTGGAGGTTGTCTCGAGGTGTTGAAG AACAGACACAAGCTTTCTTTGAAGGCTTTAATGAAATTCTTCCCCAGCA ATATTTGCAATACTTTGATGCAAAGGAATTAGAGGTCCTTTTATGTGGA ATGCAAGAGATTGATTTGAATGACTGGCAAAGACATGCCATCTACCGTC ATTATGCAAGGACCAGCAAACAAATCATGTGGTTTTGGCAGTTTGTTAA AGAAATTGATAATGAGAAGAGAATGAGACTTCTGCAGTTTGTTACTGGA ACCTGCCGATTGCCAGTAGGAGGATTTGCTGATCTCATGGGGAGCAATG GACCACAGAAATTCTGCATTGAAAAAGTTGGGAAAGAAAATTGGCTACC CAGAAGTCATACCTGTTTTAATCGCCTGGACCTGCCACCATACAAGAGC TATGAGCAACTGAAGGAAAAGCTGTTGTTTGCCATAGAAGAAACAGAAG GATTTGGACAAGAGTAACTTCTGAGAACTTGCACCATGAATGGGCAAGA ACTTATTTGCAATGTTTGTCCTTCTCTGCCTGTTGCACATCTTGTAAAA TTGGACAATGGCTCTTTAGAGAGTTATCTGAGTGTAAGTAAATTAATGT TCTCATTTAAAAAAAAAAAAAAAAAAA

Human NEDL1 nucleic acid sequence (uniprot.org/uniprot/Q76N89).

(SEQ ID NO: 30) GCGCATCAGGCGCTGTTGTTGGAGCCGGAACACCGTGCGACTCTGACCG AACCGGCCCCCTCCTCGCGCACACACTCGCCGAGCCGCGCGCGCCCCTC CGCCGTGACAGTGGCCGTGGCCTCCGCTCTCTCGGGGCACCCGGCAGCC AGAGCGCAGCGAGAGCGGGCGGTCGCCAGGGTCCCCTCCCCAGCCAGTC CCAGGCGCCCGGTGCACTATGCGGGGCACGTGCGCCCCCCAGCTCTAAT CTGCGCGCTGACAGGAGCATGATCTGTGCCCAGGCCAGGGCTGCCAAGG AATTGATGCGCGTACACGTGGTGGGTCATTATGCTGCTACACCTGTGTA GTGTGAAGAATCTGTACCAGAACAGGTTTTTAGGCCTGGCCGCCATGGC GTCTCCTTCTAGAAACTCCCAGAGCCGACGCCGGTGCAAGGAGCCGCTC CGATACAGCTACAACCCCGACCAGTTCCACAACATGGACCTCAGGGGCG GCCCCCACGATGGCGTCACCATTCCCCGCTCCACCAGCGACACTGACCT GGTCACCTCGGACAGCCGCTCCACGCTCATGGTCAGCAGCTCCTACTAT TCCATCGGGCACTCTCAGGACCTGGTCATCCACTGGGACATAAAGGAGG AAGTGGACGCTGGGGACTGGATTGGCATGTACCTCATTGATGAGGTCTT GTCCGAAAACTTTCTGGACTATAAAAACCGTGGAGTCAATGGTTCTCAT CGGGGCCAGATCATCTGGAAGATCGATGCCAGCTCGTACTTTGTGGAAC CTGAAACTAAGATCTGCTTCAAATACTACCATGGAGTGAGTGGGGCCCT GCGAGCAACCACCCCCAGTGTCACGGTCAAAAACTCGGCAGCTCCTATT TTTAAAAGCATTGGTGCTGATGAGACCGTCCAAGGACAAGGAAGTCGGA GGCTGATCAGCTTCTCTCTCTCAGATTTCCAAGCCATGGGGTTGAAGAA AGGGATGTTTTTCAACCCAGACCCTTATCTGAAGATTTCCATTCAGCCT GGGAAACACAGCATCTTCCCCGCCCTCCCTCACCATGGACAGGAGAGGA GATCCAAGATCATAGGCAACACCGTGAACCCCATCTGGCAGGCCGAGCA ATTCAGTTTTGTGTCCTTGCCCACTGACGTGCTGGAAATTGAGGTGAAG GACAAGTTTGCCAAGAGCCGCCCCATCATCAAGCGCTTCTTGGGAAAGC TGTCGATGCCCGTTCAAAGACTCCTGGAGAGACACGCCATAGGGGATAG GGTGGTCAGCTACACACTTGGCCGCAGGCTTCCAACAGATCATGTGAGT GGACAGCTGCAATTCCGATTTGAGATCACTTCCTCCATCCACCCAGATG ATGAGGAGATTTCCCTGAGTACCGAGCCTGAGTCAGCCCAAATTCAGGA CAGCCCCATGAACAACCTGATGGAAAGCGGCAGTGGGGAACCTCGGTCT GAGGCACCAGAGTCCTCTGAGAGCTGGAAGCCAGAGCAGCTGGGTGAGG GCAGTGTCCCCGATGGTCCAGGGAACCAAAGCATAGAGCTTTCCAGACC AGCTGAGGAAGCAGCAGTCATCACGGAGGCAGGAGACCAGGGCATGGTC TCTGTGGGACCTGAAGGGGCTGGGGAGCTCCTGGCCCAGGTGCAAAAGG ACATCCAGCCTGCCCCCAGTGCAGAAGAGCTGGCCGAGCAGCTGGACCT GGGTGAGGAGGCATCAGCACTGCTGCTGGAAGACGGTGAAGCCCCAGCC AGCACCAAGGAGGAGCCCTTGGAGGAGGAAGCAACGACCCAGAGCCGGG CTGGAAGGGAAGAAGAGGAGAAGGAGCAGGAGGAGGAGGGAGATGTGTC TACCCTGGAGCAGGGAGAGGGCAGGCTGCAGCTGCGGGCCTCGGTGAAG AGAAAAAGCAGGCCCTGCTCCTTGCCTGTGTCCGAGCTGGAGACGGTGA TCGCGTCAGCCTGCGGGGACCCCGAGACCCCGCGGACACACTACATCCG CATCCACACCCTGCTGCACAGCATGCCCTCCGCCCAGGGCGGCAGCGCG GCAGAGGAGGAGGACGGCGCGGAGGAGGAGTCCACCCTCAAGGACTCCT CGGAGAAGGATGGGCTCAGCGAGGTGGACACGGTGGCCGCTGACCCGTC TGCCCTGGAAGAGGACAGAGAAGAGCCCGAGGGGGCTACTCCAGGCACG GCGCACCCTGGCCACTCCGGGGGCCACTTCCCCAGCCTGGCCAATGGCG CGGCCCAGGATGGCGACACGCACCCCAGCACCGGGAGCGAGAGCGACTC CAGCCCCAGGCAAGGCGGGGACCACAGTTGCGAGGGCTGTGACGCGTCC TGCTGCAGCCCCTCGTGCTACAGCTCCTCGTGCTACAGCACGTCCTGCT ACAGCAGCTCGTGCTACAGCGCCTCGTGCTACAGCCCCTCCTGCTACAA CGGCAACAGGTTCGCCAGCCACACGCGCTTCTCCTCCGTGGACAGCGCC AAGATCTCCGAGAGCACGGTCTTCTCCTCGCAAGACGACGAGGAGGAGG AGAACAGCGCGTTCGAGTCGGTACCCGACTCCATGCAGAGCCCTGAGCT GGACCCGGAGTCCACGAACGGCGCTGGGCCGTGGCAAGACGAGCTGGCC GCCCCTAGCGGGCACGTGGAAAGAAGCCCGGAAGGTCTGGAATCCCCCG TGGCAGGTCCAAGCAATCGCAGAGAAGACTGGGAAGCTCGAATTGACAG CCACGGGCGGGTCTTTTATGTGGACCACGTGAACCGCACAACCACCTGG CAGCGTCCGACGGCAGCAGCCACCCCGGATGGCATGCGGAGATCGGGGT CCATCCAGCAGATGGAGCAAGTCAACAGGCGGTATCAAAACATTCAGCG AACCATTGCAACAGAGAGGTCCGAAGAAGATTCTGGCAGCCAAAGCTGC GAGCAAGCCCCAGCAGGAGGAGGCGGAGGTGGAGGGAGTGACTCAGAAG CCGAATCTTCCCAGTCCAGCTTAGATCTAAGGAGAGAGGGGTCACTTTC TCCAGTGAACTCACAAAAAATCACCTTGCTGCTGCAGTCCCCAGCGGTC AAGTTCATCACCAACCCCGAGTTCTTCACTGTGCTACACGCCAATTATA GTGCCTACCGAGTCTTCACCAGTAGCACCTGCTTAAAGCACATGATTCT GAAAGTCCGACGGGATGCTCGCAATTTTGAACGCTACCAGCACAACCGG GACTTGGTGAATTTCATCAACATGTTCGCAGACACTCGGCTGGAACTGC CCCGGGGCTGGGAGATCAAAACGGACCAGCAGGGAAAGTCTTTTTTCGT GGACCACAACAGTCGAGCTACCACTTTCATTGACCCCCGAATCCCTCTT CAGAACGGTCGTCTTCCCAATCATCTAACTCACCGACAGCACCTCCAGA GGCTCCGAAGTTACAGCGCCGGAGAGGCCTCAGAAGTTTCTAGAAACAG AGGAGCCTCTTTACTGGCCAGGCCAGGACACAGCTTAGTAGCTGCTATT CGAAGCCAACATCAACATGAGTCATTGCCACTGGCATATAATGACAAGA TTGTGGCATTTCTTCGCCAGCCAAACATTTTTGAAATGCTGCAAGAGCG TCAGCCAAGCTTAGCAAGAAACCACACACTCAGGGAGAAAATCCATTAC ATTCGGACTGAGGGTAATCACGGGCTTGAGAAGTTGTCCTGTGATGCGG ATCTGGTCATTTTGCTGAGTCTCTTTGAAGAAGAGATTATGTCCTACGT CCCCCTGCAGGCTGCCTTCCACCCTGGGTATAGCTTCTCTCCCCGATGT TCACCCTGTTCTTCACCTCAGAACTCCCCAGGTTTACAGAGAGCCAGTG CAAGAGCCCCTTCCCCCTACCGAAGAGACTTTGAGGCCAAGCTCCGCAA TTTCTACAGAAAACTGGAAGCCAAAGGATTTGGTCAGGGTCCGGGGAAA ATTAAGCTCATTATTCGCCGGGATCATTTGTTGGAGGGAACCTTCAATC AGGTGATGGCCTATTCGCGGAAAGAGCTCCAGCGAAACAAGCTCTACGT CACCTTTGTTGGAGAGGAGGGCCTGGACTACAGTGGCCCCTCGCGGGAG TTCTTCTTCCTTCTGTCTCAGGAGCTCTTCAACCCTTACTATGGACTCT TTGAGTACTCGGCAAATGATACTTACACGGTGCAGATCAGCCCCATGTC CGCATTTGTAGAAAACCATCTTGAGTGGTTCAGGTTTAGCGGTCGCATC CTGGGTCTGGCTCTGATCCATCAGTACCTTCTTGACGCTTTCTTCACGA GGCCCTTCTACAAGGCACTCCTGAGACTGCCCTGTGATTTGAGTGACCT GGAATATTTGGATGAGGAATTCCACCAGAGTTTGCAGTGGATGAAGGAC AACAACATCACAGACATCTTAGACCTCACTTTCACTGTTAATGAAGAGG TTTTTGGACAGGTCACGGAAAGGGAGTTGAAGTCTGGAGGAGCCAACAC ACAGGTGACGGAGAAAAACAAGAAGGAGTACATCGAGCGCATGGTGAAG TGGCGGGTGGAGCGCGGCGTGGTACAGCAGACCGAGGCGCTGGTGCGCG GCTTCTACGAGGTTGTAGACTCGAGGCTGGTGTCCGTGTTTGATGCCAG GGAGCTGGAGCTGGTGATAGCTGGCACCGCGGAAATCGACCTAAATGAC TGGCGGAATAACACTGAGTACCGGGGAGGTTACCACGATGGGCATCTTG TGATCCGCTGGTTCTGGGCTGCGGTGGAGCGCTTCAATAATGAGCAGAG GCTGAGATTACTGCAGTTTGTCACGGGAACATCCAGCGTGCCCTACGAA GGCTTCGCAGCCCTCCGTGGGAGCAATGGGCTTCGGCGCTTCTGCATAG AGAAATGGGGGAAAATTACTTCTCTCCCCAGGGCACACACATGCTTCAA CCGACTGGATCTTCCACCGTATCCCTCGTACTCCATGTTGTATGAAAAG CTGTTAACAGCAGTAGAGGAAACCAGCACCTTTGGACTTGAGTGAGGAC ATGGAACCTCGCCTGACATTTTCCTGGCCAGTGACATCACCCTTCCTGG GATGATCCCCTTTTCCCTTTCCCTTAATGAACTCTCCTTTGATTTTGGT ATTCCATGATTTTTATTTTCAAAC

Human NEDL2 nucleic acid sequence (uniprot.org/uniprot/ Q9P2P5).

(SEQ ID NO: 31) AGAGTTCCATCAGAGCCTGCAGTGGATGAAAGACAATGATATCCATGA CATCCTAGACCTCACGTTCACTGTGAACGAAGAAGTATTTGGGCAGAT AACTGAACGAGAATTAAAGCCAGGGGGTGCCAATATCCCAGTTACAGA GAAGAACAAGAAGGAGTACATCGAGAGGATGGTGAAGTGGAGGATTGA GAGGGGTGTTGTACAGCAAACAGAGAGCTTAGTGCGTGGCTTCTATGA GGTGGTGGATGCCAGGCTGGTATCTGTTTTTGATGCAAGAGAACTGGA ATTGGTCATCGCAGGCACAGCTGAAATAGACCTAAGTGATTGGAGAAA CAACACAGAATATAGAGGAGGATACCATGACAATCATATTGTAATTCG GTGGTTCTGGGCTGCAGTGGAAAGATTCAACAATGAACAACGACTAAG GTTGTTACAGTTTGTTACAGGCACATCCAGCATTCCCTATGAAGGATT TGCTTCACTCCGAGGGAGTAACGGCCCAAGAAGATTCTGTGTGGAGAA ATGGGGGAAAATCACTGCTCTTCCCAGAGCGCATACATGTTTTAACCG TCTGGATCTGCCTCCCTACCCATCCTTTTCCATGCTTTATGAAAAACT GTTGACAGCAGTTGAAGAAACCAGTACTTTTGGACTTGAGTGACCTGG AAGCTGAATGCCCATCTCTGTGGACAGGCAGTTTCAGAAGCTGCCTTC TAGAAGAATGATTGAACATTGGAAGTTTCAAGAGGATGCTTCCTTTAG GATAAAGCTACGTGCTGTTGTTTTCCAGGAACAAGTGCTCTGTCACAT TTGGGGACTGGAGATGAGTCCTCTTGGAAGGATTTGGGTGAGCTTGAT GCCCAGGGAACAACCCAACCGTCTTTCAATCAACAGTTCTTGACTGCC AAACTTTTTCCATTTGTTATGTTCCAAGACAAAGATGAACCCATACAT GATCAGCTCCACGGTAATTTTTAGGGACTCAGGAGAATCTTGAAACTT ACCCTTGAACGTGGTTCAAGCCAAACTGGCAGCATTTGGCCCAATCTC CAAATTAGAGCAAGTTAAATAATATAATAAAAGTAAATATATTTCCTG AAAGTACATTCATTTAAGCCCTAAGTTATAACAGAATATTCATTTCTT GCTTATGAGTGCCTGCATGGTGTGCACCATAGGTTTCCGCTTTCATGG GACATGAGTGAAAATGAAACCAAGTCAATATGAGGTACCTTTACAGAT TTGCAATAAGATGGTCTGTGACAATGTATATGCAAGTGGTATGTGTGT AATTATGGCTAAAGACAAACCATTATTCAGTGAATTACTAATGACAGA TTTTATGCTTTATAATGCATGAAAACAATTTTAAAATAACTAGCAATT AATCACAGCATATCAGGAAAAAGTACACAGTGAGTTCTGTTTATTTTT TGTAGGCTCATTATGTTTATGTTCTTTAAGATGTATATAAGAACCTAC TTATCATGCTGTATGTATCACTCATTCCATTTTCATGTTCCATGCATA CTCGGGCATCATGCTAATATGTATCCTTTTAAGCACTCTCAAGGAAAC AAAAGGGCCTTTTATTTTTATAAAGGTAAAAAAAATTCCCCAAATATT TTGCACTGAATGTACCAAAGGTGAAGGGACATTACAATATGACTAACA GCAACTCCATCACTTGAGAAGTATAATAGAAAATAGCTTCTAAATCAA ACTTCCTTCACAGTGCCGTGTCTACCACTACAAGGACTGTGCATCTAA GTAATAATTTTTTAAGATTCACTATATGTGATAGTATGATATGCATTT ATTTAAAATGCATTAGACTCTCTTCCATCCATCAAATACTTTACAGGA TGGCATTTAATACAGATATTTCGTATTTCCCCCACTGCTTTTTATTTG TACAGCATCATTAAACACTAAGCTCAGTTAAGGAGCCATCAGCAACAC TGAAGAGATCAGTAGTAAGAATTCCATTTTCCCTCATCAGTGAAGACA CCACAAATTGAAACTCAGAACTATATTTCTAAGCCTGCATTTTCACTG ATGCATAATTTTCTTATTAATATTAAGAGACAGTTTTTCTATGGCATC TCCAAAACTGCATGACATCACTAGTCTTACTTCTGCTTAATTTTATGA GAAGGTATTCTTCATTTTAATTGCTTTTGGGATTACTCCACATCTTTG TTTATTTCTTGACTAATCAGATTTTCAATAGAGTGAAGTTAAATTGGG GGTCATAAAAGCATTGGATTGACATATGGTTTGCCAGCCTATGGGTTT ACAGGCATTGCCCAAACATTTCTTTGAGATCTATATTTATAAGCAGCC ATGGAATTCCTATTATGGGATGTTGGCAATCTTACATTTTATAGAGGT CATATGCATAGTTTTCATAGGTGTTTTGTAAGAACTGATTGCTCTCCT GTGAGTTAAGCTATGTTTACTACTGGGACCCTCAAGAGGAATACCACT TATGTTACACTCCTGCACTAAAGGCACGTACTGCAGTGTGAAGAAATG TTCTGAAAAAGGGTTATAGAAATCTGGAAATAAGAAAGGAAGAGCTCT CTGTATTCTATAATTGGAAGAGAAAAAAAGAAAAACTTTTAACTGGAA ATGTTAGTTTGTACTTATTGATCATGAATACAAGTATATATTTAATTT TGCAAAAAAAAAAAAAAAAAAAAAAAG

In certain embodiments, the nucleic acids may encode cargo proteins having two WW domains or WW domain variants from the human ITCH protein having the nucleic acid sequence: CCCTTGCCACCTGGTTGGGAGCAGAGAGTGGACCAGCACGGGCGAGTTTACTATGT AGATCATGTTGAGAAAAGAACAACATGGGATAGACCAGAACCTCTACCTCCTGGCT GGGAACGGCGGGTTGACAACATGGGACGTATTTATTATGTTGACCATTTCACAAGAA CAACAACGTGGCAGAGGCCAACACTG (SEQ ID NO: 32). In other embodiments, the nucleic acids may encode cargo proteins having four WW domains or WW domain variants from the human ITCH protein having the nucleic acid sequence: CCCTTGCCACCTGGTTGGGAGCAGAGAGTGGACCAGCACGGGCGAGTTTACTATGT AGATCATGTTGAGAAAAGAACAACATGGGATAGACCAGAACCTCTACCTCCTGGCT GGGAACGGCGGGTTGACAACATGGGACGTATTTATTATGTTGACCATTTCACAAGAA CAACAACGTGGCAGAGGCCAACACTGGAATCCGTCCGGAACTATGAACAATGGCAG CTACAGCGTAGTCAGCTTCAAGGAGCAATGCAGCAGTTTAACCAGAGATTCATTTAT GGGAATCAAGATTTATTTGCTACATCACAAAGTAAAGAATTTGATCCTCTTGGTCCA TTGCCACCTGGATGGGAGAAGAGAACAGACAGCAATGGCAGAGTATATTTCGTCAA CCACAACACACGAATTACACAATGGGAAGACCCCAGAAGTCAAGGTCAATTAAATG AAAAGCCCTTACCTGAAGGTTGGGAAATGAGATTCACAGTGGATGGAATTCCATATT TTGTGGACCACAATAGAAGAACTACCACCTATATAGATCCCCGCACA (SEQ ID NO: 33). The nucleic acid constructs that encode the cargo proteins, described herein, that are fused to at least one WW domain or WW domain variant are non-naturally occurring, that is, they do not exist in nature.

In some embodiments the expression constructs comprise a nucleic acid sequence encoding a WW domain, or variant thereof from the nucleic acid sequence (SEQ ID NO: 23); (SEQ ID NO: 24); (SEQ ID NO: 25); (SEQ ID NO: 26); (SEQ ID NO: 27); (SEQ ID NO: 28); (SEQ ID NO: 29); (SEQ ID NO: 30); (SEQ ID NO: 31); (SEQ ID NO: 32) or (SEQ ID NO: 33). In certain embodiments, the expression constructs encode a fusion protein comprising a WW domain or multiple WW domains, a nuclear localization sequence (NLS), and a Cas9 protein or variant thereof. In certain embodiments, the expression constructs comprise the nucleic acid sequence (SEQ ID NO: 67) or (SEQ ID NO: 68). In certain embodiments, the expression constructs consist of the nucleic acid sequence (SEQ ID NO: 67) or (SEQ ID NO: 68). In certain embodiments, the expression constructs consist essentially of the nucleic acid sequence (SEQ ID NO: 67) or (SEQ ID NO: 68).

The following nucleic acid sequences encode exemplary Cas9 cargo protein sequences that have either 2 WW domains (SEQ ID NO: 65) or 4 WW domains (SEQ ID NO: 66), which were cloned into the AgeI site of the pX330 plasmid (Addgene).

(SEQ ID NO: 67) ATGCCCTTGCCACCTGGTTGGGAGCAGAGAGTGGACCAGCACGGGCGAG TTTACTATGTAGATCATGTTGAGAAAAGAACAACATGGGATAGACCAGA ACCTCTACCTCCTGGCTGGGAACGGCGGGTTGACAACATGGGACGTATT TATTATGTTGACCATTTCACAAGAACAACAACGTGGCAGAGGCCAACAC TGACCGGTGCCACCATGGACTATAAGGACCACGACGGAGACTACAAGGA TCATGATATTGATTACAAAGACGATGACGATAAGATGGCCCCAAAGAAG AAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGACAAGAAGTACA GCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGATCAC CGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACC GACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACA GCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAG ATACACCAGACGGAAGAACCGGATCTGCTATCTGCAAGAGATCTTCAGC AACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGT CCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGG CAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTAC CACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTGCGGC TGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCT GATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTC ATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCA ACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAA GAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAG AATGGCCTGTTCGGAAACCTGATTGCCCTGAGCCTGGGCCTGACCCCCA ACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCAGCTGAG CAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGC GACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCA TCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCC CCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTG ACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAG AGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGG CGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAA AAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACC TGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGAT CCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTAC CCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCC GCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGC CTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAG GAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGA CCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAG CCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAA TACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGA AAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGT GAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCC GTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACAT ACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGA GGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTT GAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGT TCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTG GGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCC GGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAA ACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACAT CCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATT GCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAG TGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGA GAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGA CAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAG AGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCT GCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATG TACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGG ACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAA GGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCC TCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGA ACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGA GAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAG CTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACT CCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGT GAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGAT TTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACG ACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCC TAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTG CGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCA AGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTAC CCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGC GAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGC GGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGT GCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGC GATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCG GCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGT GGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGG ATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTC TGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCT GCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTG GCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCA AATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGG CTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAG CACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAG TGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAA GCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTG TTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACA CCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGC CACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGAC CTGTCTCAGCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAAAAGGCCG GCCAGGCAAAAAAGAAAAAG (SEQ ID NO: 68) ATGCCCTTGCCACCTGGTTGGGAGCAGAGAGTGGACCAGCACGGGCGAG TTTACTATGTAGATCATGTTGAGAAAAGAACAACATGGGATAGACCAGA ACCTCTACCTCCTGGCTGGGAACGGCGGGTTGACAACATGGGACGTATT TATTATGTTGACCATTTCACAAGAACAACAACGTGGCAGAGGCCAACAC TGGAATCCGTCCGGAACTATGAACAATGGCAGCTACAGCGTAGTCAGCT TCAAGGAGCAATGCAGCAGTTTAACCAGAGATTCATTTATGGGAATCAA GATTTATTTGCTACATCACAAAGTAAAGAATTTGATCCTCTTGGTCCAT TGCCACCTGGATGGGAGAAGAGAACAGACAGCAATGGCAGAGTATATTT CGTCAACCACAACACACGAATTACACAATGGGAAGACCCCAGAAGTCAA GGTCAATTAAATGAAAAGCCCTTACCTGAAGGTTGGGAAATGAGATTCA CAGTGGATGGAATTCCATATTTTGTGGACCACAATAGAAGAACTACCAC CTATATAGATCCCCGCACAGGCGGAGGAACCGGTGCCACCATGGACTAT AAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACG ATGACGATAAGATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGG AGTCCCAGCAGCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACC AACTCTGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCCAGCA AGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAA CCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACAGCCGAGGCCACC CGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGA TCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAG AAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCT ACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGA CAGCACCGACAAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCAC ATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCG ACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAA CCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAG GCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGA TCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGAT TGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTG GCCGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGACGACC TGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCT GGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGACATCCTGAGA GTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGA GATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCG GCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAG AACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCT ACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACT GCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTC GACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCA TTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGA AAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCT CTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGG AAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTC CGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCC AACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCG TGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAA GCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTG TTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACT TCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGA TCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATC AAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAG ATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGA ACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAG CTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGA TCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCT GAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGAC GACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCC AGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGC CATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTG AAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCA GAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAAT GAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAA GAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGT ACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACAT CAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTT CTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGA ACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGAT GAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGA AAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGG ATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCAC AAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGAC GAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCA AGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGA GATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTG GGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGT ACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGA GCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATC ATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGA AGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGA TAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAA GTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAG AGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAA GGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCC TATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAAC TGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAG CTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAA GTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGC TGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAA GGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTG GCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGA AACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGA GCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTG GACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAG AGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGC CCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTAC ACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCA CCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAA AAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAG

Nucleic acids encoding any of the fusion proteins, described herein, may be in any number of nucleic acid “vectors” known in the art. As used herein, a “vector” means any nucleic acid or nucleic acid-bearing particle, cell, or organism capable of being used to transfer a nucleic acid into a host cell. The term “vector” includes both viral and nonviral products and means for introducing the nucleic acid into a cell. A “vector” can be used in vitro, ex vivo, or in vivo. Non-viral vectors include plasmids, cosmids, artificial chromosomes (e.g., bacterial artificial chromosomes or yeast artificial chromosomes) and can comprise liposomes, electrically charged lipids (cytofectins), DNA-protein complexes, and biopolymers, for example. Viral vectors include retroviruses, lentiviruses, adeno-associated virus, pox viruses, baculovirus, reoviruses, vaccinia viruses, herpes simplex viruses, Epstein-Barr viruses, and adenovirus vectors, for example. Vectors can also comprise the entire genome sequence or recombinant genome sequence of a virus. A vector can also comprise a portion of the genome that comprises the functional sequences for production of a virus capable of infecting, entering, or being introduced to a cell to deliver nucleic acid therein.

Expression of any of the fusion proteins, described herein, may be controlled by any regulatory sequence (e.g. a promoter sequence) known in the art. Regulatory sequences, as described herein, are nucleic acid sequences that regulate the expression of a nucleic acid sequence. A regulatory or control sequence may include sequences that are responsible for expressing a particular nucleic acid (i.e. a Cas9 cargo protein) or may include other sequences, such as heterologous, synthetic, or partially synthetic sequences. The sequences can be of eukaryotic, prokaryotic or viral origin that stimulate or repress transcription of a gene in a specific or non-specific manner and in an inducible or non-inducible manner. Regulatory or control regions may include origins of replication, RNA splice sites, introns, chimeric or hybrid introns, promoters, enhancers, transcriptional termination sequences, poly A sites, locus control regions, signal sequences that direct the polypeptide into the secretory pathways of the target cell, and introns. A heterologous regulatory region is not naturally associated with the expressed nucleic acid it is linked to. Included among the heterologous regulatory regions are regulatory regions from a different species, regulatory regions from a different gene, hybrid regulatory sequences, and regulatory sequences that do not occur in nature, but which are designed by one of ordinary skill in the art.

The term operably linked refers to an arrangement of sequences or regions wherein the components are configured so as to perform their usual or intended function. Thus, a regulatory or control sequence operably linked to a coding sequence is capable of affecting the expression of the coding sequence. The regulatory or control sequences need not be contiguous with the coding sequence, so long as they function to direct the proper expression or polypeptide production. Thus, for example, intervening untranslated but transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered operably linked to the coding sequence. A promoter sequence, as described herein, is a DNA regulatory region a short distance from the 5′ end of a gene that acts as the binding site for RNA polymerase. The promoter sequence may bind RNA polymerase in a cell and/or initiate transcription of a downstream (3′ direction) coding sequence. The promoter sequence may be a promoter capable of initiating transcription in prokaryotes or eukaryotes. Some non-limiting examples of eukaryotic promoters include the cytomegalovirus (CMV) promoter, the chicken β-actin (CBA) promoter, and a hybrid form of the CBA promoter (CBh).

In certain embodiments, the Cas9 cargo protein is expressed from the pX330 plasmid (Addgene). An exemplary nucleic acid sequence of the pX330 plasmid with the 5′ AgeI cloning site underlined (single underline) and the 3′ EcoRI cloning site underlined (double underlined) is shown as (SEQ ID NO: 34). Any of the nucleic acids encoding the WW domains or WW domain variants, described herein, may be cloned, in frame, with the sequence encoding Cas9 from SEQ ID NO: 34. For example, the two ITCH WW domains or the four ITCH WW domains encoded in the nucleic acid sequences (SEQ ID NO: 32), or (SEQ ID NO: 33) may be cloned into the 5′ AgeI cloning site or the 3′ EcoRI cloning site. It should be appreciated that a nucleic acid encoding any of the WW domains or WW domain variants, described herein, may be cloned into the Cas9 sequence of (SEQ ID NO: 34) and the examples provided are not meant to be limiting.

(SEQ ID NO: 34)    1 gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgttagagag   61 ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga  121 aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat  181 atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt GTGGAAAGGA  241 CGAAACACCg gGTCTTCgaG AAGACctgtt ttagagctaG AAAtagcaag ttaaaataag  301 gctagtccgt tatcaacttg aaaaagtggc accgagtcgg tgcTTTTTTg ttttagagct  361 agaaatagca agttaaaata aggctagtcc gtTTTTagcg cgtgcgccaa ttctgcagac  421 aaatggctct agaggtaccc gttacataac ttacggtaaa tggcccgcct ggctgaccgc  481 ccaacgaccc ccgcccattg acgtcaatag taacgccaat agggactttc cattgacgtc  541 aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc  601 caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tGtgcccagt  661 acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta  721 ccatggtcga ggtgagcccc acgttctgct tcactctccc catctccccc ccctccccac  781 ccccaatttt gtatttattt attttttaat tattttgtgc agcgatgggg gcgggggggg  841 ggggggggcg cgcgccaggc ggggcggggc ggggcgaggg gcggggcggg gcgaggcgga  901 gaggtgcggc ggcagccaat cagagcggcg cgctccgaaa gtttcctttt atggcgaggc  961 ggcggcggcg gcggccctat aaaaagcgaa gcgcgcggcg ggcgggagtc gctgcgacgc 1021 tgccttcgcc ccgtgccccg ctccgccgcc gcctcgcgcc gcccgccccg gctctgactg 1081 accgcgttac tcccacaggt gagcgggcgg gacggccctt ctcctccggg ctgtaattag 1141 ctgagcaaga ggtaagggtt taagggatgg ttggttggtg gggtattaat gtttaattac 1201 ctggagcacc tgcctgaaat cacttttttt caggttGG ac cggt gccacc ATGGACTATA 1261 AGGACCACGA CGGAGACTAC AAGGATCATG ATATTGATTA CAAAGACGAT GACGATAAGA 1321 TGGCCCCAAA GAAGAAGCGG AAGGTCGGTA TCCACGGAGT CCCAGCAGCC GACAAGAAGT 1381 ACAGCATCGG CCTGGACATC GGCACCAACT CTGTGGGCTG GGCCGTGATC ACCGACGAGT 1441 ACAAGGTGCC CAGCAAGAAA TTCAAGGTGC TGGGCAACAC CGACCGGCAC AGCATCAAGA 1501 AGAACCTGAT CGGAGCCCTG CTGTTCGACA GCGGCGAAAC AGCCGAGGCC ACCCGGCTGA 1561 AGAGAACCGC CAGAAGAAGA TACACCAGAC GGAAGAACCG GATCTGCTAT CTGCAAGAGA 1621 TCTTCAGCAA CGAGATGGCC AAGGTGGACG ACAGCTTCTT CCACAGACTG GAAGAGTCCT 1681 TCCTGGTGGA AGAGGATAAG AAGCACGAGC GGCACCCCAT CTTCGGCAAC ATCGTGGACG 1741 AGGTGGCCTA CCACGAGAAG TACCCCACCA TCTACCACCT GAGAAAGAAA CTGGTGGACA 1801 GCACCGACAA GGCCGACCTG CGGCTGATCT ATCTGGCCCT GGCCCACATG ATCAAGTTCC 1861 GGGGCCACTT CCTGATCGAG GGCGACCTGA ACCCCGACAA CAGCGACGTG GACAAGCTGT 1921 TCATCCAGCT GGTGCAGACC TACAACCAGC TGTTCGAGGA AAACCCCATC AACGCCAGCG 1981 GCGTGGACGC CAAGGCCATC CTGTCTGCCA GACTGAGCAA GAGCAGACGG CTGGAAAATC 2041 TGATCGCCCA GCTGCCCGGC GAGAAGAAGA ATGGCCTGTT CGGAAACCTG ATTGCCCTGA 2101 GCCTGGGCCT GACCCCCAAC TTCAAGAGCA ACTTCGACCT GGCCGAGGAT GCCAAACTGC 2161 AGCTGAGCAA GGACACCTAC GACGACGACC TGGACAACCT GCTGGCCCAG ATCGGCGACC 2221 AGTACGCCGA CCTGTTTCTG GCCGCCAAGA ACCTGTCCGA CGCCATCCTG CTGAGCGACA 2281 TCCTGAGAGT GAACACCGAG ATCACCAAGG CCCCCCTGAG CGCCTCTATG ATCAAGAGAT 2341 ACGACGAGCA CCACCAGGAC CTGACCCTGC TGAAAGCTCT CGTGCGGCAG CAGCTGCCTG 2401 AGAAGTACAA AGAGATTTTC TTCGACCAGA GCAAGAACGG CTACGCCGGC TACATTGACG 2461 GCGGAGCCAG CCAGGAAGAG TTCTACAAGT TCATCAAGCC CATCCTGGAA AAGATGGACG 2521 GCACCGAGGA ACTGCTCGTG AAGCTGAACA GAGAGGACCT GCTGCGGAAG CAGCGGACCT 2581 TCGACAACGG CAGCATCCCC CACCAGATCC ACCTGGGAGA GCTGCACGCC ATTCTGCGGC 2641 GGCAGGAAGA TTTTTACCCA TTCCTGAAGG ACAACCGGGA AAAGATCGAG AAGATCCTGA 2701 CCTTCCGCAT CCCCTACTAC GTGGGCCCTC TGGCCAGGGG AAACAGCAGA TTCGCCTGGA 2761 TGACCAGAAA GAGCGAGGAA ACCATCACCC CCTGGAACTT CGAGGAAGTG GTGGACAAGG 2821 GCGCTTCCGC CCAGAGCTTC ATCGAGCGGA TGACCAACTT CGATAAGAAC CTGCCCAACG 2881 AGAAGGTGCT GCCCAAGCAC AGCCTGCTGT ACGAGTACTT CACCGTGTAT AACGAGCTGA 2941 CCAAAGTGAA ATACGTGACC GAGGGAATGA GAAAGCCCGC CTTCCTGAGC GGCGAGCAGA 3001 AAAAGGCCAT CGTGGACCTG CTGTTCAAGA CCAACCGGAA AGTGACCGTG AAGCAGCTGA 3061 AAGAGGACTA CTTCAAGAAA ATCGAGTGCT TCGACTCCGT GGAAATCTCC GGCGTGGAAG 3121 ATCGGTTCAA CGCCTCCCTG GGCACATACC ACGATCTGCT GAAAATTATC AAGGACAAGG 3181 ACTTCCTGGA CAATGAGGAA AACGAGGACA TTCTGGAAGA TATCGTGCTG ACCCTGACAC 3241 TGTTTGAGGA CAGAGAGATG ATCGAGGAAC GGCTGAAAAC CTATGCCCAC CTGTTCGACG 3301 ACAAAGTGAT GAAGCAGCTG AAGCGGCGGA GATACACCGG CTGGGGCAGG CTGAGCCGGA 3361 AGCTGATCAA CGGCATCCGG GACAAGCAGT CCGGCAAGAC AATCCTGGAT TTCCTGAAGT 3421 CCGACGGCTT CGCCAACAGA AACTTCATGC AGCTGATCCA CGACGACAGC CTGACCTTTA 3481 AAGAGGACAT CCAGAAAGCC CAGGTGTCCG GCCAGGGCGA TAGCCTGCAC GAGCACATTG 3541 CCAATCTGGC CGGCAGCCCC GCCATTAAGA AGGGCATCCT GCAGACAGTG AAGGTGGTGG 3601 ACGAGCTCGT GAAAGTGATG GGCCGGCACA AGCCCGAGAA CATCGTGATC GAAATGGCCA 3661 GAGAGAACCA GACCACCCAG AAGGGACAGA AGAACAGCCG CGAGAGAATG AAGCGGATCG 3721 AAGAGGGCAT CAAAGAGCTG GGCAGCCAGA TCCTGAAAGA ACACCCCGTG GAAAACACCC 3781 AGCTGCAGAA CGAGAAGCTG TACCTGTACT ACCTGCAGAA TGGGCGGGAT ATGTACGTGG 3841 ACCAGGAACT GGACATCAAC CGGCTGTCCG ACTACGATGT GGACCATATC GTGCCTCAGA 3901 GCTTTCTGAA GGACGACTCC ATCGACAACA AGGTGCTGAC CAGAAGCGAC AAGAACCGGG 3961 GCAAGAGCGA CAACGTGCCC TCCGAAGAGG TCGTGAAGAA GATGAAGAAC TACTGGCGGC 4021 AGCTGCTGAA CGCCAAGCTG ATTACCCAGA GAAAGTTCGA CAATCTGACC AAGGCCGAGA 4081 GAGGCGGCCT GAGCGAACTG GATAAGGCCG GCTTCATCAA GAGACAGCTG GTGGAAACCC 4141 GGCAGATCAC AAAGCACGTG GCACAGATCC TGGACTCCCG GATGAACACT AAGTACGACG 4201 AGAATGACAA GCTGATCCGG GAAGTGAAAG TGATCACCCT GAAGTCCAAG CTGGTGTCCG 4261 ATTTCCGGAA GGATTTCCAG TTTTACAAAG TGCGCGAGAT CAACAACTAC CACCACGCCC 4321 ACGACGCCTA CCTGAACGCC GTCGTGGGAA CCGCCCTGAT CAAAAAGTAC CCTAAGCTGG 4381 AAAGCGAGTT CGTGTACGGC GACTACAAGG TGTACGACGT GCGGAAGATG ATCGCCAAGA 4441 GCGAGCAGGA AATCGGCAAG GCTACCGCCA AGTACTTCTT CTACAGCAAC ATCATGAACT 4501 TTTTCAAGAC CGAGATTACC CTGGCCAACG GCGAGATCCG GAAGCGGCCT CTGATCGAGA 4561 CAAACGGCGA AACCGGGGAG ATCGTGTGGG ATAAGGGCCG GGATTTTGCC ACCGTGCGGA 4621 AAGTGCTGAG CATGCCCCAA GTGAATATCG TGAAAAAGAC CGAGGTGCAG ACAGGCGGCT 4681 TCAGCAAAGA GTCTATCCTG CCCAAGAGGA ACAGCGATAA GCTGATCGCC AGAAAGAAGG 4741 ACTGGGACCC TAAGAAGTAC GGCGGCTTCG ACAGCCCCAC CGTGGCCTAT TCTGTGCTGG 4801 TGGTGGCCAA AGTGGAAAAG GGCAAGTCCA AGAAACTGAA GAGTGTGAAA GAGCTGCTGG 4861 GGATCACCAT CATGGAAAGA AGCAGCTTCG AGAAGAATCC CATCGACTTT CTGGAAGCCA 4921 AGGGCTACAA AGAAGTGAAA AAGGACCTGA TCATCAAGCT GCCTAAGTAC TCCCTGTTCG 4981 AGCTGGAAAA CGGCCGGAAG AGAATGCTGG CCTCTGCCGG CGAACTGCAG AAGGGAAACG 5041 AACTGGCCCT GCCCTCCAAA TATGTGAACT TCCTGTACCT GGCCAGCCAC TATGAGAAGC 5101 TGAAGGGCTC CCCCGAGGAT AATGAGCAGA AACAGCTGTT TGTGGAACAG CACAAGCACT 5161 ACCTGGACGA GATCATCGAG CAGATCAGCG AGTTCTCCAA GAGAGTGATC CTGGCCGACG 5221 CTAATCTGGA CAAAGTGCTG TCCGCCTACA ACAAGCACCG GGATAAGCCC ATCAGAGAGC 5281 AGGCCGAGAA TATCATCCAC CTGTTTACCC TGACCAATCT GGGAGCCCCT GCCGCCTTCA 5341 AGTACTTTGA CACCACCATC GACCGGAAGA GGTACACCAG CACCAAAGAG GTGCTGGACG 5401 CCACCCTGAT CCACCAGAGC ATCACCGGCC TGTACGAGAC ACGGATCGAC CTGTCTCAGC 5461 TGGGAGGCGA CAAAAGGCCG GCGGCCACGA AAAAGGCCGG CCAGGCAAAA AAGAAAAAGt 5521 aa gaattc CT AGAGCTCGCT GATCAGCCTC GACTGTGCCT TCTAGTTGCC AGCCATCTGT 5581 TGTTTGCCCC TCCCCCGTGC CTTCCTTGAC CCTGGAAGGT GCCACTCCCA CTGTCCTTTC 5641 CTAATAAAAT GAGGAAATTG CATCGCATTG TCTGAGTAGG TGTCATTCTA TTCTGGGGGG 5701 TGGGGTGGGG CAGGACAGCA AGGGGGAGGA TTGGGAAGAg AATAGCAGGC ATGCTGGGGA 5761 gcggccgcag gaacccctag tgatggagtt ggccactccc tctctgcgcg ctcgctcgct 5821 cactgaggcc gggcgaccaa aggtcgcccg acgcccgggc tttgcccggg cggcctcagt 5881 gagcgagcga gcgcgcagct gcctgcaggg gcgcctgatg cggtattttc tccttacgca 5941 tctgtgcggt atttcacacc gcatacgtca aagcaaccat agtacgcgcc ctgtagcggc 6001 gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga ccgctacact tgccagcgcc 6061 ctagcgcccg ctcctttcgc tttcttccct tcctttctcg ccacgttcgc cggctttccc 6121 cgtcaagctc taaatcgggg gctcccttta gggttccgat ttagtgcttt acggcacctc 6181 gaccccaaaa aacttgattt gggtgatggt tcacgtagtg ggccatcgcc ctgatagacg 6241 gtttttcgcc ctttgacgtt ggagtccacg ttctttaata gtggactctt gttccaaact 6301 ggaacaacac tcaaccctat ctcgggctat tcttttgatt tataagggat tttgccgatt 6361 tcggcctatt ggttaaaaaa tgagctgatt taacaaaaat ttaacgcgaa ttttaacaaa 6421 atattaacgt ttacaatttt atggtgcact ctcagtacaa tctgctctga tgccgcatag 6481 ttaagccagc cccgacaccc gccaacaccc gctgacgcgc cctgacgggc ttgtctgctc 6541 ccggcatccg cttacagaca agctgtgacc gtctccggga gctgcatgtg tcagaggttt 6601 tcaccgtcat caccgaaacg cgcgagacga aagggcctcg tgatacgcct atttttatag 6661 gttaatgtca tgataataat ggtttcttag acgtcaggtg gcacttttcg gggaaatgtg 6721 cgcggaaccc ctatttgttt atttttctaa atacattcaa atatgtatcc gctcatgaga 6781 caataaccct gataaatgct tcaataatat tgaaaaagga agagtatgag tattcaacat 6841 ttccgtgtcg cccttattcc cttttttgcg gcattttgcc ttcctgtttt tgctcaccca 6901 gaaacgctgg tgaaagtaaa agatgctgaa gatcagttgg gtgcacgagt gggttacatc 6961 gaactggatc tcaacagcgg taagatcctt gagagttttc gccccgaaga acgttttcca 7021 atgatgagca cttttaaagt tctgctatgt ggcgcggtat tatcccgtat tgacgccggg 7081 caagagcaac tcggtcgccg catacactat tctcagaatg acttggttga gtactcacca 7141 gtcacagaaa agcatcttac ggatggcatg acagtaagag aattatgcag tgctgccata 7201 accatgagtg ataacactgc ggccaactta cttctgacaa cgatcggagg accgaaggag 7261 ctaaccgctt ttttgcacaa catgggggat catgtaactc gccttgatcg ttgggaaccg 7321 gagctgaatg aagccatacc aaacgacgag cgtgacacca cgatgcctgt agcaatggca 7381 acaacgttgc gcaaactatt aactggcgaa ctacttactc tagcttcccg gcaacaatta 7441 atagactgga tggaggcgga taaagttgca ggaccacttc tgcgctcggc ccttccggct 7501 ggctggttta ttgctgataa atctggagcc ggtgagcgtg gaagccgcgg tatcattgca 7561 gcactggggc cagatggtaa gccctcccgt atcgtagtta tctacacgac ggggagtcag 7621 gcaactatgg atgaacgaaa tagacagatc gctgagatag gtgcctcact gattaagcat 7681 tggtaactgt cagaccaagt ttactcatat atactttaga ttgatttaaa acttcatttt 7741 taatttaaaa ggatctaggt gaagatcctt tttgataatc tcatgaccaa aatcccttaa 7801 cgtgagtttt cgttccactg agcgtcagac cccgtagaaa agatcaaagg atcttcttga 7861 gatccttttt ttctgcgcgt aatctgctgc ttgcaaacaa aaaaaccacc gctaccagcg 7921 gtggtttgtt tgccggatca agagctacca actctttttc cgaaggtaac tggcttcagc 7981 agagcgcaga taccaaatac tgtccttcta gtgtagccgt agttaggcca ccacttcaag 8041 aactctgtag caccgcctac atacctcgct ctgctaatcc tgttaccagt ggctgctgcc 8101 agtggcgata agtcgtgtct taccgggttg gactcaagac gatagttacc ggataaggcg 8161 cagcggtcgg gctgaacggg gggttcgtgc acacagccca gcttggagcg aacgacctac 8221 accgaactga gatacctaca gcgtgagcta tgagaaagcg ccacgcttcc cgaagggaga 8281 aaggcggaca ggtatccggt aagcggcagg gtcggaacag gagagcgcac gagggagctt 8341 ccagggggaa acgcctggta tctttatagt cctgtcgggt ttcgccacct ctgacttgag 8401 cgtcgatttt tgtgatgctc gtcagggggg cggagcctat ggaaaaacgc cagcaacgcg 8461 gcctttttac ggttcctggc cttttgctgg ccttttgctc acatgt

Cells Producing Microvesicles Containing Cargo Proteins

A microvesicle-producing cell of the present invention may be a cell containing any of the expression constructs or any of the cargo proteins described herein. For example, an inventive microvesicle-producing cell may contain one or more recombinant expression constructs encoding (1) an ARRDC1 protein, or PSAP motif-containing variant thereof, and (2) a cargo protein fused to at least one WW domain, or variant thereof, under the control of a heterologous promoter. In certain embodiments, the expression construct in the microvesicle producing cell encodes a cargo protein with one or more WW domains or variants thereof. In some embodiments, the expression construct encodes a Cas9 cargo protein or variant thereof fused to one or more WW domains or variants thereof. In some embodiments, the expression construct encodes a Cas9 cargo protein or variant thereof fused to at least one WW domain and at least one NLS. In some embodiments, the expression construct further encodes a guide RNA (gRNA). In some embodiments, the expression construct further encodes a TSG101 protein, or a TSG101 protein variant. It should be appreciated that the ARMMs produced by such a microvesicle producing cell typically comprise the WW domain containing cargo proteins encoded by the expression constructs described herein.

Another inventive microvesicle-producing cell may contain a recombinant expression construct encoding (1) an ARRDC1 protein, or a PSAP motif-containing variant thereof, linked to (2) a Cas9 cargo protein, or variant thereof, under the control of a heterologous promoter. Some aspects of this invention provide a microvesicle-producing cell that comprises a recombinant expression construct encoding (1) a TSG101 protein, or a UEV domain-containing variant thereof, linked to (2) a Cas9 cargo protein or variant thereof, under the control of a heterologous promoter.

Any of the expression constructs, described herein, may be stably inserted into the genome of the cell. In some embodiments, the expression construct is maintained in the cell, but not inserted into the genome of the cell. In some embodiments, the expression construct is in a vector, for example, a plasmid vector, a cosmid vector, a viral vector, or an artificial chromosome. In some embodiments, the expression construct further comprises additional sequences or elements that facilitate the maintenance and/or the replication of the expression construct in the microvesicle-producing cell, or that improve the expression of the fusion protein in the cell. Such additional sequences or elements may include, for example, an origin of replication, an antibiotic resistance cassette, a polyA sequence, and/or a transcriptional isolator. Some expression constructs suitable for the generation of microvesicle producing cells according to aspects of this invention are described elsewhere herein. Methods and reagents for the generation of additional expression constructs suitable for the generation of microvesicle producing cells according to aspects of this invention will be apparent to those of skill in the art based on the present disclosure. In some embodiments, the microvesicle producing cell is a mammalian cell, for example, a mouse cell, a rat cell, a hamster cell, a rodent cell, or a nonhuman primate cell. In some embodiments, the microvesicle producing cell is a human cell.

One skilled in the art may employ conventional techniques, such as molecular or cell biology, virology, microbiology, and recombinant DNA techniques. Exemplary techniques are explained fully in the literature. For example, one may rely on the following general texts to make and use the invention: Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., and Sambrook et al. Third Edition (2001); DNA Cloning: A Practical Approach, Volumes I and II (D. N. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gaited. 1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. (1985)); Transcription And Translation Hames & Higgins, eds. (1984); Animal Cell Culture (R I. Freshney, ed. (1986)); Immobilized Cells And Enzymes (IRL Press, (1986)); Gennaro et al. (eds.) Remington's Pharmaceutical Sciences, 18th edition; B. Perbal, A Practical Guide To Molecular Cloning (1984); F. M. Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, Inc.(updates through 2001), Coligan et al. (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc.(updates through 2001); W. Paul et al. (eds.) Fundamental Immunology, Raven Press; E. J. Murray et al. (ed.) Methods in Molecular Biology: Gene Transfer and Expression Protocols, The Humana Press Inc. (1991)(especially vol.7); and J. E. Celis et al., Cell Biology: A Laboratory Handbook, Academic Press (1994).

Delivery of ARMMs Containing Cargo Proteins

The inventive microvesicles (e.g., ARMMs) containing a cargo protein, described herein, may further have a targeting moiety. The targeting moiety may be used to target the delivery of ARMMs to specific cell types, resulting in the release of the contents of the ARMM into the cytoplasm of the specific targeted cell type. A targeting moiety may selectively bind an antigen of the target cell. For example, the targeting moiety may be a membrane-bound immunoglobulin, an integrin, a receptor, a receptor ligand, an aptamer, a small molecule, or a variant thereof . Any number of cell surface proteins may also be included in an ARMM to facilitate the binding of an ARMM to a target cell and/or to facilitate the uptake of an ARMM into a target cell. Integrins, receptor tyrosine kinases, G-protein coupled receptors, and membrane-bound immunoglobulins suitable for use with embodiments of this invention will be apparent to those of skill in the art and the invention is not limited in this respect. For example, in some embodiments, the integrin is an α1β1, α2β1, α4β1, α5β1, α6β1, αLβ2, αMβ2, αIIbβ3, αVβ3, αVβ5, αVβ6, or a α6β4 integrin. In some embodiments, the receptor tyrosine kinase is a an EGF receptor (ErbB family), insulin receptor, PDGF receptor, FGF receptor, VEGF receptor, HGF receptor, Trk receptor, Eph receptor, AXL receptor, LTK receptor, TIE receptor, ROR receptor, DDR receptor, RET receptor, KLG receptor, RYK receptor, or MuSK receptor. In some embodiments, the G-protein coupled receptor is a rhodopsin-like receptor, the secretin receptor, metabotropic glutamate/pheromone receptor, cyclic AMP receptor, frizzled/smoothened receptor, CXCR4, CCR5, or beta-adrenergic receptor.

Any number of membrane-bound immunoglobulins, known in the art, may be used as targeting moieties to target the delivery of ARMMs containing a cargo protein to any number of target cell types. In certain embodiments, the membrane-bound immunoglobulin targeting moiety binds a tumor associated or tumor specific antigen. Some non-limiting examples of tumor antigens include, CA19-9, c-met, PD-1, CTLA-4, ALK, AFP, EGFR, Estrogen receptor (ER), Progesterone receptor (PR), HER2/neu, KIT, B-RAF, S100, MAGE, Thyroglobulin, MUC-1, and PSMA (Bigbee W., et al. “Tumor markers and immunodiagnosis.”, Cancer Medicine. 6th ed. Hamilton, Ontario, Canada: BC Decker Inc., 2003.; Andriole G, et al. “Mortality results from a randomized prostate-cancer screening trial.”, New England Journal of Medicine, 360(13):1310-1319, 2009.; Schröder F H, et al. “Screening and prostate-cancer mortality in a randomized European study.” New England Journal of Medicine, 360(13):1320-1328, 2009.; Buys S S, et al. “Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.”, JAMA, 305(22):2295-2303, 2011.; Cramer D W et al. “Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.” Cancer Prevention Research, 4(3):365-374, 2011.; Roy D M, et al. “Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors.”, Breast Cancer. July 3; 6:81-91, 2014.; Tykodi S S. et al. “PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.” Onco Targets Ther. Jul 25; 7:1349-59, 2014.; and Weinberg R A. The Biology of Cancer, Garland Science, Taylor & Francis Group LLC, New York, N.Y., 2007.; the entire contents of each are incorporated herein by reference).

In certain embodiments, the membrane-bound immunoglobulin targeting moiety binds to an antigen of a specific cell type. The cell type may be a stem cell, such as a pluripotent stem cell. Some non-limiting examples of antigens specific to pluripotent stem cells include Oct4 and Nanog, which were the first proteins identified as essential for both early embryo development and pluripotency maintenance in embryonic stem cells (Nichols J, et al. “Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4.”, Cell. 95:379-91, 1998; the contents of which are hereby incorporated by reference). In addition to Oct4, Sox2 and Nanog, many other pluripotent stem cell markers have been identified, including Sal14, Dax1, Essrb, Tbx3, Tcl1, Rif1, Nac1 and Zfp281 (Loh Y, et al. “The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells.”, Nat Genet. 38:431-40, 2006). The membrane-bound immunoglobulin targeting moiety may also bind to an antigen of a differentiated cell type. For example, the targeting moiety may bind to an antigen specific for a lung epithelial cell to direct the delivery of ARMM cargo proteins to lung epithelial cells. As a non-limiting example, a membrane-bound immunoglobulin targeting moiety may bind to the alveolar epithelial type 1 cell specific protein RTI₄₀ or HTI₅₆ to deliver cargo proteins to alveolar epithelial type 1 cells (McElroy M C et al. “The use of alveolar epithelial type I cell-selective markers to investigate lung injury and repair.”, European Respiratory Jorunal 24:4, 664-673, 2004; the entire contents of which are hereby incorporated by reference). As another example, the targeting moiety may bind a mucin, such as muc5ac, or muc5b. It should be appreciated that the examples of antigens provided in this application are not limiting and the targeting moiety may be any moiety capable of binding any cellular antigen known in the art.

Some aspects of this invention relate to the recognition that ARMMs are taken up by target cells, and ARMM uptake results in the release of the contents of the ARMM into the cytoplasm of the target cells. In some embodiments, the fusion protein is an agent that affects a desired change in the target cell, for example, a change in cell survival, proliferation rate, a change in differentiation stage, a change in a cell identity, a change in chromatin state, a change in the transcription rate of one or more genes, a change in the transcriptional profile, or a post-transcriptional change in gene compression of the target cell. It will be understood by those of skill in the art, that the agent to be delivered will be chosen according to the desired effect in the target cell.

The genome of the target cell may be edited by a nuclease delivered to the cell via a strategy or method disclosed herein, e.g., by a RNA-programmable nuclease (e.g., Cas9), a TALEN, or a zinc-finger nuclease, or a plurality or combination of such nucleases. Some non-limiting aspects of this invention relate to the recognition that ARMMs can be used to deliver a cargo protein fused to at least one WW domain, or variant thereof, or a Cas9 fusion protein in ARMMs to the target cell or a population of target cells, for example, by contacting the target cell with ARMMs comprising the fusion protein to be delivered. Accordingly, some aspects of this invention provide ARMMs that comprise a fusion protein, for example, a Cas9 protein, or variant thereof, fused to a WW domain, an ARRDC1protein, or variant thereof, or a TSG101 protein or variant thereof.

Using any of the nucleases, described herein, or any of the nucleases known in the art, a single- or double-strand break may be introduced at a specific site within the genome of a target cell by the nuclease, resulting in a disruption of the targeted genomic sequence. In some embodiments, the targeted genomic sequence is a nucleic acid sequence within the coding region of a gene. In some embodiments, the strand break introduced by the nuclease leads to a mutation within the target gene that impairs the expression of the encoded gene product. In some embodiments, a nucleic acid is co-delivered to the cell with the nuclease. In some embodiments, the nucleic acid comprises a sequence that is identical or homologous to a sequence adjacent to the nuclease target site. In some such embodiments, the strand break effected by the nuclease is repaired by the cellular DNA repair machinery to introduce all or part of the co-delivered nucleic acid into the cellular DNA at the break site, resulting in a targeted insertion of the co-delivered nucleic acid, or part thereof. In some embodiments, the insertion results in the disruption or repair of a pathogenic allele. In some embodiments, the insertion is detected by a suitable assay, e.g., a DNA sequencing assay, a southern blot assay, or an assay for a reporter gene encoded by the co-delivered nucleic acid, e.g., a fluorescent protein or resistance to an antibiotic. In some embodiments, the nucleic acid is co-delivered by association to a supercharged protein. In some embodiments, the supercharged protein is also associated to the functional effector protein, e.g., the nuclease. In some embodiments, the delivery of a nuclease to a target cell results in a clinically or therapeutically beneficial disruption of the function of a gene.

In some embodiments, cells from a subject are obtained and a nuclease is delivered to the cells by a system or method provided herein ex vivo. In some embodiments, the treated cells are selected for those cells in which a desired nuclease-mediated genomic editing event has been effected. In some embodiments, treated cells carrying a desired genomic mutation or alteration are returned to the subject they were obtained from.

Methods for engineering, generation, and isolation of nucleases targeting specific sequences, e.g., Cas9, TALE, or zinc finger nucleases, and editing cellular genomes at specific target sequences, are well known in the art (see, e.g., Mani et al., Biochemical and Biophysical Research Communications 335:447-457, 2005; Perez et al., Nature Biotechnology 26:808-16, 2008; Kim et al., Genome Research, 19:1279-88, 2009; Urnov et al., Nature 435:646-51, 2005; Carroll et al., Gene Therapy 15:1463-68, 2005; Lombardo et al., Nature Biotechnology 25:1298-306, 2007; Kandavelou et al., Biochemical and Biophysical Research Communications 388:56-61, 2009; and Hockemeyer et al., Nature Biotechnology 27(9):851-59, 2009, as well as the reference recited in the respective section for each nuclease). The skilled artisan will be able to ascertain suitable methods for use in the context of the present disclosure based on the guidance provided herein.

As another example, to augment the differentiation stage of a target cell, for example, to reprogram a differentiated target cell into an embryonic stem cell-like stage, the cell is contacted, in some embodiments, with ARMMs with reprogramming factors, for example, Oct4, Sox2, c-Myc, and/or KLF4 that are fused to at least one WW domain, or variant thereof. Similarly, to affect the change in the chromatin state of a target cell, the cell is contacted, in some embodiments, with ARMMs containing a chromatin modulator, for example, a DNA methyltransferase, or a histone deacetylase fused to at least one WW domain, or variant thereof. For another example, if survival of the target cell is to be diminished, the target cell, in some embodiments, is contacted with ARMMs comprising a cytotoxic agent, for example, a cytotoxic protein fused to at least one WW domain or variant thereof. Additional agents suitable for inclusion into ARMMs and for a ARMM-mediated delivery to a target cell or target cell population will be apparent to those skilled in the art, and the invention is not limited in this respect.

In some embodiments, the ARMMs comprising a cargo protein fused to a WW domain, or variant thereof, or a Cas9 protein, or variant thereof, are provided that further include a detectable label. Such ARMMs allow for the labeling of a target cell without genetic manipulation. Detectable labels suitable for direct delivery to target cells are known in the art, and include, but are not limited to, fluorescent proteins, fluorescent dyes, membrane-bound dyes, and enzymes, for example, membrane-bound or cytosolic enzymes, catalyzing the reaction resulting in a detectable reaction product. Detectable labels suitable according to some aspects of this invention further include membrane-bound antigens, for example, membrane-bound ligands that can be detected with commonly available antibodies or antigen binding agents.

In some embodiments, ARMMs are provided that comprise a WW domain containing protein or a fusion protein comprising a WW domain or variant thereof to be delivered to a target cell. In some embodiments, the fusion protein is or comprises a transcription factor, a transcriptional repressor, a fluorescent protein, a kinase, a phosphatase, a protease, a ligase, a chromatin modulator, or a recombinase. In some embodiments, the protein is a therapeutic protein. In some embodiments the protein is a protein that affects a change in the state or identity of a target cell. For example, in some embodiments, the protein is a reprogramming factor. Suitable transcription factors, transcriptional repressors, fluorescent proteins, kinases, phosphatases, proteases, ligases, chromatin modulators, recombinases, and reprogramming factors may be fused to one or more WW domains to facilitate their incorporation into ARMMs and their function may be tested by any methods that are known to those skilled in the art, and the invention is not limited in this respect.

Methods for isolating the ARMMs described herein are also provided. One exemplary method includes collecting the culture medium, or supernatant, of a cell culture comprising microvesicle-producing cells. In some embodiments, the cell culture comprises cells obtained from a subject, for example, cells suspected to exhibit a pathological phenotype, for example, a hyperproliferative phenotype. In some embodiments, the cell culture comprises genetically engineered cells producing ARMMs, for example, cells expressing a recombinant ARMM protein, for example, a recombinant ARRDC1 or TSG101 protein, such as an ARRDC1 or TSG101 protein fused to a Cas9 protein or variant thereof. In some embodiments, the supernatant is pre-cleared of cellular debris by centrifugation, for example, by two consecutive centrifugations of increasing G value (e.g., 500G and 2000G). In some embodiments, the method comprises passing the supernatant through a 0.2 p.m filter, eliminating all large pieces of cell debris and whole cells. In some embodiments, the supernatant is subjected to ultracentrifugation, for example, at 120,000G for 2 hours, depending on the volume of centrifugate. The pellet obtained comprises microvesicles. In some embodiments, exosomes are depleted from the microvesicle pellet by staining and/or sorting (e.g., by FACS or MACS) using an exosome marker as described herein. Isolated or enriched ARMMs can be suspended in culture media or a suitable buffer, as described herein.

Methods of Microvesicle-Mediated Delivery of Cargo Proteins

Some aspects of this invention provide a method of delivering an agent, for example, a cargo protein fused to a WW domain (e.g., a Cas9 protein fused to a WW domain) to a target cell. The target cell can be contacted with an ARMM in different ways. For example, a target cell may be contacted directly with an ARMM as described herein, or with an isolated ARMM from a microvesicle producing cell. The contacting can be done in vitro by administering the ARMM to the target cell in a culture dish, or in vivo by administering the ARMM to a subject. Alternatively, the target cell can be contacted with a microvesicle producing cell as described herein, for example, in vitro by co-culturing the target cell and the microvesicle producing cell, or in vivo by administering a microvesicle producing cell to a subject harboring the target cell. Accordingly, the method may include contacting the target cell with a microvesicle, for example, an ARMM containing any of the cargo proteins to be delivered, as described herein. The target cell may be contacted with a microvesicle-producing cell, as described herein, or with an isolated microvesicle that has a lipid bilayer, an ARRDC1 protein or variant thereof, and a cargo protein.

It should be appreciated that the target cell may be of any origin. For example, the target cell may be a human cell. The target cell may be a mammalian cell. Some non-limiting examples of a mammalian cell include a mouse cell, a rat cell, hamster cell, a rodent cell, and a nonhuman primate cell. It should also be appreciated that the target cell may be of any cell type. For example the target cell may be a stem cell, which may include embryonic stem cells, induced pluripotent stem cells (iPS cells), fetal stem cells, cord blood stem cells, or adult stem cells (i.e., tissue specific stem cells). In other cases, the target cell may be any differentiated cell type found in a subject. In some embodiments, the target cell is a cell in vitro, and the method includes administering the microvesicle to the cell in vitro, or co-culturing the target cell with the microvesicle-producing cell in vitro. In some embodiments, the target cell is a cell in a subject, and the method comprises administering the microvesicle or the microvesicle-producing cell to the subject. In some embodiments, the subject is a mammalian subject, for example, a rodent, a mouse, a rat, a hamster, or a non-human primate. In some embodiments, the subject is a human subject.

In some embodiments, the target cell is a pathological cell. In some embodiments, the target cell is a cancer cell. In some embodiments, the microvesicle is associated with a binding agent that selectively binds an antigen on the surface of the target cell. In some embodiments, the antigen of the target cell is a cell surface antigen. In some embodiments, the binding agent is a membrane-bound immunoglobulin, an integrin, a receptor, or a receptor ligand. Suitable surface antigens of target cells, for example of specific target cell types, e.g. cancer cells, are known to those of skill in the art, as are suitable binding agents that specifically bind such antigens. Methods for producing membrane-bound binding agents, for example, membrane-bound immunoglobulin, for example, membrane-bound antibodies or antibody fragments that specifically bind a surface antigen expressed on the surface of cancer cells, are also known to those of skill in the art. The choice of the binding agent will depend, of course, on the identity or the type of target cell. Cell surface antigens specifically expressed on various types of cells that can be targeted by ARMMs comprising membrane-bound binding agents will be apparent to those of skill in the art. It will be appreciated that the present invention is not limited in this respect.

Co-Culture Systems

Some aspects of this invention provide in vitro cell culture systems having at least two types of cells: microvesicle producing cells, and target cells that take up the microvesicles produced. Accordingly, in the co-culture systems provided herein, there is a shuffling of the contents of the microvesicles (e.g., ARMMs) to the target cells. Such co-culture systems allow for the expression of a gene product or multiple gene products generated by the microvesicle producing cells in the target cells without genetic manipulation of the target cells.

In some embodiments, a co-culture system is provided that comprises (a) a microvesicle-producing cell population having a recombinant expression construct encoding (i) an ARRDC1 protein, or variant thereof fused to a Cas9 protein or variant thereof under the control of a heterologous promoter, and/or (ii) a TSG101 protein or variant thereof fused to a Cas9 protein variant thereof under the control of a heterologous promoter, and/or (iii) a cargo protein fused to a WW domain; and (b) a target cell population. In some embodiments, the ARRDC1 variant comprises a PSAP motif, and/or the TSG101 variant comprises a UEV domain. In some embodiments, the expression construct further encodes a guide RNA (gRNA) which may comprise a nucleotide sequence that complements a target site to mediate binding of a nuclease (e.g., a Cas9 nuclease) to a target site thereby providing the sequence specificity of the nuclease:RNA complex. In some embodiments, the host cell comprises a plurality of expression constructs encoding a plurality of ARRDC1:Cas9 fusion proteins and/or TSG101:Cas9 fusion proteins and/or cargo proteins fused to a WW domain.

One exemplary application of a co-culture system as provided herein is the programming or reprogramming of a target cell without genetic manipulation. For example, in some embodiments, the target cell is a differentiated cell, for example, a fibroblast cell. In some embodiments, the microvesicle producing cells are feeder cells or non-proliferating cells. In some embodiments, the microvesicle producing cells produce ARMMs comprising a reprogramming factor fused to one or more WW domains, or a plurality of reprogramming factors that are fused to one or more WW domains. In some embodiments, co-culture of the differentiated target cells with the microvesicle producing cells results in the reprogramming of the differentiated target cells to an embryonic state. In some embodiments, co-culture of the differentiated target cells with the microvesicle producing cells results in the programming, or trans-differentiation, of the target cells to a differentiated cell states that is different from the original cell state of the target cells.

Another exemplary application of a co-culture system, as provided herein, is the directed differentiation of embryonic stem cells. In some embodiments, the target cells are undifferentiated embryonic stem cells, and the microvesicle producing cells express one or more differentiation factors fused to one or more WW domains, for example, signaling molecules or transcription factors that trigger or facilitate the differentiation of the embryonic stem cells into differentiated cells of a desired lineage, for example neuronal cells, or mesenchymal cells.

Yet another exemplary application of a co-culture system, as provided herein, is the maintenance of stem cells, for example, of embryonic stem cells or of adult stem cells in an undifferentiated state. In some such embodiments, the microvesicle producing cells express signaling molecules and/or transcription factors fused to one or more WW domains that promote stem cell maintenance and/or inhibit stem cell differentiation. The microvesicle producing cells may create a microenvironment for the stem cells that mimics a naturally occurring stem cell niche.

The microvesicle-producing cell of a culture system may be a cell of any type or origin that is capable of producing any of the ARMMs described herein. For example, the microvesicle-producing cell may be a mammalian cell, examples of which include but are not limited to, a cell from a rodent, a mouse, a rat, a hamster, or a non-human primate. The microvesicle-producing cell may also be from a human. One non-limiting example of a microvesicle-producing cell capable of producing an ARMM is a human embryonic kidney 293T cell. The microvesicle-producing cell may be a proliferating or a non-proliferating cell. In some embodiments, the microvesicle-producing cell is a feeder cell which supports the growth of other cells in the culture. Feeder cells may provide attachment substrates, nutrients, or other factors that are needed for the growth of cells in culture.

The target cell of the culture system can be a cell of any type or origin, which may be contacted with an ARMM from any of the microvesicle-producing cells, described herein. For example, the target cell may be a mammalian cell, examples of which include but are not limited to, a cell from a rodent, a mouse, a rat, a hamster, or a non-human primate. The target cell may also be from a human. The target cell may be from an established cell line (e.g., a 293T cell), or a primary cell cultured ex vivo (e.g., cells obtained from a subject and grown in culture). Target cells may be hematologic cells (e.g., hematopoietic stem cells, leukocytes, thrombocytes or erythrocytes), or cells from solid tissues, such as liver cells, kidney cells, lung cells, heart cells bone cells, skin cells, brain cells, or any other cell found in a subject. Cells obtained from a subject can be contacted with an ARMM from a microvesicle-producing cell and subsequently re-introduced into the same or another subject. In some embodiments, the target cell is a stem cell. The stem cell may be a totipotent stem cell that can differentiate into embryonic and extraembryonic cell types. The stem cell may also be a pluripotent stem cell, a multipotent stem cell, an oligopotent stem cell or a unipotent stem cell. In other embodiments, the target cell is a differentiated cell.

Method of Gene Editing

Some aspects of the invention provide methods for gene editing by contacting a target cell with ARMMs that contain any of the RNA-programmable fusion proteins (i.e. Cas9 fusion proteins) described herein. Other aspects of the invention provide methods for gene editing by contacting a target cell with a microvesicle-producing cell comprising a recombinant expression construct encoding any of the RNA-programmable fusion proteins described herein. The RNA-guided or RNA-programmable fusion protein may be delivered to a target cell by any of the systems or methods provided herein. For example, the RNA-programmable fusion protein may contain a Cas9 nuclease, or variants thereof, one or more WW domains, or variants thereof, or optionally one or more NLSs which may be delivered to a target cell by the systems or methods provided herein.

In some embodiments, the RNA-programmable nuclease includes any of the Cas9 fusion proteins described herein. Because RNA-programmable nucleases (i.e., Cas9) use RNA:DNA hybridization to determine target DNA cleavage sites, these proteins are able to cleave, in principle, any sequence specified by the guide RNA. Methods of using RNA-programmable nucleases, such as Cas9, for site-specific cleavage (e.g., to modify a genome) are known in the art (see e.g., Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013); Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013); Hwang, W. Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature biotechnology 31, 227-229 (2013); Jinek, M. et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013); Dicarlo, J. E. et al. Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic acids research (2013); Jiang, W. et al. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nature biotechnology 31, 233-239 (2013); the entire contents of each of which are incorporated herein by reference).

Some aspects of this disclosure provide fusion proteins that have an RNA-guided or RNA-programmable fusion protein (i.e., a Cas9 protein, or Cas9 variant) that can bind to a gRNA, which, in turn, binds a target nucleic acid sequence; and a DNA-editing domain. Some non-limiting examples of DNA-editing domains include, but are not limited to, nucleases, nickases, recombinases or deaminases. As one example, a deaminase domain that can deaminate a nucleobase, such as, for example, cytidine is fused to an RNA-guided or RNA-programmable fusion protein. In some embodiments, the deaminase is fused to any of the Cas9 fusion proteins, described herein. The deamination of a nucleobase by a deaminase can lead to a point mutation at the respective residue, which is referred to herein as nucleic acid editing. Cargo proteins having a Cas9 protein or Cas9 variant, a DNA editing domain, and a protein capable of facilitating the incorporation of the cargo protein into an ARMM (e.g., a WW domain, an ARRDC1 protein, or a TSG101 protein) can thus be used for the targeted editing of nucleic acid sequences. It should be appreciated that any number of DNA editing domains (e.g., nucleases, nickases, recombinases and deaminases) known in the art may be fused to an (i) RNA-guided or RNA-programmable fusion protein (e.g., Cas9 or a Cas9 variant), and (ii) one or more WW domains or WW domain variants, or (iii) an ARRDC1 protein, or variant thereof, or (iv) a TSG101 protein, or variant thereof. Such fusion proteins are useful for targeted editing of DNA in vitro, e.g., for the generation of mutant cells or animals; for the introduction of targeted mutations, e.g., for the correction of genetic defects in cells ex vivo, e.g., in cells obtained from a subject that are subsequently re-introduced into the same or another subject; and for the introduction of targeted mutations, e.g., the correction of genetic defects or the introduction of deactivating mutations in disease-associated genes in a subject. It should also be appreciated that any of the cargo proteins, described herein, are useful for targeted editing of DNA in vivo, e.g., for the generation of mutant cells in a subject. Delivery of ARMMs containing any of the fusion proteins, described herein, may be administered to a subject by any of the methods or systems, described herein.

The methods of gene editing, described herein, may result in the correction of a genetic defect, e.g., in the correction of a point mutation that leads to a loss of function in a gene product. In some embodiments, the genetic defect is associated with a disease or disorder, e.g., a lysosomal storage disorder or a metabolic disease, such as, for example, type I diabetes. In some embodiments, the methods provided herein are used to introduce a deactivating point mutation into a gene or allele that encodes a gene product that is associated with a disease or disorder. For example, in some embodiments, methods are provided herein that employ an RNA-guided or RNA-programmable fusion protein (i.e., a Cas9 protein, or Cas9 variant) fused to a DNA editing cargo protein and at least one WW domain, or variant thereof, or an ARRDC1 protein, or variant thereof, or a TSG101 protein, or variant thereof, to introduce a deactivating point mutation into an oncogene. A deactivating mutation may, in some embodiments, generate a premature stop codon in a coding sequence, which results in the expression of a truncated gene product, e.g., a truncated protein lacking a function of the full-length protein.

The purpose of the methods provide herein may be used to restore the function of a dysfunctional gene via genome editing. The cargo proteins provided herein can be validated for gene editing-based human therapeutics in vitro, e.g., by correcting a disease-associated mutation in human cell culture. It will be understood by the skilled artisan that the cargo proteins provided herein, e.g., the fusion proteins comprising a Cas9 protein or Cas9 variant, a nucleic acid editing domain, and at least one WW domain or an ARRDC1 protein or a TSG101 protein, can be used to correct any single point T>C or A>G mutation. For example, deamination of the mutant C back to U corrects the mutation, and in the latter case, deamination of the C that is base-paired with the mutant G, followed by a round of replication, corrects the mutation.

An exemplary disease-relevant mutation that can be corrected by the instantly provided cargo proteins in vitro or in vivo is the H1047R (A3140G) polymorphism in the PIK3CA protein. The phosphoinositide-3-kinase, catalytic alpha subunit (PIK3CA) protein acts to phosphorylate the 3-OH group of the inositol ring of phosphatidylinositol. The PIK3CA gene has been found to be mutated in many different carcinomas, and thus it is considered to be a very potent oncogene (Lee J W et al. “PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.”, Oncogene. 2005; 24(8):1477-80; the entire contents of which are hereby incorporated by reference). In fact, the A3140G mutation is present in several NCI-60 cancer cell lines such as the HCT116, SKOV3, and T47D cell lines, which are readily available from the American Type Culture Collection (ATCC) (Ikediobi O N et al. “Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.”, Mol Cancer Ther. 2006; 5(11):2606-12).

In some embodiments, a cell carrying a mutation to be corrected, e.g., a cell carrying a point mutation resulting in a H1047R or A3140G substitution in the PIK3CA protein are contacted with an ARMM containing (i) a Cas9 protein or Cas9 variant fused to (ii) at least one WW domain or variant thereof, or an ARRDC1 protein or variant thereof, or a TSG101 protein or variant thereof, (iii) a deaminase fusion protein and an appropriately designed gRNA targeting the fusion protein to the respective mutation site in the encoding PIK3CA gene. Control experiments can be performed where the gRNAs are designed to target the fusion proteins to non-C residues that are within the PIK3CA gene. Genomic DNA of the treated cells can be extracted and the relevant sequence of the PIK3CA genes PCR amplified and sequenced to assess the activities of the fusion proteins in human cell culture.

It will be understood that the example of correcting point mutations in PIK3CA is provided for illustration purposes, and is not meant to limit the instant disclosure. The skilled artisan will understand that the instantly disclosed DNA-editing cargo proteins, described herein, can be used to correct other point mutations and mutations associated with other cancers and with diseases other than cancer.

The successful correction of mutations in disease-associated genes and alleles using any of the ARMMs or fusion proteins, described herein, opens up new strategies for gene correction with applications in disease therapeutics and gene study. Site-specific nucleotide modification proteins like the disclosed Cas9 variants fused to DNA-editing domains and at least one WW protein or an ARRDC1 protein or a TSG101 protein also have applications in “reverse” gene therapy, where certain gene functions are purposely suppressed or abolished. In these cases, site-specifically mutating Trp (TGG), Gln (CAA and CAG), or Arg (CGA) residues to premature stop codons (TAA, TAG, TGA) can be used to abolish protein function in vitro, ex vivo, or in vivo.

The instant disclosure provides methods for the treatment of a subject diagnosed with a disease associated or caused by a mutation that can be corrected by any of the DNA editing cargo proteins provided herein. For example, in some embodiments, a method is provided that comprises administering to a subject having such a disease, (e.g., a cancer associated with a PIK3CA point mutation) as described above, an effective amount of ARMMs containing any of the cargo proteins, described herein, that corrects the point mutation or introduces a deactivating mutation into the disease-associated gene. It should be appreciated that the inventive ARMMs may be used to target the delivery of any of the cargo proteins, described herein, to any target cell, described herein. In some embodiments, the disease is a neoplastic disease. In some embodiments, the disease is a metabolic disease. In some embodiments, the disease is a lysosomal storage disease. Other diseases that can be treated by correcting a mutation or introducing a deactivating mutation into a disease-associated gene will be known to those of skill in the art, and the disclosure is not limited in this respect.

In some embodiments, the genome of the target cell is edited by a nuclease delivered to the target cell via a system or method disclosed herein, e.g., by delivering any of the Cas9 fusion proteins using any of the ARMMs or ARMM producing cells described herein. In some embodiments, a single- or double-strand break is introduced at a specific site within the genome of a target cell by a Cas9 protein, resulting in a disruption of the targeted genomic sequence. In some embodiments, the targeted genomic sequence is a nucleic acid sequence within the coding region of a gene. In some embodiments, the targeted genomic sequence is a nucleic acid sequence outside the coding region of a gene, for example, the targeted genomic sequence may be within the promoter region of a gene. In some embodiments, the strand break introduced by the nuclease leads to a mutation within the target gene that impairs the expression of the encoded gene product.

A nucleic acid (e.g., a gRNA) may be associated with an RNA-guided protein (e.g., a Cas9 protein, or Cas9 variant) fused to a DNA editing domain and at least one WW domain, or variant thereof, or an ARRDC1 protein, or variant thereof, or a TSG101 protein, or variant thereof. Typically, a gRNA contains a nucleotide sequence that complements a target site, which mediates binding of the protein:RNA complex to a target site and providing the sequence specificity of the protein:RNA complex. Accordingly, a nucleic acid (e.g., a gRNA) may be co-expressed with any of the cargo proteins, described herein, in order to confer target sequence specificity to any of the RNA-guided fusion proteins, described herein. As one non-limiting example, a Cas9 variant fused to a WW domain may be co-expressed in a cell with a gRNA such that the gRNA associates with the Cas9 fusion protein and the Cas9 fusion protein, in complex with the gRNA, is loaded into an ARMM. In some embodiments, the nucleic acid has a sequence that is identical or homologous to a sequence adjacent to the nuclease target site. In some such embodiments, the strand break effected by the nuclease is repaired by the cellular DNA repair machinery to introduce all or part of the co-delivered nucleic acid into the cellular DNA at the break site, resulting in a targeted insertion of the co-delivered nucleic acid, or part thereof. In some embodiments, the insertion results in the disruption or repair of a pathogenic allele.

In certain embodiments, a catalytically inactive Cas9 fusion protein is used to activate or repress gene expression by fusing the inactive enzyme (that retains its gRNA-binding ability) to known regulatory domains. Cas9 variants that can be used to control gene expression have been described in detail, for example, in U.S. patent application number U.S. Ser. No. 14/216,655, filed on Mar. 17, 2014 (published as US20140273226 A1) by Wu F. et al., entitled Crispr/cas systems for genomic modification and gene modulation, and in PCT application number PCT/US2013/074736, filed on Dec. 12, 2013 (published as WO2014093655 A2) by Zhang F. et al., entitled Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains; the entire contents of each are incorporated herein by reference. For example, a catalytically inactive Cas9 fusion protein may be fused to a transcriptional activator (e.g. VP64). In certain embodiments, any of the Cas9 fusion proteins described herein may be when fused to a transcriptional activator to up-regulating gene transcription of targeted genes to enhance expression. In some embodiments, a catalytically inactive Cas9 fusion protein may be fused to a transcriptional repressor (e.g. KRAB). In certain embodiments, any of the Cas9 fusion proteins described herein may be fused to a transcriptional repressor to down-regulate gene transcription of targeted genes to reduce expression. In some embodiments, the delivery of a nuclease to a target cell results in a clinically or therapeutically beneficial disruption or enhancement of the function of a gene. It should be appreciated that the methods described herein are not meant to be limiting and may include any method of using Cas9 that is well known in the art.

The function and advantage of these and other embodiments of the present invention will be more fully understood from the Examples below. The following Examples are intended to illustrate the benefits of the present invention and to describe particular embodiments, but are not intended to exemplify the full scope of the invention. Accordingly, it will be understood that the Examples are not meant to limit the scope of the invention.

EXAMPLES Example 1 Loading of WW Domain Containing Fusion Proteins into ARMMs Introduction

Safe and efficient delivery of protein molecules into cells and tissues remains an unsolved problem in the art. The use of ARMMs as a protein delivery system may provide advantages over current delivery methods such as transfection or viral infection. For example, ARMMs are generated via an endogenous budding pathway that is mimicked by viruses and therefore has an intrinsic potential to deliver genetic materials and signaling molecules. In addition, ARMMs are unlikely to elicit a strong immune response as they may be produced by endogenous mechanisms. Furthermore, ARMMs may be targeted to specific recipient cells/tissues by incorporating antibodies or other types of molecules that recognize cell/tissue specific markers.

Targeted editing of nucleic acid sequences, for example, the introduction of a specific modification into genomic DNA, is a highly promising approach for the study of gene function and also has the potential to provide new therapies for human genetic diseases. An ideal nucleic acid editing technology possesses three characteristics: (1) high efficiency of installing the desired modification; (2) minimal off-target activity; and (3) the ability to be programmed to edit precisely any site in a given nucleic acid, e.g., any site within the human genome. Current genome engineering tools, including engineered zinc finger nucleases (ZFNs), transcription activator like effector nucleases (TALENs), and most recently, the RNA-guided DNA endonuclease Cas9 affect sequence-specific DNA cleavage in a genome. This programmable cleavage can result in mutation of the DNA at the cleavage site via nonhomologous end joining (NHEJ) or replacement of the DNA surrounding the cleavage site via homology-directed repair (HDR).

Engineered gRNA sequences can be co-expressed in a cell with Cas9 proteins to precisely edit target genome sequences. However, current delivery methods such as transfection or viral infection are not adequate for efficiently delivering Cas9, or other cargo proteins, to target cells in a subject. Accordingly, the ability of Cas9 fusion proteins to (i) load into ARMMs and (ii) perform RNA-guided genome editing is demonstrated.

Results

Two WW domains from ITCH (SEQ ID NO: 32) or Four WW domains from ITCH (SEQ ID NO: 33) were cloned into the AgeI site of the pX330 Cas9 construct (SEQ ID NO: 34) (Addgene) placing the WW domains at the N-terminus of the encoded Cas9 fusion protein (FIG. 3). Notably, the pX330 Cas9 fusion protein contains an N-terminal FLAG epitope tag. 293T cells at ˜60% confluency in 6-well plates were transfected with the following plasmids using the Turbofect transfection reagent:

-   (1) 0.5 μg GFP (pEGFP-N1)+0.5 μg Cas9 (px330) -   (2) 0.5 μg GFP (pEGFP-N1)+0.5 μg 2WW-Cas9 (px330+2WW) -   (3) 0.5 μg GFP (pEGFP-N1)+0.5 μg 4WW-Cas9 (px330+4WW) -   (4) 0.5 μg ARRDC1-GFP (pEGFP-N1+ARRDC1)+0.5 μg Cas9 (px330) -   (5) 0.5 μg ARRDC1-GFP (pEGFP-N1+ARRDC1)+0.5 μg 2WW-Cas9 (px330+2WW) -   (6) 0.5 μg ARRDC1-GFP (pEGFP-N1+ARRDC1)+0.5 μg 4WW-Cas9 (px330+4WW)

After transfection for 12 hours, culture medium was changed with fresh culture medium. About 48 hours post transfection, conditioned media were collected, and ARMMs were purified and lysed in ˜20 μl of lysis buffer. Cells were washed with PBS and lysed in ˜200 μl of lysis buffer per well. For Western blotting, 7 μg of total protein per cell lysate sample was used; 15 μl of ARMMs lysate per sample was used.

FIG. 5 shows that Cas9, 2WW-Cas9, and 4WW-Cas9 were expressed in 293T cells as evidenced by Western blot detection by Anti-FLAG. Additionally, ARRDC1-GFP expression was detected by Western blot, using an Anti-GFP antibody, in cells transfected with ARRDC1-GFP as expected (FIG. 5A, lanes4-6). ARMMs from the 293T cells transfected with the plasmids, listed above, were collected and tested for the presence of ARRDC1 and the Cas9 fusion proteins (Cas9, 2WW-Cas9, and 4WW-Cas9). Little or no Cas9 was detected in ARMMs produced by cells that either did not express ARRDC1-GFP or expressed Cas9 that was not fused to a WW domain (FIG. 5B, lanes 1-4). However, both 2WW-Cas9 and 4WW-Cas9 were efficiently incorporated into ARMMs along with ARRDC1-GFP (FIG. 5B, lanes 5 and 6) demonstrating that Cas9 fused to two or four WW domains can be efficiently delivered into ARMMs when ARRDC1 is expressed in microvesicle-producing cells.

FIG. 6 shows that no, or little, Cas9 is released from ARRDC1-null cells, but exogenous ARRDC1 expression rescued the incorporation of WW-Cas9 into ARMMs. 293T cells null for ARRDC1 (ARRDC1-KO) were transfected with following combination of plasmids:

-   (1) 0.5 μg GFP (pEGFP-N1)+0.5 μg control DNA -   (2) 0.5 μg GFP (pEGFP-N1)+0.5 μg Cas9 (px330) -   (3) 0.5 μg GFP (pEGFP-N1)+0.5 μg 4WW-Cas9 (px330+4WW) -   (4) 0.5 μg control DNA+0.5 μg Cas9 (px330) -   (5) 0.5 μg ARRDC1-GFP (pEGFP-N1+ARRDC1)+0.5 μg Cas9 (px330) -   (6) 0.5 μg ARRDC1-GFP (pEGFP-N1+ARRDC1)+0.5 μg 4WW-Cas9 (px330+4WW)

After transfection for 12 hours, culture medium was changed with fresh culture medium. About 48 hours post transfection, conditioned media were collected, and ARMMs were purified and lysed in ˜20 μl of lysis buffer. Cells were washed with PBS and lysed in ˜200 μl of lysis buffer per well. For Western blotting, 7 μg of total protein per cell lysate sample was used; 15 μl of ARMMs lysate per sample was used.

Expression of the Cas9, 4WW-Cas9 and ARRDC1-GFP constructs was detected in 293T cells null for ARRDC1 as evidenced by Western Blot (FIG. 6A). Western blots of isolated ARMMs showed that the 4WW-Cas9 fusion protein was efficiently loaded onto ARMMs when ARRDC1-GFP was exogenously expressed in 293T cells (FIG. 6B, lane 6). Only small amounts of 4WW-Cas9 were observed in ARMMs produced from cells that do not express ARRDC1 (FIG. 6B, lane3). Additionally, only small amounts of Cas9, not fused to a WW domain, were observed in cells exogenously expressing ARRDC1 (FIG. 6B, lane5). Accordingly, these results demonstrate that ARRDC1 facilitates the loading of WW domain-containing fusion proteins (e.g., a 4WW-Cas9 fusion protein) into ARMMs, which may be used to deliver the fusion protein to a target cell. A schematic of this process can be seen in FIG. 4.

As stated above, directing Cas9 activity, or Cas9 variant activity, to a specific nucleic acid sequence (e.g., a genomic sequence) requires association with a guide sequence (e.g., a gRNA). Therefore, the ability to incorporate a gRNA into ARMMs was tested. To do this, 293T cells were co-transfected with the plasmids (listed below) using 1.5 μl of turbofect and lml medium. Notably, an anti-GFP gRNA sequence was also expressed from the px330 construct (Addgene) under the U6 promoter to determine whether it can be incorporated into ARMMs.

-   (1) 1 μg control DNA -   (2) 0.5 μg control DNA+0.5 μg 2WW-Cas9 (px330+2WW) -   (3) 0.5 μg HA-ARRDC1+0.5 μg 2WW-Cas9 (px330+2WW)

ARMMs produced from 293T cells transfected with either control DNA (FIG. 7, bar 1), or 2WW-Cas9 (FIG. 7, bar 2), or 2WW-Cas9 and HA-ARRDC1 (FIG. 7, bar 3) were collected from the condition media 48 hours post transfection. RNAs were extracted from purified ARMMs to measure the amount of gRNA using qRT-PCR. Values of GAPDH gene expression were used for normalization. The data demonstrates that the gRNA was also efficiently incorporated into ARMMs when a WW domain-Cas9 fusion protein was co-expressed with ARRDC1 in the microvesicle producing cells (FIG. 7, bar 3). While the Cas9-WW domain fusion proteins and gRNAs were capable of being efficiently loaded into ARMMs, it was important to determine whether the Cas9-WW domain fusion proteins maintained their genome-editing function.

To determine whether 2WW-Cas9 was able to perform its genome-editing function, 293T cells expressing enhanced green fluorescent protein (EGFP) were transfected (1.5 ul of Turbofect in 100 μl Medium to mix, then in lml cell medium for 12 h transfection) with 1 μg of the DNA constructs listed below. Following transfection, GFP signal was examined by flow cytometry to determine whether 2WW-Cas9 associated with an anti-GFP gRNA sequence (FIG. 8D) was able to decrease GFP signal comparatively to Cas9 with an anti-GFP gRNA sequence (FIG. 8C).

-   (A) Control DNA, -   (B) Cas9 (px330); -   (C) Cas9-antiGFP (px330 containing the anti-GFP gRNA sequence) -   (D) 2WW-Cas9-anti-GFP (px330+2WW, and containing the anti-GFP sgRNA     sequence)

Expression of Cas9 without an anti-GFP gRNA (FIG. 8B) did not decrease GFP signal as compared to the control (FIG. 8A) as expected. Importantly, the 2WW-Cas9 protein associated with the anti-GFP gRNA sequence (FIG. 8D) was able to prevent/decrease GFP expression in GFP expressing 293T cells at an efficiency comparable to that of Cas9 protein associated with the anti-GFP gRNA sequence (FIG. 8C). These results demonstrate that WW-fused Cas9 is at least as effective as unmodified Cas9 in genome-editing.

It should be appreciated that the experiments laid out in FIGS. 5-8 can be used to test (i) the ability to load any cargo protein into an ARMM, (ii) the ability to load any gRNA into an ARMM, and (iii) the ability of any WW-fused Cas9 protein, or Cas9 variant, to perform a genome-editing or expression altering function. Furthermore, the ability of ARMMs to deliver their cargo proteins into a recipient cell can be tested, for example by isolating ARMMs containing a WW-fused Cas9 protein associated with an anti-GFP gRNA, and administering the ARMMs to a target cell expressing GFP (FIG. 9A). The GFP signal of the GFP expressing target cells may be measured using flow cytometry to determine whether the GFP signal is altered (FIG. 9B), thus determining whether the ARMMs were able to deliver their cargo proteins into the target cells.

REFERENCES

-   1. Hurley J H, Boura E, Carlson L A, & Rozycki B (2010) Membrane     budding. Cell 143:875-887. -   2. Thery C, Ostrowski M, & Segura E (2009) Membrane vesicles as     conveyors of immune responses. Nat Rev Immunol 9:581-593. -   3. Henne W M, Buchkovich N J, & Emr S D (2011) The ESCRT pathway.     Dev Cell 21:77-91. -   4. Katzmann D J, Odorizzi G, & Emr S D (2002) Receptor     downregulation and multivesicular-body sorting. Nat Rev Mol Cell     Biol 3:893-905. -   5. Babst M, Odorizzi G, Estepa E J, & Emr S D (2000) Mammalian tumor     susceptibility gene 101 (TSG101) and the yeast homologue, Vps23p,     both function in late endosomal trafficking. Traffic 1:248-258. -   6. Lu Q, Hope L W, Brasch M, Reinhard C, & Cohen S N (2003) TSG101     interaction with HRS mediates endosomal trafficking and receptor     down-regulation. Proc Natl Acad Sci USA 100:7626-7631. -   7. Pornillos O, Alam S L, Davis D R, & Sundquist W I (2002)     Structure of the Tsg101 UEV domain in complex with the PTAP motif of     the HIV-1 p6 protein. Nat Struct Biol 9:812-817. -   8. Pornillos O, Alam S L, Rich R L, Myszka D G, Davis D R, &     Sundquist W I (2002) Structure and functional interactions of the     Tsg101 UEV domain. EMBO J 21:2397-2406. -   9. Sundquist W I, Schubert H L, Kelly B N, Hill G C, Holton J M, &     Hill C P (2004) Ubiquitin recognition by the human TSG101 protein.     Mol Cell 13:783-789. -   10. Bache K G, Brech A, Mehlum A, & Stenmark H (2003) Hrs regulates     multivesicular body formation via ESCRT recruitment to endosomes. J     Cell Biol 162:435-442. -   11. Pornillos O, Higginson D S, Stray K M, Fisher R D, Garrus J E,     Payne M, He G P, Wang H E, Morham S G, & Sundquist W I (2003) HIV     Gag mimics the Tsg101-recruiting activity of the human Hrs protein.     J Cell Biol 162:425-434. -   12. von Schwedler U K, Stuchell M, Muller B, Ward D M, Chung H Y,     Morita E, Wang H E, Davis T, He G P, Cimbora D M, et al. (2003) The     protein network of HIV budding. Cell 114:701-713. -   13. Hurley J H & Stenmark H (2011) Molecular mechanisms of     ubiquitin-dependent membrane traffic. Annu Rev Biophys 40:119-142. -   14. Schorey J S & Bhatnagar S (2008) Exosome function: from tumor     immunology to pathogen biology. Traffic 9:871-881. -   15. Thery C, Zitvogel L, & Amigorena S (2002) Exosomes: composition,     biogenesis and function. Nat Rev Immunol 2:569-579. -   16. Bieniasz P D (2009) The cell biology of HIV-1 virion genesis.     Cell Host Microbe 5:550-558. -   17. Demirov D G & Freed E O (2004) Retrovirus budding. Virus Res     106:87-102. -   18. Morita E & Sundquist W I (2004) Retrovirus budding. Annu Rev     Cell Dev Biol 20:395-425. -   19. Garrus J E, von Schwedler U K, Pornillos O W, Morham S G, Zavitz     K H, Wang H E, Wettstein D A, Stray K M, Cote M, Rich R L, et     al. (2001) Tsg101 and the vacuolar protein sorting pathway are     essential for HIV-1 budding. Cell 107:55-65. -   20. VerPlank L, Bouamr F, LaGrassa T J, Agresta B, Kikonyogo A, Leis     J, & Carter C A (2001) Tsg101, a homologue of ubiquitin-conjugating     (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl     Acad Sci USA 98:7724-7729. -   21. Martin-Serrano J, Zang T, & Bieniasz P D (2001) HIV-1 and Ebola     virus encode small peptide motifs that recruit Tsg101 to sites of     particle assembly to facilitate egress. Nat Med 7:1313-1319. -   22. Martin-Serrano J, Zang T, & Bieniasz P D (2003) Role of ESCRT-I     in retroviral budding. J Virol 77:4794-4804. -   23. Demirov D G, Ono A, Orenstein J M, & Freed E O (2002)     Overexpression of the N-terminal domain of TSG101 inhibits HIV-1     budding by blocking late domain function. Proc Natl Acad Sci USA     99:955-960. -   24. Gottlinger H G, Dorfman T, Sodroski J G, & Haseltine W A (1991)     Effect of mutations affecting the p6 gag protein on human     immunodeficiency virus particle release. Proc Natl Acad Sci USA     88:3195-3199. -   25. Huang M, Orenstein J M, Martin M A, & Freed E O (1995) p6Gag is     required for particle production from full-length human     immunodeficiency virus type 1 molecular clones expressing protease.     J Virol 69:6810-6818. -   26. Freed E O & Mouland A J (2006) The cell biology of HIV-1 and     other retroviruses. Retrovirology 3:77. -   27. Martin-Serrano J & Neil S J Host factors involved in retroviral     budding and release. Nat Rev Microbiol 9:519-531. -   28. Rauch S & Martin-Serrano J (2011) Multiple interactions between     the ESCRT machinery and arrestin-related proteins: implications for     PPXY-dependent budding. J Virol 85:3546-3556. -   29. Ono A & Freed E O (2004) Cell-type-dependent targeting of human     immunodeficiency virus type 1 assembly to the plasma membrane and     the multivesicular body. J Virol 78:1552-1563. -   30. Pisitkun T, Shen R F, & Knepper M A (2004) Identification and     proteomic profiling of exosomes in human urine. Proc Natl Acad Sci     USA 101:13368-13373. -   31. Welton J L, Khanna S, Giles P J, Brennan P, Brewis I A,     Staffurth J, Mason M D, & Clayton A (2010) Proteomics analysis of     bladder cancer exosomes. Mol Cell Proteomics 9:1324-1338. -   32. Mathivanan S, Lim J W, Tauro B J, Ji H, Moritz R L, & Simpson R     J (2009) Proteomics analysis of A33 immunoaffinity-purified exosomes     released from the human colon tumor cell line LIM1215 reveals a     tissue-specific protein signature. Mol Cell Proteomics 9:197-208. -   33. Razi M & Futter C E (2006) Distinct roles for Tsg101 and Hrs in     multivesicular body formation and inward vesiculation. Mol Biol Cell     17:3469-3483. -   34. Hammarstedt M & Garoff H (2004) Passive and active inclusion of     host proteins in human immunodeficiency virus type 1 gag particles     during budding at the plasma membrane. J Virol 78:5686-5697. -   35. Babst M (2005) A protein's final ESCRT. Traffic 6:2-9. -   36. Scott A, Chung H Y, Gonciarz-Swiatek M, Hill G C, Whitby F G,     Gaspar J, Holton J M, Viswanathan R, Ghaffarian S, Hill C P, et     al. (2005) Structural and mechanistic studies of VPS4 proteins. EMBO     J 24:3658-3669. -   37. Alvarez C E (2008) On the origins of arrestin and rhodopsin. BMC     Evol Biol 8:222. -   38. Lefkowitz R J & Shenoy S K (2005) Transduction of receptor     signals by beta-arrestins. Science 308:512-517. -   39. Draheim K M, Chen H B, Tao Q, Moore N, Roche M, & Lyle S (2010)     ARRDC3 suppresses breast cancer progression by negatively regulating     integrin beta4. Oncogene 29:5032-5047. -   40. Nabhan J F, Pan H, & Lu Q (2010) Arrestin domain-containing     protein 3 recruits the NEDD4 E3 ligase to mediate ubiquitination of     the beta2-adrenergic receptor. EMBO Rep 11:605-611. -   41. Chantry A (2011) WWP2 ubiquitin ligase and its isoforms: new     biological insight and promising disease targets. Cell Cycle     10:2437-2439. -   42. Rotin D & Kumar S (2009) Physiological functions of the HECT     family of ubiquitin ligases. Nat Rev Mol Cell Biol 10:398-409. -   43. Denzer K, Kleijmeer M J, Heijnen H F, Stoorvogel W, & Geuze H     J (2000) Exosome: from internal vesicle of the multivesicular body     to intercellular signaling device. J Cell Sci 113 Pt 19:3365-3374. -   44. Komada M & Soriano P (1999) Hrs, a FYVE finger protein localized     to early endosomes, is implicated in vesicular traffic and required     for ventral folding morphogenesis. Genes Dev 13:1475-1485. -   45. Ono A, Demirov D, & Freed E O (2000) Relationship between human     immunodeficiency virus type 1 Gag multimerization and membrane     binding. J Virol 74:5142-5150. -   46. Fujii K, Hurley J H, & Freed E O (2007) Beyond Tsg101: the role     of Alix in ‘ESCRTing’ HIV-1. Nat Rev Microbiol 5:912-916. -   47. Wehman A M, Poggioli C, Schweinsberg P, Grant B D, & Nance     J (2011) The P4-ATPase TAT-5 Inhibits the Budding of Extracellular     Vesicles in C. elegans Embryos. Curr Biol 21:1951-1959. -   48. Skog J, Wurdinger T, van Rijn S, Meijer D H, Gainche L,     Sena-Esteves M, Curry W T, Jr., Carter B S, Krichevsky A M, &     Breakefield X O (2008) Glioblastoma microvesicles transport RNA and     proteins that promote tumour growth and provide diagnostic     biomarkers. Nat Cell Biol 10:1470-1476. -   49. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee J J, & Lotvall     J O (2007) Exosome-mediated transfer of mRNAs and microRNAs is a     novel mechanism of genetic exchange between cells. Nat Cell Biol     9:654-659.

All publications, patents and sequence database entries mentioned herein, including those items listed above, are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

EQUIVALENTS AND SCOPE

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the present invention is not intended to be limited to the above description, but rather is as set forth in the appended claims.

In the claims articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention also includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.

Furthermore, it is to be understood that the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the claims or from relevant portions of the description is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Furthermore, where the claims recite a composition, it is to be understood that methods of using the composition for any of the purposes disclosed herein are included, and methods of making the composition according to any of the methods of making disclosed herein or other methods known in the art are included, unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.

Where elements are presented as lists, e.g., in Markush group format, it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It is also noted that the term “comprising” is intended to be open and permits the inclusion of additional elements or steps. It should be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements, features, steps, etc., certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements, features, steps, etc. For purposes of simplicity those embodiments have not been specifically set forth in haec verba herein. Thus for each embodiment of the invention that comprises one or more elements, features, steps, etc., the invention also provides embodiments that consist or consist essentially of those elements, features, steps, etc.

Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. It is also to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values expressed as ranges can assume any subrange within the given range, wherein the endpoints of the subrange are expressed to the same degree of accuracy as the tenth of the unit of the lower limit of the range.

In addition, it is to be understood that any particular embodiment of the present invention may be explicitly excluded from any one or more of the claims. Where ranges are given, any value within the range may explicitly be excluded from any one or more of the claims. Any embodiment, element, feature, application, or aspect of the compositions and/or methods of the invention, can be excluded from any one or more claims. For purposes of brevity, all of the embodiments in which one or more elements, features, purposes, or aspects is excluded are not set forth explicitly herein. 

What is claimed is:
 1. An arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicle (ARMM), comprising: a lipid bilayer and an ARRDC1 protein or variant thereof, and a cargo protein, wherein the cargo protein is fused to at least one WW domain or variant thereof.
 2. The microvesicle of claim 1, wherein the cargo protein comprises two, three, four or five WW domains.
 3. The microvesicle of claim 1 or 2, wherein the WW domain is derived from a WW domain of the ubiquitin ligase WWP1, WWP2, Nedd4-1, Nedd4-2, Smurf1, Smurf2, ITCH, NEDL1 or NEDL2.
 4. The microvesicle of any of claims 1-3, wherein the WW domain comprises a sequence selected from the group consisting of (SEQ ID NO: 36), (SEQ ID NO: 37), (SEQ ID NO: 38), (SEQ ID NO: 39), (SEQ ID NO: 40), (SEQ ID NO: 41), (SEQ ID NO: 42), (SEQ ID NO: 43), (SEQ ID NO: 44), (SEQ ID NO: 45), (SEQ ID NO: 46), (SEQ ID NO: 47), (SEQ ID NO: 48), (SEQ ID NO: 49), (SEQ ID NO: 50), (SEQ ID NO: 51), (SEQ ID NO: 52), (SEQ ID NO: 53), (SEQ ID NO: 54), (SEQ ID NO: 55), (SEQ ID NO: 56), (SEQ ID NO: 57), (SEQ ID NO: 58), (SEQ ID NO: 59), (SEQ ID NO: 60), (SEQ ID NO: 61), (SEQ ID NO: 62), (SEQ ID NO: 63), and (SEQ ID NO: 64).
 5. The microvesicle of any of claims 1-4, wherein the WW domain is a variant of a WW domain.
 6. The microvesicle of any of claims 1-5, wherein the cargo protein is a recombinant protein.
 7. The microvesicle of any of claims 1-6, wherein the cargo protein is a Cas9 protein or variant thereof.
 8. The microvesicle of claim 7, wherein the Cas9 protein or variant thereof comprises at least one nuclear localization sequence (NLS).
 9. The microvesicle of any of claims 7-8, further comprising a guide RNA (gRNA).
 10. The microvesicle of any of claims 1-9, wherein the WW domain is fused to the N-terminus of the cargo protein.
 11. The microvesicle of any of claims 1-10, wherein the WW domain is fused to the C-terminus of the cargo protein.
 12. The microvesicle of any of claims 1-11, wherein the cargo protein comprises the sequence (SEQ ID NO: 65) or (SEQ ID NO: 66).
 13. The microvesicle of any of claims 1-12, wherein the cargo protein consists of the sequence (SEQ ID NO: 65) or (SEQ ID NO: 66).
 14. The microvesicle of any of claims 1-13, wherein the ARRDC1 protein or variant thereof comprises at least one PPXY motif.
 15. The microvesicle of any of claims 1-14, further comprising a TSG101 protein or variant thereof.
 16. The microvesicle of claim 15, wherein the TSG101 protein variant comprises a TSG101 UEV domain.
 17. An arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicle (ARMM), comprising: a lipid bilayer and an ARRDC1 protein or variant thereof, and a Cas9 cargo protein, wherein the Cas9 cargo protein is linked to the ARRDC1 protein or variant thereof.
 18. The microvesicle of claim 17, wherein the ARRDC1protein or variant thereof is covalently linked to the Cas9 cargo protein or variant thereof.
 19. The microvesicle of claim 17 or 18, wherein the ARRDC 1protein or variant thereof is linked to the Cas9 protein or variant thereof via a cleavable linker.
 20. The microvesicle of any of claims 17-19, wherein the linker comprises a protease recognition site.
 21. The microvesicle of any of claims 17-20, wherein the linker comprises a UV-cleavable linker.
 22. An arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicle (ARMM), comprising: a lipid bilayer and an ARRDC1 protein or variant thereof, a TSG101 protein or variant thereof, and a Cas9 cargo protein, wherein the Cas9 cargo protein is linked to the TSG101 protein or variant thereof.
 23. The microvesicle of claim 22, wherein the TSG101 protein variant comprises a TSG101 UEV domain.
 24. The microvesicle of any one of claims 17-23 further comprising a nuclear localization sequence (NLS).
 25. The microvesicle of any of claims 17-25, wherein the TSG101 protein or variant thereof is covalently linked to the Cas9 protein or variant thereof.
 26. The microvesicle of any of claims 22-25, wherein the TSG101 protein or variant thereof is linked to the Cas9 protein or variant thereof via a cleavable linker.
 27. The microvesicle of any of claims 22-26, wherein the linker comprises a protease recognition site or a UV-cleavable moiety.
 28. The microvesicle of any of claims 22-26, wherein the linker comprises a UV-cleavable moiety.
 29. A Cas9 fusion protein comprising: a Cas9 protein or a variant thereof, and a WW domain or variant thereof.
 30. The Cas9 fusion protein of claim 29, wherein the polypeptide comprises a nuclear localization sequence (NLS) or variant thereof.
 31. The Cas9 fusion protein of claim 29 or 30, wherein the WW domain is a WW domain variant.
 32. The Cas9 fusion protein of any of claims 29-31, wherein the WW domain is derived from a WW domain of the ubiquitin ligase WWP1, WWP2, Nedd4-1, Nedd4-2, Smurf1, Smurf2, ITCH, NEDL1 or NEDL2.
 33. The Cas9 fusion protein of any of claims 29-32, wherein the WW domain comprises a sequence selected from the group consisting of (SEQ ID NO: 36), (SEQ ID NO: 37), (SEQ ID NO: 38), (SEQ ID NO: 39), (SEQ ID NO: 40), (SEQ ID NO: 41), (SEQ ID NO: 42), (SEQ ID NO: 43), (SEQ ID NO: 44), (SEQ ID NO: 45), (SEQ ID NO: 46), (SEQ ID NO: 47), (SEQ ID NO: 48), (SEQ ID NO: 49), (SEQ ID NO: 50), (SEQ ID NO: 51), (SEQ ID NO: 52), (SEQ ID NO: 53), (SEQ ID NO: 54), (SEQ ID NO: 55), (SEQ ID NO: 56), (SEQ ID NO: 57), (SEQ ID NO: 58), (SEQ ID NO: 59), (SEQ ID NO: 60), (SEQ ID NO: 61), (SEQ ID NO: 62), (SEQ ID NO: 63), and (SEQ ID NO: 64).
 34. The Cas9 fusion protein of any of claims 29-33, wherein the Cas9 fusion protein comprises the sequence of (SEQ ID NO: 65) or (SEQ ID NO: 66).
 35. The Cas9 fusion protein of any of claims 29-34, wherein the Cas9 fusion protein consists of the sequence (SEQ ID NO: 65) or (SEQ ID NO: 66).
 36. The Cas9 fusion protein of any of claims 29-35 further comprising a guide RNA (gRNA).
 37. The Cas9 fusion protein of any of claims 29-36, wherein the WW domain is fused to the N-terminus of the Cas9 fusion protein.
 38. The Cas9 fusion protein of any of claims 29-37, wherein the WW domain is fused to the C-terminus of the Cas9 fusion protein.
 39. An ARRDC1 fusion protein comprising: an ARRDC1 protein or a variant thereof, and a Cas9 protein or a variant thereof.
 40. The ARRDC1 fusion protein of claim 39 further comprising a nuclear localization sequence (NLS).
 41. The AARDC1 fusion protein of claim 39 or 40, wherein the ARRDClprotein or variant thereof is covalently linked to the Cas9 protein or variant thereof.
 42. The AARDC1 fusion protein of any of claims 39-41, wherein the ARRDClprotein or variant thereof is linked to the Cas9 protein or variant thereof via a cleavable linker.
 43. A TSG101 fusion protein comprising: a TSG101 protein or a variant thereof, and a Cas9 protein or a variant thereof.
 44. The TSG101 fusion protein of claim 43 further comprising a nuclear localization sequence (NLS).
 45. The TSG101 fusion protein of claim 43 or 44, wherein the TSG101 protein or variant thereof is covalently linked to the Cas9 protein or variant thereof.
 46. The TSG101 fusion protein of any of claims 43-45, wherein the TSG101 protein or variant thereof is linked to the Cas9 protein or variant thereof via a cleavable linker.
 47. A nucleic acid construct encoding the Cas9 fusion protein of any of claims 29-38.
 48. A nucleic acid construct encoding the ARRDC1 fusion protein of any of claims 39-42.
 49. A nucleic acid construct encoding the TSG101 fusion protein of any of claims 43-46.
 50. A microvesicle-producing cell comprising: a recombinant expression construct encoding an ARRDC1 protein or a variant thereof under the control of a heterologous promoter, and a recombinant expression construct encoding a cargo protein under the control of a heterologous promoter, wherein the cargo protein is fused to at least one WW domain or variant thereof.
 51. The cell of claim 50, wherein the cargo protein comprises two, three, four or five WW domains.
 52. The cell of claim 50 or 51, wherein the WW domain is derived from a WW domain of the ubiquitin ligase WWP1, WWP2, Nedd4-1, Nedd4-2, Smurf1, Smurf2, ITCH, NEDL1 or NEDL2.
 53. The cell of any of claims 50-52, wherein the WW domain comprises a sequence selected from the group consisting of (SEQ ID NO: 36), (SEQ ID NO: 37), (SEQ ID NO: 38), (SEQ ID NO: 39), (SEQ ID NO: 40), (SEQ ID NO: 41), (SEQ ID NO: 42), (SEQ ID NO: 43), (SEQ ID NO: 44), (SEQ ID NO: 45), (SEQ ID NO: 46), (SEQ ID NO: 47), (SEQ ID NO: 48), (SEQ ID NO: 49), (SEQ ID NO: 50), (SEQ ID NO: 51), (SEQ ID NO: 52), (SEQ ID NO: 53), (SEQ ID NO: 54), (SEQ ID NO: 55), (SEQ ID NO: 56), (SEQ ID NO: 57), (SEQ ID NO: 58), (SEQ ID NO: 59), (SEQ ID NO: 60), (SEQ ID NO: 61), (SEQ ID NO: 62), (SEQ ID NO: 63), and (SEQ ID NO: 64).
 54. The cell of any of claims 50-53, wherein the WW domain is a WW domain variant.
 55. The cell of any of claims 50-54, wherein the cargo protein is a recombinant protein.
 56. The cell of any of claims 50-55, wherein the cargo protein is a Cas9 protein or variant thereof.
 57. The cell of claim 56, wherein the Cas9 protein or variant thereof comprises at least one nuclear localization sequence (NLS).
 58. The cell of any of claims 50-57 further comprising a recombinant expression construct encoding a guide RNA (gRNA).
 59. The cell of any of claims 50-58, wherein the WW domain is fused to the N-terminus of the cargo protein.
 60. The cell of any of claims 50-59, wherein the WW domain is fused to the C-terminus of the cargo protein.
 61. The cell of any of claims 50-60, wherein the cargo protein comprises the sequence (SEQ ID NO: 65) or (SEQ ID NO: 66).
 62. The cell of any of claims 50-61, wherein the cargo protein consists of the sequence (SEQ ID NO: 65) or (SEQ ID NO: 66).
 63. The cell of any of claims 50-62, wherein the ARRDC1 protein or variant thereof comprises at least one PPXY motif.
 64. The cell of any of claims 50-63, wherein the recombinant expression construct encoding the cargo protein is the nucleic acid construct of claim C1.
 65. A microvesicle-producing cell comprising: a recombinant expression construct encoding an ARRDC1 protein or a variant thereof under the control of a heterologous promoter, wherein the ARRDC1 protein or variant thereof is linked to a Cas9 cargo protein or variant thereof.
 66. The cell of 65, wherein the recombinant expression construct encoding the ARRDC1 protein or variant thereof is the nucleic acid construct of C2.
 67. A microvesicle-producing cell comprising: a recombinant expression construct encoding a TSG101 protein or variant thereof, wherein the TSG101 protein or variant thereof is linked to a Cas9 cargo protein or variant thereof.
 68. The cell of claim 67, wherein the TSG101 protein variant comprises a TSG101 UEV domain.
 69. The cell of claim 67 or 68, wherein the recombinant expression construct encoding the TSG101 protein or variant thereof is the nucleic acid construct of C3.
 70. The cell of any of claims 67-69, further comprising a recombinant expression construct encoding an ARRDC1 protein or a variant thereof under the control of a heterologous promoter.
 71. A method of delivering a cargo protein to a target cell, the method comprising contacting the target cell with the microvesicle of any of claims 1-26.
 72. A method of delivering a cargo protein to a target cell, the method comprising contacting the target cell with the microvesicle-producing cell of any of claims 49-69.
 73. The method of claim 71 or 72, wherein the target cell is a human cell.
 74. The method of any of claims 71-73, wherein the target cell is a stem cell.
 75. The method of any of claims 71-74, wherein the target cell is a cell in vitro, and wherein the method comprises administering the microvesicle to the cell in vitro, or co-culturing the target cell with the microvesicle-producing cell in vitro.
 76. The method of any of claims 71-75, wherein the target cell is a cell in a subject; and wherein the method comprises administering the microvesicle or the microvesicle-producing cell to the subject.
 77. The method of claim 76, wherein the subject is a mammalian subject.
 78. The method of claim 77, wherein the subject is a human subject.
 79. The method of any of claims 71-78, wherein the target cell is a pathological cell.
 80. The method of any of claims 71-79, wherein the target cell is a cancer cell.
 81. The method of any of claims 71-80, wherein the microvesicle is linked to a binding agent that selectively binds an antigen of the target cell.
 82. The method of claim 81, wherein the antigen of the target cell is a cell surface antigen.
 83. The method of claim 81 or 82, wherein the binding agent is a membrane-bound immunoglobulin, an integrin, a receptor, or a receptor ligand.
 84. A method of gene editing comprising contacting the target cell with the microvesicle of any of claims 1-28.
 85. A method of gene editing comprising contacting the target cell with the microvesicle-producing cell of any of claims 50-70.
 86. A method of altering expression of at least one gene comprising contacting the target cell with the microvesicle of any of claims 1-28.
 87. A method of altering expression of at least one gene comprising contacting the target cell with the microvesicle-producing cell of any of claims 49-70.
 88. The method of claim 86 or 87, wherein the expression of one or more gene products is decreased.
 89. The method of any of claims 86-88, wherein the expression of one or more gene products is increased. 